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ABSTRACT 
Mutations in the CulZn-superoxide dismutase (SOD-l) gene are responsible for a familial 
form of the motor neuron disease, amyotrophic lateral sclerosis (fALS). Aggregation of 
mutant SODI and formation of cytoplasmic inclusions are pathological hallmarks of the 
clisease in patients and in transgenic mouse models of fALS, and their occurrence suggests 
overload of proteolytic and protein chaperoning pathways. We studied proteasomal function 
in transgenic mi ce over-expressing human SODI carrying the fALS-related mutation G93A 
(SODI 093). Reduction in proteasomal activities in the lumbar spinal cord (containing 
vulnerable motor nuclei), but not thoracic spinal cord (less affected area) of pre-symptomatic 
Ç'OD G93A •• 1· . 1· d SOD IWT • d - transgeruc mlCe re atIve to non-transgeruc Ittermates an - transgeruc 
mi ce was measured early in disease pathogenesis. In addition, there was reduction of a-
subunits of the 20S proteasome in lumbar spinal motor neurons relative to the surrounding 
neuropil with disease progression. Decreased proteasome activity in lumbar spinal cord 
c:orresponded with reduced levels of ~3 (non-catalytic) and ~5 (chymotrypsin-like activity) 
subunits of the 20S proteasome, despite normal levels of 20Sa subunits in the tissue as a 
whole. Even though leve1s of ~3 and ~5 were decreased, they were incorporated into 20S and 
26S proteasome complexes as determined by native gel electrophoresis. Levels of ~3 and ~5 
mRNA were not decreased in lumbar spinal cord of SOD 1 O93A transgenic mice prior to onset 
of symptoms, indicating unimpaired transcription and rnRNA stability. Nor was there 
evidence that mutant SODI inhibited the proteasome by remaining assaciated with and 
blocking proteasomes. The relevance of findings in this mouse model of fALS to sporadic 
ALS was investigated by measuring proteasome activities and expression of proteasomal 
subunits in autopsy tissue from sporadic ALS patients As in fALS mice, proteasome activity 
was reduced in extracts of an affected region of spinal cord from ALS patients as compared to 
controls, whereas the proteasome activity in cerebellar tissue from these patients was not 
affected. This impairment was coupled with a decrease of 20S ~5 and 19S5a protein levels in 
spinal cord tissue suggesting that proteasome function is compromised in both familial and 
sporadic forms of ALS 
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RÉSUMÉ 
Des mutations du gène de l'enzyme superoxyde dismutase Cu/Zn (SOD I) sont la cause d'une 
t<mne familiale de la sclérose latérale amyotrophique (SLAf), une maladie des neurones 
moteurs. L'aggrégation de la SODI mutée et la formation d'inclusions cytoplasmiques 
semblent être corrélées au développement de la maladie chez les patients et les modèles 
murins de la SLAf. Ces phénomènes suggèrent une surcharge des voies protéolytique et du 
chaperonnage protéiques. Nous avons étudié le mode de fonctionnement du protéasome de 
souris transgéniques surexprimant la SODI humaine portant la mutation liée à la SLAf, G93A 
(SODI G93A). Nous avons constaté que très tôt dans la pathogénèse de la maladie se produisait 
une réduction des activités protéasomales dans la moelle épinière de la région lombaire (ou se 
trouve les nucleus vulnérables des neurones moteurs) des souris transgéniques SODI G93A pré-
symptomatiques. Ce phénomène ne se produit pas dans la région thoracique de ces souris 
(une région moins touchée par la maladie), ni chez les souris non-transgéniques issues de cette 
même portée, ou portant la mutation SOD-I WT. De plus, le nombre de sous-unités a du 
protéasome 20S dans les neurones moteurs de la moelle épinière de la région lombaire 
diminue au cours de la progression de la maladie, par rapport à ceux de la matière neuropil 
environnante. Une réduction de l'activité protéasomale dans la moelle épinière de la région 
lombaire coïncide à une diminution des taux des sous-unités ~3 (non-catalytique) et ~5 
(activité type chymotrypsine) du protéasome 20S, bien que les taux globaux de sous-unités a 
dans le tissue soient normaux. Malgré la diminution des taux de ~3 et ~5, ceux-ci ont été 
isolés dans les complexes protéasomales 20S et 26S par électrophorèse native. De plus, les 
taux en ARN messager des sous-unités ~3 et ~5 ne diminuent pas dans la moelle épinière de 
la région lombaire des souris transgéniques SOD I G93A pré-symptomatiques, indiquant la 
préservation de la transcription et la stabilité de l'ARN messager. Aucun signe d'inhibition du 
protéasome par des protéines mutantes SODI, que ce soit par association ou par blocage, n'a 
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pu être détecté. Pour démontrer l'importance de ces travaux pour l'étude de la SLA 
sporadique, l'activité protéasomale et l'expression de sous-unités protéasomales a été mesurée 
dans des tissus appartenant à des patients décédés de SLA. Comme pour les souris atteintes de 
SLAf, une réduction de l'activité protéasomale dans des extraits d'une région de la moelle 
épinière de patients atteints de SLA a été observée, en comparaison aux contrôles. Cependant, 
l"activité protéasomale dans les tissus cerebellaires de ces patients n'est pas affectée. Cette 
diminution d'activité est couplée à une baisse des taux en protéines 20S (35 et 19S 5a dans les 
tissus de moelle épinière, ce qui suggère une activité protéasomale limitée à la fois pour les 
:D~rmes familiales et sporadiques de la SLA. 
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PREFACE 
The thesis was written in the classical fonnat according to guidelines by Mc Gill University. 
The chapter that introduces mechanisms of ALS pathogenesis and the role of the ubiquitin-
proteasome in this disease has been published previously in a review and a book chapter: 
Kabashi E., Durham H.D. (2006) Failure of protein quality control in amyotrophic lateral 
sc1erosis. Biochim Biophys Acta. June 18; (Epub ahead of print). 
Durham H.D., Kabashi E., Taylor D.M., Agar J.N. (2005) Motor neuron diseases: THE 
PROTEASOMEIUDPS IN NEURODEGENERATIVE DISEASES AND AGING Plenum 
US. 
Rationale and research objectives are presented in Chapter 2, followed by a materials and 
methods section in Chapter 3 that includes all procedures utilized in chapters describing 
results of this thesis. A brief introduction, general approach, results and discussion of these 
results are described in Chapters 4, 5 and 6. The results appear in the following articles that 
have been pub li shed or are in the submission process as indicated below: 
Kabashi E., Agar lN., Taylor D.M., Minotti S., Durham H.D. (2004) Focal dysfunction of 
the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. 
Journal ofNeurochemistry 89:1325-35. 
Kabashi E., Agar J.N., Hong Y, Minotti S.M., Figlewicz D.A., and Durham H.D. Mechanism 
of proteasome dysfunction in a mouse model of Amyotrophic Lateral Sc1erosis, T 0 be 
submitted for review to Journal ofBiological Chemistry .. 
Kabashi E., Agar J.N., Leystra-Lantz C, Strong M.J., and Durham H.D. Focal Impainnent of 
the Proteasome in Spinal Cord of sporadic Amyotrophic Lateral Sc1erosis patients. 
Manuscript in preparation 
A general discussion containing a section with future directions is presented in Chapter 7. 
References are cited in Chapter 8. An appendix of supporting documents is located at the 
end of the thesis. 
Throughout the PhD studies, 1 participated in several other projects and studies that are not 
covered in this thesis. Several of these studies have been published or are in the submission 
process as indicated below: 
Taylor D.M., Kabashi E., Agar J.N., Minotti S., Durham H.D. (2005) Proteasome activity or 
expression is not altered by activation of the heat shock transcription factor Hsfl in cultured 
fibroblasts or myoblasts. Cell Stress Chaperones 10: 230-41. 
Agar J.N., ,Kabashi E., Gibbs, B.F.,.Bateman K.P., Taylor D.M., and Durham H.D. (2005) In 
Vivo Oxidative Modification of Superoxide Dismutase: Characterization by Mass 
Spectrometry. Manuscript in preparation. 
VI 
Taylor D.M., Gibbs B.F., Aguiar M., Kabashi E., Minotti S., Durham H.D., Agar J.N., -
Tryptophan 32 is required for cytotoxicity and aggregation of a mutant superoxide dismutase 
(G93A) in familial amyotrophic lateral sclerosis. Submitted to Proc. Natl. Acad. Sci. USA 
l carried out most experiments presented in this thesis with these notable exceptions. After 
designing the experiments, immunohistochemical analyses shown in Figures 3 and 10 were 
performed by David Taylor in Dr. Heather Durham 's laboratory. After designing the 
experiments and several of the primers used in the studies described in Figures 16 and 17, all 
rt-PCR experiments and statistical analysis of the data were carried out by Yu Hong in Dr. 
Denise Figlewicz's laboratory. Dr. Jeffrey Agar and David Taylor carried out the experiments 
in Figure 20B and l participated in designing these experiments. These results were inc1uded 
in the thesis since the data presented are important in describing mechanisms of proteasome 
impairment in lumbar spinal cord tissue of SOD 1 G93A transgenic mice. As previously 
acknowledged, Dr. Jeffrey Agar, a post-doctoral fellow in Dr. Heather Durham 's laboratory 
was instrumental in assisting me with designing experiments, analyzing data, discussing ideas 
and participated actively in the experiments presented in Chapter 4. Sandra Minotti, 
technician in Heather Durham' s laboratory was in charge of maintaining the animal colony 
and removal of the spinal cord tissues used in the experiments in Chapter 4 and 5. 
The members of my advisory committee, Dr Simon Wing and Dr. Ted Fon, two experts on 
the ubiquitin-proteasome pathway, were instrumental in discussing projects and the 
experimental approach taken during my PhD studies. Finally, Dr. Heather Durham provided 
all the scientific and financial support to complete the studies described in this thesis. 
Other significant contributors include Sorana Ciura from Dr. Charles Bourque laboratory for 
continuous input and help with the project, Drs. Giovanna Pellecchia, Dr. Brad Kauffman and 
Dr. Florin Sassarman, post-doctoral fellows from Dr. Eric Shoubridge's laboratory at the 
Montreal Neurological Institute who provided a lot of technical support for Blue native gel 
electrophoresis and immunoprecipitation protocols. Dr. Marco DiFalco and Dr. Leonid 
Kriazhev at McGill University conducted mass spectrometric analysis of proteins from native 
gels. Dr. Vita Vemace from City University of New York and Dr. Daniel Finley from 
Harvard University helped immensely with protocols for native gel electrophoresis. Dr. Luke 
Szweda at the University of Oklahoma provided an antibody specific to HNE-modified 
proteins. Finally, all experiments presented in Chapter 6 were possible by the kind donation of 
banked tissue from sporadic ALS patients and control cases from Dr. Michael Strong. Cheryl 
Leystra-Lantz in Dr. Strong's laboratory, was very helpful with methodology and shipping of 
the tissues. 
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CONTRIBUTION TO ORIGINAL KNOWLEDGE 
Several mechanisms of disease pathogenesis have been described in ALS and the 
accumulating evidence points to ALS being a multifactorial disease. However, even though 
there are many initial causes of ALS, common downstream pathways could contribute to 
pathogenesis and provide targets for therapy. Ubiquitinated inclusion bodies in motor neurons 
of ALS patients are a pathological hallmark of this neurodegenerative disorder. In animal 
models of fALS there is evidence of protein misfolding and aggregation very early in disease 
pathogenesis in affected tissues by the disorder. An increase in ubiquitinated and misfolded 
proteins, mostly degraded by the proteasome complex, would suggest an overload and 
possible impairment of the proteolytic capacity of the proteasome may be a common 
phenomenon in ALS pathogenesis. In this thesis, the role that the ubiquitin-proteasome 
pathway plays in ALS was described. 
Using a well-established mouse model of fALS, SODI G93A transgenic mi ce it was 
demonstrated that the three major activities of the proteasome are reduced to about half of 
control activities early in the course of the disease, and specifically within the lumbar spinal 
cord, and that motor neuron-specific loss of proteasome expression occurred in SO DI G93A 
mice at the symptomatic stage. That proteasomal dysfunction occurred early and specifically 
in a region responsible for clinical symptoms indicates this property is important in the 
aetiology and progression of the disease. This was first time-course study of proteasomal 
function in a model of neurodegenerative disease and the first demonstration of either a focal 
decline of proteasome levels in a vulnerable cell-type or the impairment of the specifie 
activity of the proteasome in an affected region as the disease progresses. These results are 
presented in Chapter 4 were previously published in Kabashi et al. 2004: Focal dysfunction of 
the proteasome: a pathogenic factor in a mouse model of amyotrophie lateral sclerosis. 
JournalofNeurochemistry Vol. 89 p.1325-35. 
Vll1 
Analysis of proteasome structure and composition as well as the effect that mutant 
SODI exerts on the proteasome activity was performed to de scribe molecular mechanisms of 
proteasome impairment in lumbar spinal cord ofSODl G93A. A specific decrease of 
constitutive 20S ~ subunits coincided with impairment of the proteasomal activity. These 
changes were not due to catalytic switches of ~ subunits to known immunoproteasome 
subunits, impaired transcription, or failure of these subunits to assemble in multimeric 
proteasomal complexes. These results are novel to the field of ALS research and this is the 
first study of proteasomal complex assembly in an animal model of neurodegeneration. These 
results are presented in Chapter 5 and a manuscript has been prepared for submission to 
Journal of Biological Chemistry. 
Since fALS with SOD1 mutations accounts for only 2% of ALS patients, proteasome 
activity and its levels were determined in thoracic spinal cord tissue and a less affected tissue, 
cerebellum of ALS patients. Impairment of the three major activities of the proteasome were 
associated with decrease the functional constitutive ~5 occurred solely in spinal cord tissue. 
These results are presented in Chapter 6 and are being prepared for publication. 
The results presented in this thesis highlight the importance that the ubiquitin-
proteasome pathway plays in ALS pathogenesis. In light of these experiments, therapeutic 
options that would help to specifically restore the impaired activity of the proteasome should 
be considered in ALS as well as in other neurodegenerative disorders where protein 
misfolding is a contributor of pathogenesis. 
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Chapter 1 Introduction 
Two highly important systems for maintaining prote in quality control in cells, namely 
protein chaperones and the ubiquitin-proteasome pathway, are responsible for clearing 
damaged or misfolded proteins. Failure of these systems would contribute to the progression 
of amyotrophie lateral sclerosis (ALS), a neurodegenerative disorder that preferentially targets 
motor neurons. In this chapter, the CUITent state of knowledge about ALS pathogenesis and 
the role that protein-quality control systems might play are reviewed. 
1.1 Amyotrophie Lateral Sclerosis 
1.1.1 Clinical Features orALS 
Amyotrophie lateral sclerosis (ALS) was first characterized by French physiologist 
Jean-Martin Charcot in 1869 (Mulder et al., 1986). The original diagnosis was based on 
neuropathological findings of degeneration of anterior horn cells and pathology of the 
corticospinal tract (Ince et al., 1998). The primary features of ALS include selective 
dysfunction and degeneration of upper and lower motor neurons (Cleveland and Rothstein, 
2001). The term motor neuron disease, intending to encompass multiple idiopathic 
degenerative motor system diseases includes ALS, spinal bulbar muscular atrophy, 
progressive bulbar paIsy, progressive muscular atrophy, and primary lateral sclerosis. Since 
ALS is the most common of these disorders, the term motor neuron disease is often used 
synonymously with ALS. 
ALS, as described by Charcot, is a disease usually presenting in adulthood (around 50-
60 years of age) as progressive muscle weakness and atrophy, muscle fasciculations and 
difficulties with speech and swallowing. The diagnosis of ALS is made in accordance with 
criteria established by the World Federation ofNeurology Research Group on Neuromuscular 
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Diseases (Brooks, 1994). The predominant presenting symptom of ALS, muscle weakness, is 
due to the dysfunction and loss of motor neurons in the ventral horn of the spinal cord and 
brain stem that extend axons to synapse with muscle (Wang and Melhem, 2005b). In certain 
cases, there is also involvement of upper motor neurons in the motor cortex that synapse onto 
lower (brain stem and spinal) motor neurons (Bruijn et al., 2004). Depending upon which 
motor nuclei are involved, difficulty moving limbs and sustaining posture, speaking, 
swallowing and breathing may develop. Symptoms progressively spread within a region and 
to other regions of the neuromuscular system. As muscle fibres are denervated because of 
dysfunction or death of lower motor neurons, they may be re-innervated through sprouting of 
adjacent motor axons. Failure of re-innervation and decreased mobility result in muscle 
atrophy, giving a wasted appearance to the musculature. 
The course of the disease can be devastatingly rapid, leading to progressive paralysis 
within the first year of clinical diagnosis. Failure of neurons that innervate the respiratory 
muscles usually results in the death of most ALS patients. The fatal event usually occurs 
within 3-5 years of clinical presentation (Cudkowicz et al., 2004). 
1.1.2 Neuropathological Findings inALS 
Microscopic findings at autopsy include extensive loss of motor neurons, as weIl as 
reactive gliosis (both astrocytes and microglia) in the spinal cord and brain stem of patients. 
Surviving motor neurons present a number of ultrastructural abnormalities of surviving motor 
neurons including presence of ubiquitinated inclusions, neurofilament-rich hyaline inclusions, 
proximal axonal swellings filled with accumulations of neurofilaments, and dendritic atrophy 
(Hirano, 1982; Leigh et al., 1988; Murayama et al., 1989). Despite the selective vulnerability 
of motor neurons in ALS, other brain areas are not completely spared and in sorne cases may 
become sufficiently involved to manifest clinicaIly, for example, neurons in the frontal cortex 
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controlling executive (planning) functions (Hasegawa et al., 1992; Strong et al., 2005). 
Interestingly, certain pools of motor neurons are spared in ALS, in particular those in the 
oculomotor and abducens nuclei that control eye movements (Okamoto et al., 1993) and those 
in onurs nucleus in the sacral spinal cord that control urinary and rectal sphincters (Schroder 
and Reske-Nielsen, 1984). AlI the se characteristics have been reported in both sporadic and 
hereditary cases implying commonalities in pathogenesis regardless of the initiating cause. 
ALS is a clinical syndrome with multiple underlying causes to which certain pools of 
motor neurons are particularly vulnerable. An important point is that multiple initiating 
factors (whether simple or complex genetic traits, environmental factors or a combination) 
manifest with similar pathology. The reaction of cells to the disease challenge may be just as 
important in their demise/survival as the se causative factors and will depend on the other 
stresses to which they are subjected and the protective mechanisms at their disposaI. 
Understanding the se properties in motor neurons and the cells with which they interact 
provides the basis for design of therapeutic agents to prevent the cascade of events leading to 
cell death. 
1.1.3 Epidemiology orALS 
The disease occurs with an incidence of 2/1 00,000 population or 3-4/1 00,000 over 20 
yrs old, with a slightly higher affliction of women (male/female = 1.3/1.6: 1) (Bobowick and 
Brody, 1973). The lifetime risk is about 1 in 2000 (Majoor-Krakauer et al., 2003). The ALS 
Society of Canada states that there are approximately 3000 people presently living with this 
disease in this country (refer to www.als.ca). The cause of most ALS cases is unknown, even 
though various genetic and environmental factors have been implicated (Shaw et al., 2001; 
Gros-Louis et al., 2006). Also the progression of the disease is quite variable suggesting that 
there might be a number of different factors involved. Among various environmental factors 
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to be associated with ALS, the toxin ~-methylaminoalanine (BMAA), a potent excitotoxin of 
glutamate receptors found in the cycad fruit, common in the diet of people from the island of 
Guam, has received wide attention. Recently, a report has demonstrated biomagnification of 
BMAA in the flying fox, a dietary delicacy, that may have been associated with ALSIPDC 
(Cox et al., 2003). Attempts to correlate environmental or occupational exposures with ALS 
have identified clusters of ALS cases; for example a higher prevalence of ALS has been 
reported in professional soccer players in ltaly (Chio et al., 2005) and in Gulf War veterans 
(Armon, 2004). However, the relatively small numbers of patients in most studies renders the 
statistical analysis unfeasible. 
1.1.4 Genetics orALS 
Whereas sorne forms of ALS have a clear pattern of inheritance, 80-90% of cases 
remain ofunknown cause, and thus are termed "sporadic". The hereditary form of the disease, 
familial ALS (fALS), is clinically and neuropathologically similar to sporadic ALS. In 1993, 
the first gene on chromosome 21 (ALS 1) responsible for fALS was cloned and characterized 
(Rosen et al., 1993a). Over 100 mutations spanning aB 5 SODI exons have been identified 
(see http://alsodl.iop.kcl.ac.uk) and are thought to cause disease because of a toxic gain of 
function. Most are missense mutations causing ALS in a dominantly inherited fashion with 
high penetrance, although a few are truncations. One missense mutation, D90A, exhibits a 
recessive or dominant pattern depending on genetic background (Jonsson et al., 2002). 
Several other genes linked to motor neuron disease have been recently cloned and 
characterized. ALS2 causes a rare, juvenile-onset (3-23 year oId) form of motor neuron 
disease and the gene was recently cloned (Hentati et al., 1994). Aisin, the gene product of 
ALS2, is a putative guanine exchange factor and has been implicated in organization of the 
actin cytoskeleton and vesicle trafficking and might have a role in maintaining motor neuron 
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survival (Jacquier et al., 2006). Surprisingly, two groups that generated alsin knockout mice 
did not report a neuronal phenotype and these mice had no developmental abnormalities 
(Devon et al., 2006; Hadano et al., 2006). Gene mutations in ALS4 (senataxin) (Chen et al., 
2004) and ALS8 (vesicle-associated membrane protein B) (Ni shimura et al., 2004) in fALS 
patients were recently described. However, these genes, similarly to ALS2, do not lead to 
dominantly inherited fALS, hence development of in vivo models using these genes might 
prove challenging. Gene defects in ALS3, ALS6 and ALS7 lead to classical dominantly 
inherited, adult onset fALS. Recently, loci have been identified for ALS3 on chromosome 18q 
(Hand et al., 2002), ALS6 on chromosome 16q (Abalkhail et al., 2003), and ALS7 on 
chromosome 20p (Sapp et al., 2003). Several groups are collaborating to map the regions and 
identify genetic mutations in these loci in order to develop new in vitro and in vivo models to 
study ALS pathogenesis (Gros-Louis et al., 2006). 
1.1.5 Models offALS 
1.1.5.1 SOD1 
The major finding that mutations in Cu/Zn superoxide dismutase (SOD 1) causes fALS 
led to the development of various in vivo and in vitro models of ALS. SOD 1 is an enzyme 
whose main function is to detoxify free radicals in the form of superoxide anions (02'-), by-
products of mitochondrial oxidative phosphorylation, into water or hydrogen peroxide 
molecules, thus reducing oxidative stress on the cell. The reaction is a two-step process that 
involves reduction of SODI copper atoms by superoxide, followed by an oxidation step 
(Beckman and Koppenol, 1996). After 13 years of extensive study using these models, it still 
remains a mystery how mutations in the SODI gene lead to ALS. The loss-of-function 
hypothesis has not been convincing since knocking out the SOD 1 gene in mice did not lead to 
neurodegeneration and most SODI mutants retain their dismutase activity (Borchelt et al., 
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1994; Reaume et al., 1996). This evidence and the fact that fALS caused by SODI mutations 
is dominantly inherited indicates that a toxic gain-of-function of mutant SODI leads to motor 
neuron degeneration and ALS. 
Indeed, toxicity of mutant SODI has been shown in various in vitro models, including 
motor neurons from spinal cord cultures, pure cultures of motor neurons, and neuronal cell 
lines (Durham et al., 1997; Menzies et al., 2002; Perrin et al., 2005). Overexpression of 
mutant SODI in motor neurons, but not in dorsal root ganglion (DRG) or hippocampal 
neurons led to formation of microscopically visible inclusion bodies and motor neuronal death 
(Durham et al., 1997). These in vitro models have proven valuable for studying mechanisms 
of disease pathogenesis and testing therapies to decrease mutant SODI aggregation and motor 
neuronal death. 
The disease has been modeled in transgenic animaIs. Ubiquitous expression of various 
forms of mutant SODI in mice [human SOD1 G93A (Gurney et al., 1994), human SOD1 G37R 
(Wong et al., 1995), human SODI G85R (Bruijn et al., 1997), human SOD1 L126Z (Wang et al., 
2005a), murine SODI G86R (Ripps et al., 1995)] led to a neurodegenerative disorder associated 
with motor neuronalloss (see Table 1). Many other pathological features identified in spinal 
cord tissue from ALS patients, including ubiquitin-positive inclusion bodies in motor neurons 
and astrocytes, astrogliosis and microglial activation have been replicated in these murine 
models (DaI Canto and Gurney, 1995; Hall et al., 1998). Molecular and biochemical features, 
disease onset (usually indicated by hindlimb weakness and weight loss), as weIl as the 
progressive paralysis are remarkably reproducible within a particular strain of mice, providing 
a great tool for studying pathogenesis and testing therapeutics (Bendotti and Carri, 2004). The 
models described above, express very high levels ofmutant SODI. Recently, a mouse model 
of ALS has been generated expressing very low levels of truncated human SODI Gl27X and 
could provide an alternative model to the lines described above (Jons son et al., 2004). 
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Interestingly, this gene product has a higher propensity to aggregate than other SODI mutants 
even in tissue that is not affected (liver). 
As seen in Table 1, most of these animal models have common features, such as loss 
of motor neurons at late stages of the disease, glial reactivity in spinal cord tissue and 
presence of ubiquitinated inclusions in motor neurons and astrocytes. Differences include 
mitochondrial vacuolation in motor neurons prominent in SOD 1 G93A early in disease 
pathogenesis but not in other lines, most likely due to high gene expression ofmutant SODI 
(DaI Canto and Gumey, 1995). On the other hand, whereas formation of inclusion bodies is 
fairly rare in SODI G93A transgenic mice, the line of mice carrying SODI G85R have more 
prominent inclusions in spinal cord cells (Bruijn et al., 1997). These differences in murine 
models of fALS are important to consider since a mechanisms of disease pathogenesis might 
be more prominent in a certain line and might not model changes that occur in sporadic and 
fALS pathogenesis. Also, treatments that might prove very beneficial in one line might not 
change the progression of ALS pathogenesis in another line. 
Recently, other animal models have been generated in order to better study ALS 
pathogenesis. C.elegans expressing mutant SODI have been very useful to study and 
visualize in vivo SODI aggregation (Oeda et al., 2001). Recently, two transgenic lines of rats 
overexpressing SODI G93A and SODI H46R were developed since larger tissue size (spinal cord) 
might help researchers understand mechanisms of ALS pathogenesis (Nagai et al., 2001; 
Rowland et al., 2002). 
1.1.5.2 Other Animal Models 
Prior to cloning and characterization of SODI mutations, spontaneous mutations that 
would lead to selective degeneration of motor neurons were used as animal models of ALS. 
The spontaneous mutation that causes motor neuron pathology in one of the most popular of 
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these animal models, the wobbler mouse (Pioro and Mitsumoto, 1995) was recently 
characterized as a mutation in Vacuolar-vesicular prote in sorting (Vps54) gene (Schmitt-John 
et al., 2005). The knowledge that a point mutation in the V sp54 gene (the gene product plays 
a role in retrograde vesicular transport from the Golgi) leads to selective motor neuronal 
degeneration might open avenues of research to study molecular mechanisms of motor neuron 
pathogenesis in this model. 
Several groups have also attempted to generate motor neuronal disorders by mutating 
genes to disrupt important molecular mechanisms of ALS pathogenesis in mice. Dynein, is a 
protein important in retrograde axonal transport along the microtubules (Ahmad et al., 1998). 
Expression of mutant dyne in leads to disrupted axonal transport and selective degeneration of 
motor neurons with pathological features similar to murine models of fALS (vide supra) 
(Hafezparast et al., 2003). Vascular endothelial growth factor (VEGF) is important in motor 
neuron survival and treatment of lumbar spinal cord of SODIG93A with VEGF delays the 
disease progression (see Section 1.3). Deleting the hypoxia inducible factor region of VEGF 
was demonstrated to lead to motor neuron degeneration and motor function abnormalities in 
mice (Oosthuyse et al., 2001). Peripherin is an intermediate filament up-regulated in neurons 
upon injury or inflammatory response (Troy et al., 1990). Overexpression of WT peripherin in 
mice provokes massive and selective degeneration of motor axons and motor neuron death by 
6 months of age (Beaulieu et al., 1999). These mice provide the opportunity to identify 
common mechanisms of pathogenesis with different initiators of motor neuron disease and to 
possibly test the efficacy of pharmaceutical treatments that are successful in mutant SODI 
transgenic mice (see Therapeutical Perspectives). 
1.2 Hypotheses of ALS pathogenesis 
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There is extensive evidence from studies of recombinant mutant SOD 1 in vitro, from 
cell culture models and from transgenic animal models that a toxic gain of function conferred 
by disease-causing mutations of SOD 1 leads to altered solubility of the prote in and that 
insoluble proteins including mutant SODI collect into large, microscopically visible 
aggregates, although how this ultimately leads to death of motor neurons is not certain. 
However, mechanisms of mutant SOD 1 misfolding and aggregation are becoming better 
understood (see Section 1.2.5.1). Various factors may contribute to motor neuron 
vulnerability are discussed below: increased oxidative stress; high level glutamatergic 
excitotoxic input and mitochondrial abnormalities; induction of the glial response; 
abnormalities in intermediate filament organization; and malfunction of the prote in quality 
control systems. In a cellular context there is cross-talk between these molecular pathways as 
illustrated in Figure 1. Evidently, since ALS is a multifactorial disorder, aIl these mechanisms 
of pathology might occur simultaneously to varying degrees in each ALS patient and efficient 
treatments of ALS should take each one of the se pathways into account. 
1.2.1 Oxidative Stress 
As is the case with each pathogenic mechanism described below, the major, 
unresolved debate remains whether increased oxidative stress is a primary cause of ALS 
pathogenesis or merely a consequence of this neurological disorder. Recent evidence as 
presented below demonstrates that in fALS 1 animal models, oxidative stress is not the 
initiator of ALS pathogenesis but has a major contribution in disease progression through 
mechanisms that are independent of mutant SOD 1 catalytic activity. 
There is very good evidence for increased oxidative stress from studies in ALS 
patients and in vivo models of ALS (Barber et al., 2006). This includes increased protein 
carbonyl levels, increased 3-nitrotyrosine levels, and prominent immunolabeling for other 
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markers of protein and lipid oxidation specifically in affected areas of the spinal cord of ALS 
patients and mutant SOD 1 transgenic mice as well as in affected cells (motor neurons, 
astroctes, microglia) (Shaw et al., 1995; Abe et al., 1995; Fitzmaurice et al., 1996; BeaI et al., 
1997). AIso, increased oxidative damage to DNA as weIl as increased 4-hydroxynonenal 
(HNE) (indicative of lipid peroxidation), and ascorbate free radicallevels have been reported 
in cerebrospinal fluid (CSF) samples from ALS patients (Fitzmaurice et al., 1996; Smith et 
al., 1998; Ihara et al., 2005). This hypothesis became much more persuasive in 1993, with the 
discovery that mutations of the anti-oxidant enzyme, SODI, causes fALS (Rosen et al., 1993). 
However, a large body of evidence argues against mutant SODI causing oxidative stress by 
generating rather than detoxifying superoxide anions (refer to Sectionl.l.5). 
Since copper plays an important role in SODI catalytic activity, other theories 
centered on the mishandIing of active site copper in SODI. Mutant SODI was shown in vitro 
to catalyze a backward reaction to produce more superoxide, which could combine with nitric 
oxide (NO) to form peroxynitrite, a potent protein-damaging agent (Beckman, 1994). This in 
vitro data correlated weIl with discoveries of increased NO synthases (NOS) and 3-
nitrotyrosine in SODIG93A (Bruijn et al., 1997; Ferrante et al., 1997; AImer et al., 1999; Cha et 
al., 2000; Sasaki et al., 2002) and human patients (BeaI et al., 1997; Tohgi et al., 1999; Phul et 
al., 2000; Anneser et al., 2001; Sasaki et al., 2001; Catania et al., 2001). However, this 
mechanism does not appear to be crucial to ALS pathogenesis since inhibition of neuronal 
NO synthase (NOS) had no effect on survival of mutant SODI transgenic mice and cultured 
motor neurons (Facchinetti et al., 1999; Doroudchi et al., 2001). 
Two in vivo studies were instrumental in determining that fALS caused by mutant 
SODI in transgenic mice is copper independent. Crossing several lines of mutant SODI 
transgenic mice with mice that lack the copper chaperone for SODI (CCS) did not alter 
disease progression (Subramaniam et al., 2002). To follow up, Borchelt and colleagues 
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combined disease-causing SODI mutations, SODIH46RfH48Q with an inability to bind copper in 
transgenic mice and found no change in survival or motor neuron degeneration (Wang et al., 
2003). 
All this evidence arguing against the original hypothesis that mutation in SODI 
resulted in SODI that generated, rather than detoxified radicals, does not exclude the fact that 
mutant SODI may induce oxidative stress in a mechanism beyond its own catalytic activity. 
Recently, expression of mutant SODI in cell lines lowered by 3-fold the expression of an 
important anti-oxidant factor, Nrf2, a transcription factor that regulates the expression of anti-
oxidant response element (ARE) genes (Kirby et al., 2005). This transcription factor is quite 
important because it regulates various "programmed cell life" genes as weIl as the expression 
of various proteasomal subunits (see Section 1.2.6.4). AIso, as it will be discussed proteins 
severely damaged by oxidative stress, including mutant SODI, may be powerful inhibitors of 
the proteasome activity (refer to Section 8.3). 
1.2.2 High Level Glutamatergic input and Mitochondrial Abnormalities 
1.2.2.1 Glutamatergic Excitotoxicity 
Motor neurons are very large cells that are highly excitable because they express 
abundant levels of glutamate receptors and highly vulnerable to glutamate toxicity due to their 
reduced protective mechanisms. For this reason, excitoxicity, neuronal damage due to over-
stimulation of glutamate receptors and elevation of intracellular Ca2+ levels by Ca2+-
permeable glutamate receptors, has an important role in ALS pathogenesis (Van Den et al., 
2006). In motor neurons derived from primary dissociated and organotypic cultures, 
excitotoxicity is largely mediated by excitation of AMP A receptors as in other CNS neurons 
(Rothstein et al., 1993; Carriedo et al., 1996; Roy et al., 1998). Several lines of evidence 
support the involvement of glutamate receptor excitation in ALS including increased 
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glutamate levels in CSF of sorne, but not aIl ALS patients (Plaitakis et al., 1988; Perry et al., 
1990). Pronounced loss of the glial glutamate transporter, EAAT2, responsible for clearing 
glutamate from the synaptic cleft, was measured in affected brain regions of ALS patients and 
in spinal cord of mutant SODI transgenic mice (Roth stein et al., 1995; Sasaki et al., 2000). 
Also, several studies have demonstrated that expression of several mutant SOD 1 can impair in 
vivo glial glutamate transport in Xenopus oocytes (Trotti et al., 1999), therefore reducing the 
clearance of excess glutamate from around motor neurons by supporting glia. 
Excitation of Ca2+ -permeable AMP A receptors appear to be another important factor 
in ALS pathogenesis since joro-spider toxin, an inhibitor of Ca2+ -permeable AMP A receptor 
preserved viability ofmotor neurons injected with mutant SODI and reduced mutant SODl-
specific aggregate formation (Roy et al., 1998; Kruman et al., 1999). Also, transgenic mice 
with increased Ca2+ permeability of glutamate receptors due to expression of GluR-B(N)-
containing AMP A receptors had a late-onset motor neuron pathology independent of mutant 
SODI expression (Brusa et al., 1995). FinaIly, motor neurons express low levels of Ca2+_ 
buffering proteins, whereas less vulnerable motor neurons such as those in the oculomotor, 
trochlear, abducens and Onufs nucleus clearly express higher levels of tCa2+ -binding proteins 
(Ince et al., 1993; Alexianu et al., 1994; Elliott and Snider, 1995; Reiner et al., 1995). 
Increasing resistance to calcium-mediated toxicity by overexpression of the Ca2+ -buffering 
proteins, calbindin-D28K in cultured motor neurons reduced motor neuron death and mutant 
SODI positive inclusion body formation (Roy et al., 1998). AIso, cross-breeding of 
parvalbumin-overexpressing mice with SODI G93A transgenic mice, significantly prolonged 
survival and onset of disease (Beers et al., 2001). 
1.2.2.2 Mitochondrial Dysfunction 
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As illustrated in Figure 1, elevated intracellular Ca2+ levels would cause mitochondrial 
abnormalities and activation of cell death pathways since mitochondria are a major organelle 
responsible for buffering cytosolic Ca2+. AIso, since reactive oxygen species are generated in 
the mitochondrial respiratory chain, elevated levels of oxidative stress can further damage 
mitochondria. As mentioned previously, the se mechanisms of ALS pathogenesis are certainly 
not independent entities but seem to act in concert. 
Mitochondrial abnormalities have been identified in post-mortem muscle and spinal 
cord of sporadic and fALS patients (Fujita et al., 1996; Browne et al., 1998). Mitochondrial 
vacuolation in motor neurons and a focal decrease of various mitochondrial electron transfer 
chain complexes activity in spinal cord is an early event in mutant SODI pathogenesis of 
SODI G93A transgenic mice (DaI Canto and Gumey, 1995; Higgins et al., 2002). However, this 
phenomenon might be an artifact of very high levels of mutant SOD 1 expression in the se 
mice since motor neurons from other mutant SODI transgenic lines did not have a 
pronounced mitochondrial vacuolation. Recent evidence suggests that mitochondrial 
dysfunction might play a more central role in ALS pathogenesis (Manfredi and Xu, 2005). 
Liu et al. demonstrated that in spinal cord tissue from mutant SODI transgenic mice, SODI 
progressively accumulates and aggregates in the outer mitochondrial membrane, causing 
clogging of the protein translocation machinery, and eventually resulting in mitochondrial 
dysfunction (Liu et al., 2004). Studies from yeast propose that sorne SOD 1 is imported into 
the mitochondria where it is folded, metallated and becomes enzymatically active. Mutant 
SOD 1 may fail to fold properly and to form the intracellular disulfide bond and clogs the 
import machinery of mitochondria (Culotta et al., 2006). There is sorne in vivo evidence to 
support this mechanism. Pasinelli and colleagues recently demonstrated that an interaction of 
Bcl-2 with mutant SODI in pre-symptomatic spinal cord tissue of SODI G93A led to its 
sequestration in high molecular weight inclusions at the mitochondrial surface, which likely 
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depleted its antiapoptotic function contributing to disease pathogenesis (Pasinelli et al., 2004). 
However, the contribution of intramitochondrial mutant SODI to disease remains 
controversial since recent reports demonstrate that high hSODl expression rates can cause 
artificial loading of mitochondria and abnormalities (Bergemalm et al., 2006) that might not 
occur in animal models offALS caused by a lower expression of mutant SODI (also refer to 
Section 1.1.5.1) 
1.2.3 The Glial Response in ALS 
1.2.3.1 Implications of Cellular Neighborhood 
Two independent studies demonstrated that transgenic animaIs expressing mutant 
SODI driven by the neuronal promoters ofNF-L (Pramatarova et al., 2001) or Thy1.2 (Lino 
et al., 2002), or by the astrocytic promoter GF AP (Gong et al., 2000) failed to develop motor 
neuronal disease and lacked developmental abnormalities. These studies strongly indicate that 
interplay between motor neurons and other cells in the region might be essential for ALS 
pathogenesis. Further evidence of this multicellular involvement came from a study where 
chimeric mice were composed of both normal cells and cells expressing mutant SODI in 
different mixtures in the spinal cord. This study demonstrated that motor neurons expressing 
high levels of mutant SODI survive much longer when surrounded by a wild-type glial 
environment than when mutant SODI is ubiquitously expressed. Recently, selective 
inactivation of the mutant SOD 1 gene in microglia and motor neurons of SOD 1 G37R mice with 
Cre-Lox recombination demonstrated that diminishing mutant SOD 1 in motor neurons slowed 
down the onset of the disease but did not affect significantly its progression, whereas 
reduction of mutant SOD 1 specifically in microglia did not affect disease onset, but slowed 
down the disease progression (Boillee et al., 2006). These results led the authors to propose 
that the initiating phase of fALSI is caused by mutant SODI damage within motor neurons, 
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and a mechanistically divergent later phase encompassing the progression to complete 
paralysis is linked to the inflammatory response of microglia and mutant toxicity within these 
cells. 
1.2.3.2 Microglia and the Inflammatory response 
These studies underline the importance of the glial response in ALS disease 
progression. Astrocytes participate by clearing glutamate levels in the synaptic cleft and 
releasing trop hic factors, but when astrocytes become reactive, a phase characterized by high 
levels of OF AP expression, they can damage neurons (Barbeito et al., 2004). However, as 
indicated above, the most important players in the glial response are microglia. Damage to the 
CNS activates microglia which release cytotoxic and inflammatory substances that further 
damage neuronal cells. Dying motor neurons can release substances that activate microglia 
which in tum release cytotoxic and inflammatory substances causing a further augumentation 
of neuronal damage (Bruijn et al., 2004). Microglial and astrocytic activation and proliferation 
have been demonstrated in spinal cord of ALS patients and are an early event in mutant SOD 1 
pathogenesis in lumbar spinal cord of transgenic mice (Figure 4) (Alexianu et al., 2001; 
Sargsyan et al., 2005). AIso, levels of pro-inflammatory factors (TNFa, IFNy, COX2) are 
highly up-regulated early and specifically in spinal cord tissue of SODIG93A transgenic mice 
(Hensley et al., 2003). The glial response and the resulting neuroinflammation might 
contribute to fALS pathogenesis and pharmaceutical treatments to reduce this response are 
currently being investigated (Refer to Section 1.3 and Table 2). 
1.2.4 Abnormalities in Intermediate Filaments Organization 
Proper neurofilament (NF) organization is essential for axonal transport and motor 
neuronal homeostasis. Abnormal organization resulting in NF accumulation is a common 
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pathological hallmark in affected tissue from sporadic and fALS patients (Carpenter, 1968; 
Hirano et al., 1984). Further research highlighted the important role of NF organization in 
ALS pathogenesis including discovery of deletion and insertion mutations in the heavy NF 
(NF-H) gene in sporadic ALS patients (Figlewicz et al., 1994; Tomkins et al., 1998) 
suggested that disruption of normal NF function is an important part of ALS pathogenesis. 
This theory was supported by experiments in which overexpression ofhuman NF-H subunits 
led to a six-month extension of lifespan in an SODI G37R model. (Couillard-Despres et al., 
1998). AIso, dominant mutation in the light NF (NF-L) genes are a primary cause of the 
motor neuropathy in Charcot-Marie-Tooth disease (Type II) (De Jonghe et al., 2001). These 
studies highlight that proper NF assembly is a contributor as weIl as a probable risk factor for 
ALS (Bruijn et al., 2004). However, a recent study failed to link NF mutations to sporadic 
and/or fALS, which implied that NF assembly and organization might not be a significant 
primary cause of ALS (Garcia et al., 2006). 
Peripherin, an intermediate filament prote in expressed during spinal motor neuronal 
development also may contribute to ALS pathogenesis (Robertson et al., 2002). Peripherin 
and NF expression were detected in the majority ofaxonal inclusions of ALS patients (Corbo 
and Hays, 1992). Overexpression of a splice variant, peripherin 58, in motor neurons was 
found toxic in transgenic mice (Beaulieu et al., 1999). AIso, expression of peripherin 61 at 
low levels in primary cultured motor neurons was found to be highly toxic (Robertson et al., 
2003). Peripherin 61 was also detected in lumbar spinal cord of ALS patients but not in 
controls (Robertson et al., 2003). Frameshift mutations as weIl as a missense mutation of the 
peripherin gene have been discovered in a few sporadic ALS patients (Gros-Louis et al., 
2004; Leung et al., 2004). However, since eliminating or overexpressing peripherin did not 
change the pathophysiological course of the disease in SODIG37R mice, its role in disease 
pathogenesis has come under question (Lariviere et al., 2003). Further studies are required to 
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clarify the contribution of specifie splice variants and the factors that promote production of 
toxic isoforms. 
1.2.5 Prote in Mis(Olding in ALS 
Many reports have demonstrated that genetic mutations and post-translational 
modifications cause proteins to misfold. In neurodegenerative disorders as well as 
physiological aging, prote in misfolding is enhanced. Accumulating evidence demonstrates 
that cellular failure to clear these abnormal proteins might be a determining step in ALS 
pathogenesis. Research is striving to better understand the pathogenic proteins that might 
trigger disease, the events that might contribute to misfolded protein accumulation, as well as 
the possibility of enhancing the physiological responses of neurons to rid themselves of 
misfolded proteins. 
1.2.5.1 Evidence of Protein Insolubility and Aggregation 
Whereas SOD 1 WT is for the most part a soluble enzyme, disease-causing mutant 
proteins can be isolated in three different biochemical states: soluble in nonionic detergent, 
nonionic detergent-insoluble/SDS-soluble (up to 10%), and SDS-insoluble polymers (see 
Figure 6) (less than 0.5%) (Johnston et al., 2000), (Shinder et al., 2001) and (Wang et al., 
2002). Large aggregates can be trapped by passing tissue homogenates through filter traps 
(Wang et al., 2002) and visualized as inclusions by immunohistochemical labeling of tissue 
sections or transfected cells (Shibata et al., 1996b), (Bruijn et al., 1997), (Wang et al., 2002) 
and (Watanabe et al., 2001). In transgenic mice, the amount of insoluble and high molecular 
weight mutant SODI is highest in tissue most vulnerable to disease, suggesting that cells in 
the se regions process the mutant protein differently or inefficiently (Johnston et al., 2000), 
(Wang et al., 2002), (Kabashi et al., 2004) and (Wang et al., 2005a). Similarly, the propensity 
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of mutant SODI to form aggregates visible by microscopy depends on the cell type. The 
selective vulnerability of motor neurons manifests itself in culture, mutant SODI forming 
inclusions in motor neurons of spinal cord cultures following gene transfer, but not in dorsal 
root ganglion or hippocampal neurons (Durham et al., 1997). In various cell lines, treatment 
with proteasomal inhibitors (Johnston et al., 2000) promotes the formation of these inclusion 
bodies. Even mutant SOD 1 that is immunolabeled diffusely may be in the form of small 
oligomers rather than the normal dimeric structure of SODIWT (Matsumoto et al., 2005), 
consistent with a significant fraction of the protein being detergent-insoluble even in the 
absence of distinct inclusions (Shinder et al., 2001). This evidence points to the essential role 
that prote in insolubility and aggregation plays in the pathogenesis of ALS. 
Whereas there is evidence that inclusions may protect cells from accumulated 
misfolded prote in rather than being inherently toxic, they do reflect failure of the proteolytic 
system to rid cells of potentially harmful proteins (Kopito, 2000). In the case of mutant 
SODl, there are many studies in which inclusions served as a marker oftoxicity, although this 
by no means demonstrates they are the cause of toxicity: the load of prote in aggregates 
correlates with motor neuron dysfunction in a transgenic mouse model (Wang et al., 2005a); 
cultured motor neurons with inclusions develop DNA fragmentation and chromatin 
condensation (Durham et al., 1997); loss of viability correlates with formation of mutant 
SODI inclusions (Durham et al., 1997), (Johnston et al., 2000), (Matsumoto et al., 2005), and 
(Ghadge et al., 2006), and treatments that reduced formation of inclusions prolonged viability 
of mutant SODl-expressing motor neurons (Bruening et al., 1999) and (Durham et al., 1997) 
and neuro-2A cells (Takeuchi et al., 2002). On the other hand, survival of differentiated PC12 
cells transduced with mutant SOD 1-YFP adenoviral vectors did not correlate with inclusions 
(however, aggregation of SODIWT was also observed in the study) (Lee et al., 2002), and 
targeting mutant SODI to mitochondria induced cell death in the absence of cytoplasmic 
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inclusions, although oligomerization of mutant SODI in mitochondria was not excluded 
(Takeuchi et al., 2002). This is a complex issue that is influenced by the experimental 
paradigm (e.g., culture versus animal models, tagged versus untagged constructs, stable 
versus transient expression, exposure to additional stresses). Another issue that requires a lot 
of attention is which of these abnormal SODI forms (insoluble high-molecular weight 
species, filter-trap aggregates, proteolytic fragments, oligomers) is the most toxic to motor 
neurons. 
Application of more sensitive techniques to resolve smaller oligomeric forms of 
mutant protein in cells and tissues is needed in order to visualize the process of 
oligomerization during ALS progression, since these are the species considered most likely to 
be toxic in celllines (Mukai et al., 2005). 
1.2.5.2 Post-Translation Modifications 
Evidence points to a "toxic gain of function" conferring disease properties, with 
conformational abnormalities as the common property. Over 100 mutations in SODI cause 
disease, but have variable effects on enzymatic activity, and overexpression of SODI WT failed 
to cause ALS-like disease (Cleveland and Rothstein, 2001) and (Bruijn et al., 2004). Mutant 
SODI proteins in cells are catabolized by the proteasome (Hoffman et al., 1996), (Johnston et 
al., 2000), (Niwa et al., 2002) and (puttaparthi et al., 2003), and recombinant SODI mutants 
are good substrates for the 20S proteasome in vitro, particularly as metal deficient monomers 
lacking the intrasubunit disulfide bond (Di Noto et al., 2005). 
Studies of recombinant proteins in vitro or transfected cultured cells subjected to 
oxidizing conditions show that dimer destabilization (SODI functions as a homodimer) and 
polymerization of monomeric SODI are promoted by disease-causing mutations, 
demetallation, disulphide reduction, and oxidative modifications (Cardoso et al., 2002), 
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(Rakhit et al., 2002), (Rodriguez et al., 2002), (Tiwari and Hayward, 2002), (Urushitani et al., 
2002), (Elam et al., 2003), (Chung et al., 2003), (DiDonato et al., 2003), (Strange et al., 2003), 
(Rakhit et al., 2004), (Furukawa et al., 2004), (Zhang et al., 2004), (Hough et al., 2004), 
(Tiwari et al., 2005), (Antonyuk et al., 2005) and (Lindberg et al., 2005).Whereas these 
modifications alter solubility and promote aggregation in vitro, it is not known if the 
conformational alteration conferred by the mutation is sufficient to cause proteotoxicity in 
vivo or if other post-translational modifications contribute. In vivo, the major conformational 
changes ofSODl in affected tissues reported are oxidation, protein nitration and 4-hydroxy-2-
nonenal (HNE) modifications of amino acids (Pedersen et al., 1998), (Poon et al., 2005), 
(Perluigi et al., 2005) and (Casoni et al., 2005) and disulfide-reduced SOD 1 has been 
observed in the CNS ofmutant SODI transgenic mice (Jons son et al., 2004). 
1.3 Protein Quality Control Systems 
Many neurodegenerative disorders, including ALS, have in common the sequestration 
of aberrant proteins into inclusions leading sorne researchers to name these disorders as 
"proteinopathies". The identity of the constituent proteins and morphology of the inclusions 
are pathognomonic of the disease. Proteins within the se inclusions often are ubiquitinated, 
and prote in chaperones and proteasomal subunits also may be sequestered (Watanabe et al., 
2001), (Sherman and Goldberg, 2001), (Ciechanover and Brundin, 2003) and (Strong et al., 
2005). Most investigations of the role of the ubiquitin-proteasome pathway in ALS have been 
conducted using experimental models of the most common familial form of ALS due to 
dominantly inherited mutations Cu/Zn-superoxide dismutase (SODl) (Rosen et al., 1993). 
Inclusions containing mutant SODI are found in motor neurons and sometimes surrounding 
astrocytes of fALS patients (Shibata et al., 1996a) and (Kato et al., 2000) and transgenic 
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rodent models (Bruijn et al., 1997) and (Aoki et al., 2005), as well as in primary cultured 
neurons expressing several different SODI mutants (Durham et al., 1997). 
The ubiquitin-proteasome system performs many homeostatic functions within cells 
inc1uding nascent prote in folding, transport and degradation of proteins, signal transduction, 
cell growth and differentiation, and control of apoptotic pathways. The proteasome is also the 
major route for catabolizing misfolded proteins, preventing them from aggregating into 
insoluble complexes. Protein chaperones facilitate the restoration of functional protein 
conformation or target misfolded proteins for degradation. These pathways act in concert in 
ridding cells of unwanted proteins. 
Mutant proteins, inc1uding SOD-l, misfold acquiring a "toxic gain offunction", which 
in tum leads to exposed hydrophobie patches overloading two of the main cellular defense or 
"quality control" mechanisms for aberrant proteins, namely the prote in chaperones and 
proteasomes. The main cytosolic prote in chaperones, Hsp70 and Hsp90 attempt to refold the 
misfolded proteins. Proteins in this intermediate misfolded state that cannot be properly 
folded by chaperones are selectively degraded after being ubiquitinated by the 26S 
proteasomes (see Figure 1). They can also be degraded independently of ubiquitin and A TP 
via the 20S proteasome. In animal models, human neurological disorders and normal aging 
there is extensive evidence illustrating that dysfunction of both chaperone and ubiquitin-
proteasome systems could lead to neuronal failure and ultimately cell death (Carrard et al., 
2002; Hartl and Hayer-Hartl, 2002; Ross and Pickart, 2004; Ciechanover and Schwartz, 
2004). 
1.3.1 The role ofthe ubiquitin-proteasome system in protein turnover 
Proteasomes are barrel-shaped prote in complexes in the cytoplasm and nucleus 
responsible for degrading most non-vesicular proteins including short-lived regulatory 
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molecules, damaged (oxidized, glycated, nitrated, etc.), incompletely translated, and mutant 
proteins in cells (Baumeister et al., 1998) and (Sherman and Goldberg, 2001). The ubiquitin-
proteasome system works in partnership with molecular chaperones, highly conserved 
families of proteins important for prote in folding and transport. Various forms of cellular 
stress can promote conformational changes that can alter the function of a protein and 
promote aggregation with like or other proteins (Muchowski, 2002). Misfolding and 
aggregation are facilitated by molecular crowding in the intracellular milieu (Young et al., 
2004). Chaperones aid partially folded or unfolded polypeptides to revert to their functional 
conformation, preventing their interaction with inappropriate partners and aggregation 
(Hohfeld et al., 2001). They are also involved in various cellular processes inc1uding nascent 
folding, transport and degradation of proteins, as well as signal transduction, cell growth and 
differentiation, and preventing apoptosis (Jolly and Morimoto, 2000; Nollen and Morimoto, 
2002). The most studied chaperones are the constitutively expressed heat shock cognate 
proteins (HSCs) as well as stress-inducible heat shock proteins (HSPs) [e,g., 
Hsp70(68,n,73), 40, 60, 90 and 110; the small HSPs: heme oxygenase, ubiquitin, Hsp25/27, 
aB-crystallin; the glucose regulated proteins: Grp75,78,94] (parsell and Lindquist, 1994). 
They proteet cells by refolding or targeting abnormal proteins to the proteasome for 
degradation. HSPs are induced in response to a variety of stressful conditions (hyperthermia, 
oxidative stress, ischemia, calcium ionophore, trauma, exposure to toxic chemicals, mutant 
proteins, etc), a process termed the heat shock response. Cells that can mount a robust heat 
shock response are better positioned to survive the initial and subsequent insults. Figure 1 
summarizes the major pathways by which HSPs and proteasomes regulate protein degradation 
in cells. 
1.3.2 Targeting aberrant proteins to the proteasome for degradation 
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Although all HSPs have in common the ability to recognize and sequester misfolded 
proteins, HSP70 and HSP40, with associated proteins and ATP, have the capacity to refold 
proteins to their functional conformation (Fan et al., 2003; Macario and Conway, 2005). If 
proteins cannot be refolded, they are escorted to the proteasome for degradation. As a general 
princip le, proteins are targeted to the proteasome by polyubiquitination, a process whereby 
ubiquitinating enzymes catalyze the covalent attachment of a chain of at least four ubiquitin 
molecules (Ciechanover, 2005). Ubiquitin is adenylated and activated by binding of El 
(ubiquitin activating enzyme) in an ATP-dependent fashion, then transferred to an E2 
ubiquitin conjugating enzyme. Then, RECT domain or RING-finger motif-containing E3 
ligases mediate linkage of ubiquitin to lysinyl side-chains of the substrates (Hochstrasser, 
2006). Whereas only one mammalian El gene exists, hundreds of E3 ligases provide a degree 
of specificity to ubiquitination of thousands of prote in substrates (Ardley and Robinson, 
2005). Polyubiquitination is facilitated by E4 enzymes, including C-terminus of HSP70-
Interacting Protein (CHIP) (Hoppe, 2005). CHIP shuttles misfolded proteins from HSP70 to 
be degraded by the proteasome, inhibiting HSP70's refolding activity through N-terminal 
TPR motifs and facilitating ubiquitination of substrate through its V-box (ubiquitin-ligase) 
domain (Connell et al., 2001). CHIP promotes degradation of several disease-associated 
proteins including mutant SODI (Choi et al., 2004) and (Urushitani et al., 2004). 
Linkage of at least four ubiquitins via lysine 48 targets the substrates to the proteaseome; 
however, monoubiquitination, or lysine 63-linked ubiquitin chains do not target proteasomal 
degradation, but serve other functions inc1uding signaling, endocytosis, vesicular transport, 
prote in sorting and transcriptional regulation (Voges et al., 1999). The process of 
ubiquitination is reversed by deubiquitinating (DUB) enzymes (Wing, 2003). 
1.3.3 Proteasomal Structure 
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The 26S proteasome is a complex of approximately 2.5 MDa in size comprised of a 20S 
catalytic core and two regulatory subunits that recognize and unfold substrates (Baumeister et 
al., 1998). The 20S proteasome is a cylindrical unit consisting of 28 subunits (14 gene 
products), arranged as four heptameric staggered rings. The two outer rings contain the 
structural a subunits (al- a7), while the two inner rings contain two copies of the ~-subunits 
(~1- ~7), three of which (~1, ~2 and ~5) harbour the six active sites (Kloetzel, 2001). ~5 
cleaves preferentially after hydrophobic residues [chymotrypsin-like activity], ~2 after basic 
residues [trypsin-like activity], and ~1 after acidic residues [caspase-like activity, a.k.a. 
peptidyl-glutamyl peptide hydrolase (pGPH)] as illustrated in Figure 2. Sorne of the ~ 
subunits are transcribed as proforms and need to be cleaved during the assembly process in 
order to be functional (Gaczynska et al., 1996). The assembly of the mammalian 20S 
proteasome is not weIl understood, but appears to be mediated by POMP or protoassemblin 
and Hsc73 (Kruger et al., 2001) and (Heink et al., 2005). Recently, two chaperones, PAC1 
and PAC2, were identified that associate with proteasome precursors and promote 
proteasomal maturation (Hirano et al., 2005). The 19S is composed of 18 different subunits 
and is responsible for recognizing ubiquitinated substrates, unfolding them and chaperoning 
them towards the proteolytic cavity (DeMartino and Slaughter, 1993). In yeast, the molecular 
chaperone, Hsp90, plays an important role in assembly of 20S and 19S complexes and 
maintenance of the resulting 26S proteasome (Imai et al., 2003). 
In addition to general prote in degradation, a key function of proteasomes is to generate 
peptides for antigen presentation by MHC class 1. The cytokines LPS, TNF-a, and/or IFN-y 
induce expression of three altemate cata1ytic subunits, 135i, 132i, I3li and components of a 
different regulatory subunit, Il S, also known as PA28 (Stohwasser et al., 2000). The 
inducible subunits replace the constitutive counterparts forming another complex known as 
the immunoproteasome (Rivett et al., 2001).Various intermediate/hybrid subtypes of 
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proteasome also have been isolated including 20S core alone (Shringarpure et al., 2001), 20S 
associated with one 19S and one Ils subunit (Tanahashi et al., 2000), (Kopp et al., 2001) and 
(Cascio et al., 2002) and 26S proteasomes with different ~ subunits. Differences in subunit 
composition correlate with different hydrolytic activity, the initial cleavage site used and the 
peptide products generated. Although ubiquitination is the major signal for proteasomal 
degradation, the 20S proteasome is able to break down proteins in the absence of regulatory 
particles, particularly oxidatively damaged proteins (Grune et al., 1997). 
1.3.4 Regulation ofproteasome gene transcription 
In comparison to regulation of immunoproteasome subunits, the molecular 
mechanisms regulating constitutive and stress-induced expression of proteasome subunits in 
mammalian cells are less well understood. In yeast, coordinated regulation of genes encoding 
components of the proteasomal and ubiquitin systems is achieved through binding of the 
transcription factor Rpn4 to a common proteasome-associated control element (PACE) 
(Mannhaupt et al., 1999) and (Xie and Varshavsky, 2001). Rpn4 regulates proteasome gene 
expression through a negative-feedback loop. The transcription factor is itself a proteasomal 
substrate, accumulating when proteasome levels are insufficient, and being quickly degraded 
when activity is restored (Xie and Varshavsky, 2001) and (Fleming et al., 2002). No homolog 
of Rpn4 or its DNA-binding element has been identified in the mammalian genome. 
However, indirect antioxidants stimulate transcription of numerous genes encoding 20S, 19S 
and Il S proteasomal subunits, in addition to antioxidantldetoxifying enzymes, through the 
antioxidant response element (ARE), an action dependent on the Keapl-Nrf2 signaling 
pathway (Kwak et al., 2003a) and (Kwak et al., 2003b). The transcription factor Nrf2 is 
negatively regulated by binding to Keapl in the cytoplasm (Motohashi and Yamamoto, 2004) 
and (Nguyen et al., 2004), which also promotes its degradation by the ubiquitin-proteasome 
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system (UPS). Thus, like Rpn4 in yeast, Nrf2 is maintained at low levels under low stress 
conditions by proteasomal degradation (Nguyen et al., 2003). Upon exposure to xenobiotic 
electrophiles generated by xenobiotic or physiological stress, Nrf2 is released from Keapl, 
translocates to the nucleus and initiates transcription of a variety of stress response genes 
including phase II detoxifying enzymes and proteasomal subunÏts. Peroxisome proliferators 
also increase expression of proteasome genes, but independent of Nrf2 (Anderson et al., 
2004), indicating that proteasome levels can be altered through multiple pathways. Recently, 
Zif268was identified as a repressor of transcription of sorne proteasomal subunits (James et 
al., 2006). Although in yeast, the major heat shock transcription factor (Hsfl) influences 
expression of ubiquitin-proteasome subunits (ubiquitin, an E3 ligase, and a ubiquitin 
conjugating enzyme) (Hahn et al., 2004), HSFI does not appear to regulate proteasome genes 
or activity in mammalian cells (Taylor et al., 2005). 
1.3.5 Methods o(measuring proteasomal activity 
Distinct catalytic activities have been assigned to each of the three active ~-subunits and 
can be measured in cellltissue homogenates using fluorogenic peptide substrates specifically 
hydrolyzed by chymotrypsin-like (~5), trypsin-like (~2), and PGPHlcaspase-like (~1) 
activities (Arribas and Castano, 1990), (Keller et al., 2000a), (McNaught and Jenner, 2001) 
and (McNaught and Jenner, 2001). This technique measures the ability of proteasomes 
present in the tissue extract to catabolize an additional substrate load (fluorogenic substrates) 
and can be expressed relative to a housekeeping prote in in the sample (total proteasome 
activity) or to levels of specific proteasome subunits (specific activity). Proteolytic activity of 
both 20S core alone and 20S with regulatory particles attached (26S) is measured. The 
relative contribution to total activity will depend upon the abundance in the tissue and the 
method of tissue preparation; i.e., whether 26S remains intact or 19S/11 S detach. Addition of 
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glycerol and ATP to the buffer preserves the interaction of 20S core with regulatory particles 
(Elsasser et al., 2005). 
To obtain measures of proteasome activity in vivo, fluorescent reporter proteins have 
been constructed. Kopito's group coupled green fluorescent protein (GFP) to a short degron, 
CU [ACKNWFSSLSHFVIHL] (GFpU), which promotes its polyubiquitination and 
degradation by the 26S proteasome (Bence et al., 2001). Dantuma's group has constructed 
two different ubiquitin-tagged GFP substrates. The first construct, the 'N-end rule' substrate, 
Ub-R-GFP, in which the N-terminal arginine of GFP is recognized by the E3 Ubrl after 
cleavage by deubiquitinating (DUB) enzymes. In the second construct, UbG76V_GFP, an N-
terminally linked ubiquitin serves as the acceptor for polyubiquitination, but the G76V 
substitution prevents de-ubiquitination, thereby promoting efficient degradation (Dantuma et 
al., 2000) and (Lindsten and Dantuma, 2003a). All ofthese reporter proteins have short half-
lives because of their efficient degradation by the ubiquitin-proteasome pathway and 
accumulate when proteasome activity is inhibited; thus increase in GFP fluorescence is a 
measure of reduced ubiquitin-dependent proteasomal activity. Lines of mice carrying the 
UbG76V_GFP (Lindsten et al., 2003b) or GFP-CL1 (GFPdgn) (Kumarapeli et al., 2005) 
transgene have been generated to provide a readout of proteasome function in vivo. The 
ability to monitor proteasome function in individual cells without lysing tissue is more 
meaningful than having a measure of activity in homogenate. However, this in situ method is 
not completely straightforward. Only ubiquitin-dependent proteolysis is monitored (i.e., 26S 
activity) and the GFP reporter can itself aggregate and compromise chaperoning capacity if 
expression levels are too high (Link et al., 2006). The other issue is that rather high level 
inhibition of specific proteasome activity, as measured by fluorogenic substrates in 
homogenates, is required to observe substantial increase in GFP reporter fluorescence 
(Dantuma et al., 2000), (Lindsten et al., 2003b) and (Bennett et al., 2005). If such levels of 
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inhibition represent a threshold of function that is only compatible with life over the short 
term, the reporters may only monitor end-stages of pathogenesis. On the other hand, 
biochemical measures of proteasome activity do not provide sufficient information on 
functional impairment or cell type differences. A combined approach using both biochemical 
and in situ techniques is more informative. 
Native gel electrophoresis is useful to examine the subunit composition of proteasomes. 
Separation of 20S, 26S, precursors and unassembled subunits can be accomplished by the 2-D 
Coomassie-Blue native gel method; tissue lysates are run in the first dimension on Blue native 
gels, then gel strips are placed horizontally over denaturing SDS-polyacrylamide gels for 
separation of the complexes into subunits in the second dimension (Camacho-Carvajal et al., 
2004). The native gel electrophoresis method described by Finley and colleagues is enriched 
with ATP and glycerol and favours retention of the 26S complex (Eisasser et al., 2005). In gel 
activity assays using fluorogenic substrates provides a crude determination of the proteolytic 
activity in the tissue samples (Elsasser et al., 2005). These are powerful techniques to evaluate 
proteasome composition in small tissue samples. We are the fIfSt to use the native gel 
electrophoresis methods to determine proteasome assembly and composition in 
neurodegenerative disorders. 
1.3.6 Proteasome Impairment inALS 
1.3.6.1 Interaction ofmutant SODI with UPS components 
Inclusions in spinal cord of several mutant SOD 1 transgenic mouse models often are 
labeled by antibodies to members of the ubiquitin-proteasome pathway (Watanabe et al., 
2001). There is bipchemical evidence showing that mutant SODl, but not WT is poly-
ubiquitinated both in neuronal and non-neuronal cells and is subsequently degraded by the 
26S proteasome (Hoffman et al., 1996; Johnston et al., 2000; Urushitani et al., 2002; Niwa et 
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al., 2002). Several E3 ligases can poly-ubiquitinate mutant SODI in vitro. The E3 ligase, 
dorfin interacts with mutant SODI and its overexpression decreases mutant SODI toxicity 
(Niwa et al., 2002). Two other E3 ligases, CHIP and NEDLI also can interact with and 
ubiquitinate mutant SODI (Choi et al., 2004), (Miyazaki et al., 2004; Urushitani et al., 2004). 
Using microfluorometric imaging techniques.' Matsumoto et al showed stable association of 
transfected ~5i (LMP7) proteasomal subunits with mutant SODI inclusions in differentiated 
PCI2 cells (Matsumoto et al., 2005). 
1.3.6.2 Focal Dysfonction of the UPS inALS 
Collectively, these data show that mutant SODI, but not WT SODI proteins are 
catabolized by the proteasome and that biophysical species with altered solubility are 
precursors of larger inclusions. Under most circumstances cells are capable of handling 
mutant SOD 1 proteins sufficiently to prevent them from exerting toxicity and/or being 
sequestered into inclusions. Even motor neurons develop and function into adulthood. 
However, under circumstances of increased physiological or environmental stress or 
compromise of protective mechanisms with aging, the ubiquitin-proteasome pathway may 
become overloaded and impaired. This hypothesis was tested in these studies and an 
impairment of the proteasome activity was determined in our published studies (Kabashi et 
al., 2004), in in vitro and in vivo models offALS (Chapter 4). This impairment was associated 
with decreases in 20S ~ catalytic subunits (Chapter 5) but no transcriptional defects and 
complex malformation were observed. A similar impairment of the proteasome was 
determined in spinal cord tissue from sporadic ALS patients (Chapter 6). 
1.3.7 Rote of Prote in Chaperones in ALS 
1.3.7.1 Reduced prote in chaperoning activity 
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Protein chaperones also play major roles in maintaining protein quality control, 
working in complementary fashion with antioxidant enzymes and proteasomes. The capacity 
for both proteasomal prote in degradation and protein chaperoning are preferentially reduced 
in lumbar spinal cord of mutant SODI transgenic mice, but not in tissues resistant to disease. 
In two lines of SODI G93A SODI and SODIG85R transgenic mice, chaperoning capacity was 
reduced in the lumbar region of the spinal cord prior to the onset of symptoms (Bruening et 
al., 1999) and (Tummala et al., 2005). Why chaperoning activity is diminished is not known, 
but logically would involve increased load of misfolded proteins without increased levels of 
HSPslHSCs to maintain chaperoning function. The following evidence supports direct 
interaction: Hsp70 was detected in the insoluble fraction of spinal cord from SODI G93A, but 
not SODIWT, transgenic mice and in spinal cord cultures prepared from E13 SODI G93A mice 
(Shinder et al., 2001). Similarly, the small HSPs Hsp25 and aB-crystallin cofractionated with 
mutant SODI in a transgenic mouse expressing SODI with the four copper-coordinating 
histidines mutated (Wang et al., 2003). This could result from association with SODI or other 
misfolded proteins. Post-translational modification of Hsp70 by HNE has also been reported 
in the se mice and cou Id affect its chaperoning activity or solubility (Perluigi et al., 2005). 
AIso, HNE-modified proteins are potent inhibitors of the proteasome complex (Friguet and 
Szweda, 1997). Direct association of HSPs with mutant SODI is indicated by the presence of 
Hsc70 in inclusion bodies in spinal cord of G93A and G85R SODI transgenic mice 
(Watanabe et al., 2001) and by transient association ofHsp70 with mutant SODI inclusions in 
transfected cells (Matsumoto et al., 2005). Urushitani et al. reported transient association of 
HspIHsc70 with SODI and CHIP (Urushitani et al., 2004). However, Hsp70 was not detected 
in inclusion bodies from mutant SODI transgenic mice and was rare in ALS patients 
(Watanabe et al., 2001) and (Batulan et al., 2003). 
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1.3.7.2 Regulation of HSP gene transcription 
Eukaryotic expression of HSPs is mediated by binding and activation of heat shock 
transcription factors (HSF) to heat shock elements (HSEs) on HSP promoters (Morimoto, 
1998), (Voellmy, 2004) and (Westerheide and Morimoto, 2005). Environmental and 
physiological stresses activate transcription of HSP genes in mammals largely through Hsfl 
(Morimoto, 1998). In the most accepted mode l, Hsfl is sequestered in the cytoplasm bound to 
a multichaperone complex including Hsp90 and Hsp70. Upon stress, misfolded proteins 
compete for HSPs, releasing Hsfl to translocate to the nucleus and bind as a trimer to HSE in 
HSP promoters. Subsequent steps are required to activate Hsfl including phosphoryation of 
key residues in its regulatory domain, and release of inhibitory chaperone complexes 
(Morimoto, 1998), (Voellmy, 2004) and (Voellmy, 2005). Redox-dependent activation of 
HSF 1 through oxidation of cysteine residues could also promote trimerization and DNA 
binding (Ahn and Thiele, 2003). 
Another HSF, Hsf2, is an important developmental regulator (Rallu et al., 1997), but 
might also be involved in the heat shock response in association with Hsfl (Sistonen et al., 
1994). Like many transcription factors, Hsf2 is a proteasomal substrate and accumulates with 
proteasome inhibition (Mathew et al., 1998). Treatment of cultured motor neurons with 
proteasome inhibitors causes both nuclear accumulation of Hsf2 and expression of Hsp70 
(Batulan et al., 2003). It is not clear to what extent Hsf2 is responsible, but this pathway is 
potentially an alternative therapeutic target to enhance HSP production. 
1.4 Therapeutical Perspectives 
As described above, the development of transgenic animal models has increased the 
understanding of ALS pathophysiology. Various therapies have been proposed, tested and 
sorne of the pharmacological treatments proved quite effective in animal models. 
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Unfortunately, none of the se therapies has worked to increase lifespan and/or quality oflife in 
ALS patients. Since ALS is a multifactorial disease, a combination of pharmacological 
treatments that target various molecular pathways of ALS pathogenesis will be necessary in 
the future. Several potential candidates to treat ALS are listed below and a more complete 
analysis including fALS animal model used, age of animal when treatment started, as well as 
benefit in disease onset and progression of the se treatment is presented in Table 2. 
Treatment of SOD 1 G93A transgenic mice at disease onset with catalytic antioxidant 
manganese porphyrin significantly increased lifespan and improved motor function of these 
mice (Crow et al., 2005). Aiso Nrf2 activation by tert-butylhydroquinone (tBHQ) (Lee et al., 
2003) decreased SODI G93A astrocytic apoptosis and preserved motor neurons in co-cultures 
(Vargas et al., 2006). Nrf2 regulates transcription of phase II anti-oxidant enzymes, but also 
increases expression of subunits as well as the proteolytic activities of the proteasome (K wak 
et al., 2003); therefore this transcription factor might play an important role in increasing 
degradation of mutant SODI and decreasing its toxic gain of function. Several studies 
suggested that lowering excitotoxicity might be a determining step in motor neuron survival 
in ALS. However, treatments with riluzole (reduces glutamate toxicity and modulates AMPA 
receptors) and ceftriaxone (increases levels of the glutamate transporter, EAATI, in 
astrocytes, and limits excitotoxic effects of glutamate by taking up the neurotransmiiter into 
astrocytes) had moderate effect in increasing lifespan of SODI G93A transgenic mice (Gumey 
et al., 1996; Rothstein et al., 2005). AIso, pharmacological treatments that can reduce 
mitochondrial damage, such as Cyclosporin A, might be effective in ALS patients (Keep et 
al., 2001). Several agents that decrease CNS inflammation and/or microglial reactivity were 
tested in murine models of ALS (see Table 2). Minocycline (inhibitor ofmicroglia activation) 
and celecoxib (COX2 inhibitor) were found to be promising therapeutics in several mutant 
SODI transgenic mouse models, but do not seem to be effective in phase III ALS clinical 
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trials. Finally, delivery of IGFI and VEGF trophic factors selectively to the affected region 
(lumbar spinal cord) by viral vector injection at disease onset dramatically improved lifespan 
and motor function in SODI G93A transgenic mice by keeping motor neurons alive. Combined 
treatment using several of these agents that act in different pathways of ALS pathogenesis 
might increase their efficiency in clinical trials. AIso, non-pharmacological treatments, such 
as exercise and high fat diet, which have been found to be efficacious in the ALS murine 
model might help slow down ALS progression in patients. 
Over the last decade various pharmacological treatments that were found to be 
effective in animal models of fALS went into clinical trials but did not prove successful. 
Sorne of the major failures were usage of only one line of mouse to determine 
pharmacological bene fit (refer to Table 2) as weIl as non-repeatibility of the se published 
results from independent researchers (refer to http://www.als.net and unpublished lecture by 
Dr. Robert Brown Jr.). New strategies are required to discover novel pharmacological 
treatment for ALS patients that would include more rigorous animal studies of 
pharmacological therapies, generation of new animal models of fALS more suitable than mice 
for high-throughput drug research, and use of transgenic mouse models with low expression 
ofmutant SODI. 
1.4.1 Treating Prote in Misfolding 
1.4.1.1 Gene Inhibition Therapy in ALS 
The toxic gain of function hypothesis would indicate that inhibiting the action of 
mutant SODI in transgenic mice would alleviate ALS pathology. Indeed, studies from two 
groups demonstrated that retrograde lentiviral delivery of short hairpin RNAs that inhibit 
mutant SODI gene expression through intramuscular injection in SODI G93A transgenic mice 
dramatically preserved motor neuron viability and prolonged lifespan (Ralph et al., 2005; 
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Raoul et al., 2005). AIso, antisense oligonucleotides to human SOD 1 extend survival in 
SOD 1 G93A transgenic rats (Smith et al., 2006). Even though only 2% of ALS patients have 
SOD 1 mutations, gene therapy might help to decrease or boost expression of gene products 
that are involved in ALS pathogenesis. 
1.4.1.2 Up-regulating Prote in Cha perones inALS 
Over-expression of Hsp70 in cultured motor neurons significantly decreased mutant 
SOD1 toxicity (Bruening et al., 1999), although this chaperone alone did not significantly 
affect disease in transgenic mice (Liu et al., 2005). However, upregulation of multiple 
chaperones is more likely to have therapeutic bene fit. A combination of Hsp70 and Hsp27 
were more protective in combination than individually in dorsal root ganglion neurons 
transduced to express mutant SOD 1 (patel et al., 2005). Arimoclomol, a coinducer of heat 
shock gene transcription, improved hind 1imb muscle function, delayed motor neuron death, 
and led to a 22% increase in lifespan of SOD1 G93A transgenic mice (Kieran et al., 2004). In 
the primary culture model of fALS, co-expression of a constitutively active form of the major 
heat shock transcription factor, Hsfl, or treatment with geldanamycin (also known to activate 
Hsfl) dramatically induced expression of Hsp70 and Hsp40 and was highly protective 
(Batulan et al., 2003) and (Batulan et al., 2006). 
1.4.1.3 Targeting Protein Quality Control Systems 
Matching levels of protein chaperones and the ubiquitin-proteasome pathway to the 
substrate demand in times of stress is highly important to maintain homeostasis. Sorne cells, 
sorne tissues and sorne individuals do that better than others (Franklin et al., 2005). In models 
of familial ALS, both proteasome and chaperoning function are abnormal in the tissue most 
vulnerable to the disease process. Whether this is the case in familial and sporadic ALS 
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patients is under investigation in our laboratory. The broad spectrum capability for 
cytoprotection makes these pathways attractive as targets for therapy in ALS, and other 
neurodegenerative diseases. However, HSPs also can be toxic (NoIlen and Morimoto, 2002) 
and the mechanisms goveming their regulation at the transcriptional and post-transcriptional 
levels are highly complex. Similarly, a generalized increase of the proteasome activity in ALS 
might be detrimental since this pathway has been involved in muscle wasting conditions. 
Therefore, a better understanding of the specifie mechanisms of proteasome impairment as 
weIl as biogenesis, formation of the proteasome complex and transcriptional regulation of its 
subunits is needed. A better understanding of these mechanisms, development of treatments 
that upregulate these pathways in a coordinated manner, and use of preclinical test models 
that evaluate effectiveness of therapeutics in models that represent the cell types affected in 
the disease are encouraged. 
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Table t 
Animal models of fALSt 
Severallines of mutant SOD 1 transgenic mi ce and rats have been generated in the last decade. 
Motor neuron loss, glial reactivity, ubiquitin inclusion formation in motor neurons and 
astrocytes has been determined in most of these rnodels. The first line to be generated by 
Gumey still remains the rnost popular of these rnodels when rnechanisrns of pathogenesis as 
weIl as pharmaceutical treatrnents are tested. Mutant SOD 1 has also been overexpressed in 
other organisms, including Drosophila and Celegans where it produced a neuronal 
pathology. Table was modified from (Bendotti and Carri, 2004). 
Model Transgene Neurological Phenotype Disease Complete Reference 
Promoter Onset Paralysis 
MN Ubb Glial 
Loss Inclusion Re~onse 
Mouse SODt 
hSODllJ~jA Genomic + + + 91 136 (Chiu et al., 
(high copy G 1 H) (herni) 1995) 
hSODllJ~jA Genomic + + + 150 180-210 (Gumeyet 
(slow line G20) (herni) al., 1994) 
hSODl l14tlK Genornic + + + 140 169 Chang-
(hemi) Hong 
hSOD IlC"u1Vt1'1~\.l Genomic + N.D + 120-180 N.D (Wang et 
(herni) al., 2003) 
hSODl lJJ /K Mouse Prion + N.D + 301 336 (Wong et 
al., 1995) 
hSODl lJj /K. Genomic + + + 210 330 (Wang et 
(hemi) al.,2005b) 
hSODl lJ1S)K Genomic + N.D 240 255 (Bruijn et 
(herni) al., 1997) 
mSODllJ~tlK Genornic + N.D + 100 107 (Ripps et 
(hemi) al., 1995) 
hSODl lJJ .ltl,-. Genomic + + + N.D 240 (Wang et 
(herni) al.,2005a) 
hSODl lJJWI. Genomic 114 124 (Jonsson et 
(herni) al.,2004) 
Rat SODt 
hSODllJ~JA Genornic + + + 99 113 (Howland et 
(hemi) al.,2002) 
SODl l14tlK Genornic + + + 145 170 (Nagai et 
(herni) al.,2001) 
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Table 2 
List of pharmaceuticals and their success rates in animal models of fALSl 
Sorne of the most effective phannacological treatments and their effect in the survival of 
various ALS murine models are presented. Most of these treatments are tested at various 
stages in ALS patients. The results of sorne these drug trials can be viewed at 
http://www .alsa.orglpatientldrug.cfm. 
Treatment Disease Delivery Molecularl ALS St art of Lifespan Reference 
Mechanism Mode Cellular Murine treatment increase s 
Target model 
Minocycline Neuro- Diet Microglial G37R 36 out of 21 days (Kriz, 
inflammation Inhibition SOD 52 weeks Gowing, 
and Julien 
429-36) 
Celecoxib Neuro- Diet Cox2 G93A 4 out of 28 days (Drachma 
inflammation inhibitor SOD high 18 weeks n et al. 
copy 771-78) 
Arimoclomol Protein IP injection Hsp co- G93A 10 out of 23 days (Kieran et 
, 
Aggregation inducer SOD high 18 weeks al. 402-05) 
i copy 
IGF-1 Neuronal Intramuscular Motor G93A 13 out of 37 days (Kaspar et 
Apoptosis adenovirus neuron SOD high 18 weeks al. 839-42) 
injection trophic copy 
support 
VEGF Neuronal Lentiviral Motor G93A 13 out of 19 days (Azzouz et 
Apoptosis vector neuron SOD high 18 weeks al. 413-17) 
injection trophic copy 
support 
Cyclosporin Mitochondrial Intrathecal Mito G93A Hindlimb 12 days (Keep et 
A damage infusion penneability SOD high weakness al. 327-31) 
pore copy 
inhibitor 
Manganese Oxidative IP injection Peroxynitrite G93A 12 out of 24 days (Crow et 
porphyrin damage decomposer SOD high weeks al. 258-65) 
copy 
Riluzole Excitoxicity Diet Inhibition of G93A 7 out of 10-15 (Gumeyet 
glutamate SOD high 19 weeks days al. 147-57) 
re1ease copy 
Ceftriaxone Excitoxicity IP injection Inactivation G93A 12 out of 10 days (Rothstein 
ofGLT-l SOD high 18 weeks et al. 73-
copy 77) 
, Oxidized N euro filament Intramusclul Axonal H46R 10 out of 12 days (Chang-
1 galectin-1 accumulation ar injection regeneration SOD 23 weeks Hong et al. 
203-11) 
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Figure 1 
The role of protein chaperones and the ubiquitin-proteasome system (UPS) in 
maintaining protein quality control 
During polypeptide synthesis, HSPs act as chaperones to prevent inappropriate prote in-
protein interactions and assist nascent proteins in taking on and maintaining their functional 
conformation. Translational errors, genetic mutation or post-translational modifications 
promote misfolding of proteins, which can expose hydrophobic domains and lead to 
inappropriate interactions with like or other proteins. These protein aggregates have reduced 
solubility and tend to come together as insoluble inclusions. HSPs prevent aggregation by 
recognizing hydrophobic domains of misfolded proteins and sequestering them to be refolded 
(by Hsp70, Hsp40 and other co-chaperones in an ATP-dependent process) or targeted to the 
proteasome for degradation. Proteasomes also degrade abnormal proteins from the 
endoplasmic reticulum, and as such, ER stress also increases the substrate load of cytosolic 
HSPs and proteasomes. Neurotransmission also depends upon proteasome function. Not only 
is the UPS involved in turnover of glutamate receptors at the cell membrane, but 
glutamatergic neurotransmission promotes aggregation of mutant protein in a calcium-
dependent manner. Cells that maintain a balance between the levels of HSPs and UPS 
components and the substrate load will be better positioned to defend themselves. HSP gene 
transcription is regulated by a negative feedback system whereby the major transcription 
factor controlling heat shock gene transcription (Hsfl) is maintained in an inactive state by 
binding to a Hsp90 chaperone complex. When misfolded proteins compete for these 
chaperones, Hsfl can translocate to the nucleus and binds as a trimer to heat shock elements 
(HSE) of heat shock genes. DNA-binding is not sufficient to initiate transcription. Rather 
subsequent steps are required to activate Hsfl including phosphorylation and possibly 
dissociation of inhibitory proteins. Neurons, motor neurons in particular, have a high 
38 
threshold for activation of Hsfl, which can compromise their response to disease-related 
stresses. The major pathway identified in upregulation of proteasomal gene transcription is 
through antioxidant response elements (ARE) involving the Nrf2-Keapl pathway which also 
controls transcription of phase II antioxidant/detoxification enzymes. Nrf2 is sequestered in 
the cytoplasm by binding to Keapl, which also promotes its degradation by the UPS. 
Oxidative stress signaIs dissociation of the Nrf2/Keapl complex, permitting translocation of 
Nrf2 to the nucleus and initiation of gene transcription. (For references see text). 
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Figure 2 
Ubiquitination process, the structure of the proteasome and its proteolytic activities 
Ubiquitin is activated by the ubiquitin-activating enzyme, El and transferred to a ubiquitin-
conjugating enzyme, E2. REeT domain or RING-finger motif-containing E3 ligases mediate 
linkage of ubiquitin to lysinyl side-chains of the substrates. Successive conjugation of 
ubiquitin moieties to one another generates a chain of polyubiquitin bound to the target 
prote in substrate which serves as the binding and degradation signal for the downstream 26S 
proteasome. The substrate is degraded to short peptides, and DUBs release free and reusable 
ubiquitin. The proteasome is a large, multicatalytic protease that degrades polyubiquitinated 
proteins to small peptides composed of the 20S core partic1e that carries the proteolytic 
activities, and regulatory partic1e, 19S and/or Il S. The 20S is a barrel-shaped structure 
composed of four stacked heptameric rings, two identical outer rings composed of seven a. 
subunits, and two identical inner rings composed of seven ~ subunits, three of which (~1, ~2 
and ~5) harbour the six active sites. ~5 c1eaves preferentially after hydrophobie residues 
[chymotrypsin-like activity], ~2 after basic residues [trypsin-like activity], and pl after acidic 
residues [caspase-like activity, a.k.a. peptidyl-glutamyl peptide hydrolase (PGPH)]. The 19S 
is composed of 18 different subunits and is responsible for recognizing ubiquitinated 
substrates, unfolding them, chaperoning them towards the proteolytic cavity and opening the 
orifice in the a. ring of20S. For complete references see Section 1.2.6.2 and 1.2.6.3. 
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Chapter 2 Rationale and Specifie Aims 
2.1 Rationale 
Treatment with proteasomal inhibitors in cells expressing mutant SODI promotes 
insolubility and accumulation of the mutant protein, as weIl as formation of microscopically 
visible inclusions. There is also biochemical evidence that mutant SODI, but not SODI wr 
proteins are polyubiquitinated and rapidly degraded by the proteasomal machinery. Therefore, 
it would be logical that the presence of inclusions in cells affected in ALS would indicate 
compromise of proteasomal function; i.e., overload of the proteasome or reduced efficiency in 
degrading mutant SOD 1 and/or other substrates resulting in their accumulation and increasing 
the opportunity for aberrant protein interactions and aggregation into insoluble complexes. 
Moreover, impaired function of the proteasome, whether due to substrate overload or altered 
composition and/or assembly of proteasomal complexes (20S, 26S, immunoproteasome) 
could disrupt the proteolysis of other important cellular proteins that are crucial for cellular 
homeostasis including transcriptions factors, kinases, and caspases. This study set out to 
examine the role of the proteasome in FALS by testing the following hypothesis: 
2.2 Specifie Aims 
General Hypotbesis: Expression of mutant SODI and other misfolded proteins abrogates 
proteasomal function and contributes to fALS pathogenesis. 
Specifie Aim 1: To determine if levels, localization and proteolytic activities of the 
proteasome are impaired during disease pathogenesis in various affected and unaffected 
tissues from a murine model of fALS 
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Specifie Aim 2: To detennine mechanisms that lead to in vivo proteasome impainnent and 
consequences of proteasome dyfunction in a murine model of fALS 
Specifie Aim 3: To detennine if levels, localization and activities of the proteasome complex 
are affected in autopsy tissue from sporadic ALS patients 
2.3 Choiee of In Vivo Experimental Model 
In order to detennine the role of the ubiquitin-proteasome pathway in the pathogenesis 
of ALS, we have used the transgenic mouse line B6SJL-TgN(SODI G93A) IGur overexpressing 
a high copy number of the gene encoding human SOD 1 with the ALS-causing mutation, 
G93A, and the line overexpressing similar levels of human SODI WT as control, both 
expressed from the SODI promoter. This model offers several advantages. Since its 
generation over 10 years ago, hundreds of reports have been published using this model, 
characterizing the histological, biochemical, electrophysiological and behavioral phenotype. 
The highly reproducible time course of these changes pennitted us to analyze proteasomal 
activity and composition at well-defined stages of pathogenesis, to assess function in both 
vulnerable regions of the nervous system and in organs more resistant to mutant SOD 1 
toxicity, and to detennine if any dysfunction was an early event or occurred later in the 
disease as a consequence of neuronal damage and/or death. These data are presented in 
Chapter 4. 
Several mechanisms could lead to proteasome dysfunction, including direct inhibition 
ofthe proteasome by mutant SODI or other substrates, changes in subunit gene and/or prote in 
expression, and/or impainnent of the assembly of the proteasome complex. These results are 
presented in detail in Chapter 5. 
Finally, since only a small percentage of ALS is genetically inherited it is important to 
detennine the relevance of the prote in quality control systems to the disease in general, 
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particularly in sporadic ALS. The levels of proteasomal subunits as well as its proteolytic 
activities were assessed in autopsy tissue from ALS patients and age-matched non-
neurological cases. The results from these experiments are presented in Chapter 6. 
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Chapter 3 Materials and Methods 
3.1 Transgenic Mice 
AlI experiments were approved by the McGill University Animal Care Committee and 
followed the guidelines of the Canadian Council on Animal Care. Two lines of mice were 
used in this study. B6SJL-TgN(SODI G93A)IGur, transgenic for human SODI with the ALS-
associated mutation, G93A, and B6SJL-TgN(SODIWT)2Gur, transgenic for human SODIWT, 
which express similar levels of human SOD 1 prote in (DaI Canto and Gurney, 1995). These 
lines ofmice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and maintained 
in our animal facility (Montreal Neurological Institute). Mice hemizygous for the transgene 
were obtained by breeding hemizygous males with non-transgenic B6SJL females. Mice were 
genotyped for human SODI as previously described (Shinder et al., 2001) and litters 
including at least three transgenic and three non-transgenic littermates were used at P30, P45, 
P75 and at symptomatic stage (approximately PI20). SODI G93A transgenic mice were 
designated 'symptomatic' by positive hindlimb extensor reflex. Mice were euthanized by deep 
anesthesia with intraperitoneal injection of a mixture of 180 III ketamine and 20 III xylazine. 
Tissues from spinal cord and liver were collected, weighed, and placed immediately on ice. 
The lumbar enlargement (LI-VÙ and thoracic (TI-XIII) segments of the spinal cord as seen in 
Figure 3 were processed separately. 
3.2 Human Autopsy Tissue 
Post-mortem human tissue was obtained from Dr. Michael Strong, University of 
Western Ontario. Tissue was frozen at -80°C immediately after autopsy. Sufficient spinal cord 
tissue (100 mg - 1 g) for biochemical analysis from the cervical region and the thoracic region 
from 5 ALS patients and 4 controls was shipped in dry ice. Aiso cerebellar tissue from these 
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ALS patients and controls was shipped to serve as an internaI control for tissue that is not 
substantiaIly affected in the disease. ALS patients and control individuals were matched as 
closely as possible for age, sex, and postmortem interval to autopsy account; these data are 
presented in Table 3. Cross-sections of spinal cord were cut into ventral and dorsal sections 
and prote in levels and proteolytic activities of the proteasome were determined in individual 
sections of the spinal cord. AlI handling of human tissue was carried out using standard 
universal precautions according to biosafety guidelines and with an approved McGill 
University Biohazard Certificate. Spinal cord sections from adjacent areas of spinal cord of 
ALS patients as weIl as controls used for the biochemical analysis reported in Chapter 6 were 
fixed in 10% formalin overnight and the processing, embedding and sectioning of paraffin 
blocks was performed according to standard protocols in the Pathology Laboratory at the 
Robarts Research Institute (London, ON). Spinal cord sections were cut into 6 J.lffi thick and 
si ide mounted in order to determine motor neuron pathology as weIl as glial reactivity in these 
tissues. 
3.3 NIH-3T3 ceUs 
Clones of NIH 3T3 ceIl lines stably expressing human SOD-I WT or with the disease-
related mutations, SOD_I G93A or SOD_I G41S,were previously established (Bruening). SODI 
expression was determined by Western blotting and immunocytochemical analysis with 
appropriate human SODI antibodies (see Antibody section). CeIls were cultured in minimal 
essential medium enriched with 5 g/l glucose supplemented with 10% fetal calf serum and 
250 J.lg/ml of Geneticin (Invitrogen Corp., Grand Island, NY) for mutant Hnes and 700 J.lg/ml 
for wild type lines to maintain selection. Cells were used for experimentation at 80-100% 
confluency. Ce Ils were subcultured by trypsin-dissociation. 
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3.4 Tissue Preparation 
For proteasome activity assay and SDSIPAGE gel electrophoresis, tissue was 
suspended in TrislEDTA solution [20 mM Tris/ 2 mM EDTA, pH 7.5] at a concentration of 
0.1 g/ml (spinal cord) or 0.4 g/ml (liver), homogenized for 2 min using a Dinamix 
homogenizer (Fisher Scientific Co., Nepean, ON), aliquoted, flash frozen in liquid nitrogen 
and stored at -80 C in 100 JlI aliquots. For as say, samples were thawed on ice. Thirty minutes 
following addition of 5 Jlg DNase and 400 JlI TRISIEDTA, samples were sonicated for three 
10 sec cycles at 50% duty (Vibrocell, Sonics and Materials Inc., Danbury, CT), and 
centrifuged at 15400 x g for 10 min. Supernatants were collected for determination of protein 
concentration (DC prote in assays, BioRad Laboratories, Hercules, CA), proteasome activity 
assays, and Western blotting. Pellets were resuspended to original volume in TrislEDTA by 
trituration and vortexing and were washed three times with 0.1% Triton X in TrislEDTA 
solution and in 0.1 % SDS in TrislEDTA solution. In the final step, pellets were resuspended 
in saturated 10 M urea in 1/30 of the initial volume of TrislEDTA used to resuspend the tissue 
to determine and compare the levels of insoluble to soluble proteins. Tissue extracts were 
used only once after thawing, i.e., not refrozen. Preliminary Western blotting and proteasome 
activity assays indicated that approximately 90% of proteasome a-subunits and the three 
proteasomal activities were in the supernatant of symptomatic mutant SOD-l G93A and their 
age-matched LM spinal cord tissue. Therefore, supernatants were used in subsequent 
experiments and taken to be representative oftotal proteasome. 
A different buffer (50 mM Tris, pH 7.4, 10% glycerol, 5mM ATP, 5 mM MgCh) was 
used to homogenize tissue for native gel including A TP and glycerol in order to preserve the 
integrity of 26S proteasomes. Preliminary native gel experiments determined that flash-
freezing the samples in liquid nitrogen did not affect the composition and assembly of the 
proteasome, hence tissue was thawed in ice and loaded in gels. 
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For immunohistochemistry and laser capture for real-time (rt) PCR analysis of motor 
neuronal rnRNA, cervical, thoracic and lumbar segments of the spinal cord were embedded in 
Tissue-Tek frozen tissue embedding medium (OCT) (VWR Torrance, CA) on liquid nitrogen 
cooled 2-methylbutane (American Chemicals Ltd., Montreal, QC). The blocks were stored at 
-80°C. Frozen sections were cut using a Microm Mode 1 HM 500 M Cryostat (Microm 
International, Walldorf, Germany) as described below. 
3.5 Proteasome activity 
Assays were based on generation of the fluorescent species, amino methyl coumarin 
(AMC), from peptide substrates specific for individual 20S/26S proteasome hydrolytic 
activities as described previously (Arribas and Castano, 1990; Rock et al., 1994; Keller et al., 
2000a). Each assay was conducted in the absence and presence of proteasomal inhibitor 
[either 20 J.1M MG132 or 50 J.1M lactacystin, which gave indistinguishable results]. Assays 
were conducted in 96 weIl opaque plates using 50 /lI of tissue sample or cellline extracts and 
50 /lI of2X Proteasome Buffer [4 mM ATP; 10 mM MgCh, 8 mM dithiothreitol (DIT)]. To 
avoid experimental activation of 20S proteasomes, no SDS was included in any assay buffer. 
AIl samples were assayed in quadruplicate using 10 /lg of total protein with and without 
proteasomal inhibitor. Chymotrypsin-like, trypsin-like, and caspase-like activities were 
measured by adding 2.5 /lI of 1 mM Suc-LLVY-AMC peptide, Boc-LRR-AMC or Z-LLE-
AMC, respectively (peptide International Inc., Louisville, KY). Fluorescence of generated 
AMC was measured at intervals of 30 min for 3 hrs using a FX600 multiplate reading 
fluorometer (Bio-Tek Instruments, Ine., Winooski, VT). AlI assays were linear in this range. 
As a standard, free AMC was added to separate wells at the same concentration as in 
fluorogenic peptides. To convert AMC generated from peptide substrates to nmol of 
AMC/min/mg protein, values in fluorescence units/minlmg prote in were divided by 
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fluorescence units offree AMC measured at 150 min. To obtain total proteasome activity, this 
value was normalized to actin levels quantified on Western blots using enhanced 
chemifluorescence. A measure of specifie proteasomal activity was determined by subsequent 
normalization to the level of 20S proteasome core a subunits (see Western blotting and 
Antibodies below). Removal and initial processing of tissues from an entire mouse litter (n = 
4 ± 1 for transgenic and n = 4 ± 1 for LM) were carried out simultaneously. Similarly, aIl 
samples of lumbar and thoracic spinal cord from an entire litter were processed 
simultaneously in prote in assays, proteasomal activity assays, and Western blots. Liver tissues 
from SOD-l WT and SOD-l G93A transgenics and their respective LM for a given age group 
were processed and assayed simultaneously. Untransfected NIH 3T3 cell lines, and three 
clones stably expressing human SOD-lwT, SOD_I G93A and SOD_I G41S were assayed 
simultaneously. 
3.6 Gel electrophoresis 
3.6.1 SDS-PAGE/Western blotting 
SDSIPAGE gels with a separating dimension of 15% acrylamide and a stacking 
dimension of 4% were used in these experiments. Ten J.lg of total soluble protein was loaded 
in each lane. Gels were run until the blue colour of the Laemli loading buffer ran out of the 
gel. Gels were transferred to nitrocellulose membranes overnight at a constant voltage of 40 V 
at 4°C for low-weight proteins (10-30 kDa) and at 120 V for 3 hours for higher-weight 
proteins (30-100 kDa). 
3.6.2 2D-Coomassie/Blue Native Gel Electrophoresis 
The method of Blue native gel electrophoresis allows for two dimensional high-
resolution separation and identification of multi-protein complexes. In the first dimension, 
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multi-protein complexes are separated under native conditions. Each lane of the gel is cut and 
is run in a second dimension in the presence of SDS. This dimension allows further resolution 
of the components and subunits that compose multi-protein complexes according to their 
molecular weight. 
The method in Camacho-Carvajal et al. (2004) was used with few modifications to 
determine in vivo proteasome composition and assembly from spinal cord tissue extracts. 
Briefly, a continuous native acrylamide gradient gel (4-15%) was poured with no stacking gel. 
Tissue lysates containing 50-100 J.lg prote in were loaded in each lane and electrophoresed at 
100 V. Molecular weight markers were run on each gel (Thyroglobullin: 669 kDa; Ferritin: 
440 kDa; Catalase: 232 kDa and lower) (Amersham Biosciences, UK). When the blue front 
had run approximately 2/3 of the way through the gel, the cathode buffer was replaced with 
buffer lacking Coomassie blue and the power supply was interrupted when the front reached 
the bottom of the gel. lndividual lanes were excised using a sharp scalpel blade and 
equilibrated in 2X SDS Laemli Buffer with 5% ~-mercaptoethanol for 20 minutes, then 
washed 5 times with the same buffer without ~-mercaptoethanol. An individual strip was 
placed on top of a second-dimension SDS-PAGE gradient gel (4-15%) of the same thickness 
and run as previously described. 
3.6.3 ID-Native Gel Electrophoresis 
The methodology described in Elsasser et al. (2005) was followed with the few 
modifications listed below. The homogenization buffer was 50mM Tris, pH 7.4, 10% 
glycerol, wl ATP (5 mM) and MgCh (5 mM). Samples containing 50-80 mg of prote in were 
run on gels consisting of three layers of acrylamide (3, 4 and 5%) including rhinohide 
acrylamide gel strengthener (Molecular Probes) that preserves the integrity of low percentage 
acrylamide gels (Vemace et al. 2006). The gels were run at 110 V for 3 hours, then 
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transferred onto nitrocellulose membranes at 45 V overnight at 4°C. The resolving buffer used 
for making and running the gels was 90 mM Tris, 90 mM boric acid, pH 8.3 w/ ATP (1 mM), 
MgCh (5 mM) and EDTA (0.5 mM). Preliminary native gel experiments determined that 
flash-freezing the samples did not affect the composition and assembly of the proteasome, as 
long as A TP and glycerol are added to the samples prior to loading in the gel. 
3.6.4 Western Blotting and Analysis 
AlI gels (including the native gels) were transferred onto nitrocellulose paper at 4°C 
overnight at 45 V or for 3 hours at 120 V depending on the molecular weight of proteins 
being probed. Membranes were blocked in 3% bovine serum album in in TBS with 0.1% 
Tween20, probed with primary antibodies and secondary antibodies corresponding to the 
species the primary antibodies were raised. Western blots were exposed to Western Lightning 
chemiluminescence reagents (perkinElmer, Boston, MA) or SuperSignal West Femto 
substrates (pierce, USA) and exposed on Kodak Film. The films were scanned as high-
resolution images and the bands corresponding to the appropriate molecular weight of the 
protein were quantified using Scion Image (NIH) software. Three to four mice were used for 
each of the following groups: SODIG93A mice and their non-transgenic littermates (GLm), 
SODI WT mice and their non-transgenic littermates (WLm). Every Western blot was repeated 
twice for each of the proteasomal subunits and reprobed for actin which was used as loading 
control. Protein levels for each experimental condition (groups of mice) were normalized to 
actin levels and were quantified as means ± standard error of means (SEM). A two-tailed 
distribution, two-sample equal variance t-test was used to assess significant difference 
between the actin-normalized ratios of SODI G93A mice and each of the other three 
experimental groups. 
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3.7 Immunohistochemistry 
Twenty J.ll11 cross-sections of murine spinal cord were fixed in 3% paraformaldehyde 
in phosphate buffered saline (PBS), pH 7.3 for 30 min, permeabilized in 0.5% Nonidet-
P40IPBS for 5 min, and further fixed in 3% paraformaldehyde for 2 min. Sections were 
blocked in 3% bovine serum albumin (BSA) for 3 hr at room temperature, then in AffiniPure 
FAB fragment anti-mouse IgG H+L (Jackson ImmunoResearch Laboratories Inc.,West Grove, 
PA) for 30 min. Primary antibody in blocking solution was applied ovemight (15-17 hr at 
4°C) and secondary antibodies were applied for 1 hr at room temperature. Antibody labeling 
was visualized using Vectastain ABC (Vector Laboratories Inc., Burlingame, CA) with 3,3'-
diaminobenzidine tetrahydrochloride dihydrate (lCN Biomedicals Inc., Irvine, CA) as 
substrate. 
3.8 Real-Time PCR 
3.8.1 Laser Capture Microdissection (LCM) 
Ten J.ll11 cryostat sections of mouse lumbar or cervical spinal cord were placed on 
LCM microslides (Arcturus, Mountain View, CA) and immediately placed in a slide box on 
dry ice. Unless immediately processed, the slides were stored at -80°C. For LCM, selected 
slides were thawed for 30s, hydrated by sequential immersion into 75%, 50% ethanol and 
DEPC treated water for 30s, stained with 1 % cresyl violet acetate for Imin. Slides were then 
dehydrated by sequential immersion into 50%, 75%, 95% and 100% ethanol. Finally the 
slides were cleared in xylene twice for 3 min eachand air-dried. Using a PixCell II Laser 
Capture Microdissector (Arcturus, Mountain View, CA) according to manufacturer 
instructions, motor neurons were captured onto CapSure HS LCM caps using the laser spot 
size of 7.5 J.ll11 diameter. Motor neurons were identified as the large cresyl violet stained 
neurons in the ventral hom of the spinal cord section. 
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3.8.2 RNA Isolation and Reverse Transcription 
Microdissected motor neurons were immediately processed using the PicoPure RNA 
isolation Kit (Arcturus, Mountain View, CA). Approximately 50 microdissected cells were 
collected onto each LCM cap. 20 III of extraction buffer were placed into the LCM 
cap/ExtracSure/0.5 ml microcentrifuge tube assembly and incubated for 30 min at 42°C. After 
incubation, total RNA was extracted according to instructions and treated with DNase. 
Reverse transcription was performed using iScript cDNA Synthesis kit (Bio-Rad, Hercules, 
CA). Briefly, 4 III of 5x iScript Reaction Mix, 1 III of iScript Reverse Transcriptase and total 
RNA template were included in a final volume of 20 Ill. Reaction conditions were 5 min at 
25°C, 30 min at 42°C, and 5 min at 85°C. 
3.8.3 SYBR Green Rea/-rime peR 
AlI rt-PCR reactions were carried out in 96-well 0.2 ml PCR plates sealed with iCycler 
Optical Sealing tapes (Bio-Rad, Hercules, CA, USA). PCR was performed using cDNA from 
laser captured motor neurons and the primers for mouse 20S ~3 (PSMB3 - PCR product 289 
bp), 20S ~5 (PSMB5 - PCR product 202 bp), 20S ~5i (LMP7 - PCR product 82 bp), 20S (1.7 
(PSMA3 - PCR product 168 bp), and GAPDH (see Table 4). The PCR reactions contained: 
IX SYBR Green iCycler iQ mixture (Bio-Rad, Hercules, CA, USA), 0.2 JlM of each forward 
and reverse primer and cDNA preparation in a 25 III total volume. Amplification and 
fluorescence detection were performed using iCycler iQ Real-time Detection System (Bio-
Rad, Hercules, CA, USA). The PCR amplification profile was: 95°C for 5 min, 45 cycles of 
denaturation at 95°C for 30 s, annealing at 58°C for 1 min, and extension at noc for 30 s, 
followed by noc for 5 min. At the end of the PCR, melting curves were obtained from 46 
subsequent temperature increments, by measuring fluorescence every 10 s with +0.5°C/step 
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increments and beginning at noc. The quality of PCR products was determined by melting 
curves analysis. The fluorescence threshold value (CT) was calculated using iCycler iQ 
system software and the levels were normalized to values obtained for GAPDH. A 
nontemplate control (NTC) was run with every assay. 
3.8.4 Primer specificity 
PCR was performed by cDNA from laser captured motor neurons and whole tissue 
with specifie primers for mouse 20S ~3 (PSMB3 - PCR product 289 bp), 20S ~5 (PSMB5 -
PCR product 202 bp), 20S ~5i (LMP7 - PCR product 82 bp), 20S a7 (PSMA3 - PCR product 
168 bp), and GAPDH. For the primer sequence refer to Table 4. The results from rt-PCR 
quantitation were expressed as means ± SEM. 
3.9 Antibodies 
Primary antibodies used for immunohistochemistry (IH), immunofluorescence 
microscopy (IF) and Western blotting (WB) were: rabbit anti-GFAP (Z0334 Dako Corp., 
Mississauga, ON. IH 1 : 1000); rat anti-MAC-l (a kind gift from Dr. Samuel David. IH 1 : 
10); mouse anti-SOD-l (SD-G6 Sigma-Aldrich Co., St. Louis, MO. IH 1 : 5000); mouse anti-
actin (clone C4 ICN WB 1 : 10000); mouse anti-neurofilament 68Kd (NF-L; clone NR-4 
ICN; IH 1 : 200); mouse antibody to ubiquitinated (mono and poly) proteins (clone FK2 WB 
1 : 2000, IH 1 : 100); and mouse antibody to 20S proteasome subunits al,2,3,5,6&7 (clone 
MCP231; WB 1 : 2500, IH 1:50) ~3 (clone HCI0) (1 : 100 IHC; 1 : 3000 WB); polyclonal 
antibodies to ~5i (LMP7 (1 : 100 IHC; 1 : 2000 WB), 19S5a (1 : 3000 WB), 19S6b (1 : 2000 
WB), and USa, all from Biomol (Plymouth Meeting, PA). Monoclonal antibody to Hsp70 
(clone SPA810) (1 : 1000 WB), rabbit polyclonal to Hsp40 (SPA400) (1 : 5000 WB), and 
polyclonal antibody to SOD 1 (SOD 1 00) (1 : 3000 WB) were obtained from Stressgen 
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Biotechnologies (Ann Arbor, Michigan). Monoclonal antibody to actin was purchased from 
ICN (Irvine, CA) (l : 10000 WB). Mouse monoclonal antibody (clone 6C5) to GAPDH 
antibody was a kind gift from Dr. Peter McPherson (l : 500 IHC). 
Secondary antibodies were: Alexafluor-conjugated anti-rabbit, anti-mouse, or anti-rat 
IgG(H+L) (Molecular Probes Inc., Eugene, OR. 1 : 100) for IF; biotinylated anti-rabbit or 
anti- mouse IgG(H+L) (Vector; 1 : 100) or anti-rat IgG(H+L) (Jackson; 1 : 100) for IH; anti-
rabbit or anti-mouse IgG(H+L) conjugated to horseradish peroxidase (Dako; 1 : 3000) or 
fluorescein (Amersham; 1 : 1000) for WB. 
3.10 Immunoprecipitation 
Immunoprecipitation experiments were performed as previously described (Shinder et 
al., 2001). Briefly, 3 III ofSOD-l antibody (SOD-I00) was added to 400 Ilg of total prote in 
from soluble tissue extracts and incubated at 4°C overnight on a rotating platform. Immune 
complexes were captured on 40 III of protein G-Sepharose, 4 Fast Flow (Amersham 
Pharmacia Biotech) by incubation on a rotating platform at 4°C for 3 h; the beads were 
washed with lysis buffer, resuspended in 30 III of 1 x sample buffer, and boiled for 5 min. The 
beads were pelleted, half of the supernatant was electrophoresed on a 12.5% SDS-
polyacrylamide gel, and immunoprecipitated proteins were detected by Western blotting. 
3.11 Statistical Analysis 
The results from Western blots, proteasome activity assays and rt-PCR quantitation 
were expressed as means ± SEM. To determine statistical significance, a two-tailed 
distribution, two-sample equal variance t-test was performed using Microsoft Excel and 
SigmaPlot softwares. 
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Table 3 
Autopsy time, age and sex of sporadic ALS patients and control cases and the tissues 
obtained 
Tissue was obtained from Dr. Michael Strong bank at the Robarts Research Institute in 
London, ON. Tissue was shipped frozen and processed as described in Chapter 3. 
ALS Patient I.D. Sex Age Time of autopsy Tissue obtained 
98-A027 M 50 Same day Thoracic S.C, Cerebellum 
00-A183 F 52 NID Thoracic S.C, Cerebellum 
00-A41O M 72 Same day Thoracic S.C, Cerebellum 
00-A417 F 38 10'10" Thoracic S.C, Cerebellum 
01-A217 M 68 3'30 Thoracic S. C, Cerebellum 
Control cases I.D. 
93-A062 M 71 14'30" Thoracic S.C, Cerebellum 
94-A190 F 82 15'45" Cervical S.C, Cerebellum 
96-A146 M 58 15' Cervical S.C, Cerebellum 
99-A071 F 72 19'40" Thoracic S.C, Cerebellum 
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TABLE 4 
Primer sequence for genes en co ding proteasomal subunits used to determine mRNA 
levels by rt-PeR. 
These primers were obtained from the literature in studies that measured mRNA levels of 
r 
murine proteasomal subunits. The rest of the prim ers were designed by Yu Hong at the 
University of Michigan Ann Arbor. 
G N ene ame p. s nmer equence P d ro uct R~ e erence 
PSMB3 TTCAGCGTCCTGGTGGTGAT 289bp 
Forward 
PSMB3 ACAGAGCCTGTCATTGCTGG 
Reverse 
PSMB5 GCTGGCTAACATGGTGTATCAT 202 bp Kwak et al. 
Forward 2003 
PSMB5 CACTTTCAGGTCATAGGAGTAGCC 
Reverse 
LMP7 AGGAGTCGTCAACATGTACCACA 82 bp Allen et al. 
Forward 2004 
LMP7 ACTTGTACAGCAGGTCACTGACATC 
Reverse 
PSMA3 TAGGTCCAACTTCGGCTATAACA 168 bp 
Forward 
PSMA3 GATGGGTCGATCATATAGAGCTG 
Reverse 
GAPDH AGTATGTCGTGGAGTCTACTGGTG 152 bp 
Forward 
GAPDH TGAGTTGTCATATTTCTCGTGGTT 
Reverse 
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Lumbar and thoracic spinal cord segments in mice Spinal cord was obtained after careful 
dissection and spinal cords were cleaned from the ventral and dorsal roots and only the spinal 
cord tissue was used for further experimentation. Tissue was cut in three different places as 
indicated in the figure. The lumbar and thoracic sections of each mouse were processed 
separately in our biochemical analysis of the ubiquitin-proteasome pathway. 
Figure 3 
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Chapter 4 Focal Proteasome Impairment Plays a Critical Role in 
Pathogenesis of a Murine Model of ALS 
This chapter reports results of experiments to test Specific Aim 1: To determine if 
levels, localization and proteolytic activities of the proteasome are impaired during disease 
pathogenesis in various affected and unaffected tissues from a murine model of ALS. 
Chymotrypsin-like, trypsin-like and caspase-like activities were measured in homogenates of 
various tissues from SODI G93A, SODI WT and nontransgenic littermates from an early, pre-
symptomatic stage (P45) through to development of motor dysfunction (symptomatic) and 
correlated with extent of pathological abnormalities. Specific proteasomal enzyme activity 
was reduced in lumbar spinal cord of SODI G93A mice, prior to motor neuron death and 
reactive gliosis, but affected much later and to a lesser extent in the less vulnerable thoracic 
region of the spinal cord and unchanged in liver. These data were published in 2004 as 
Kabashi et al. J. Neurochem. 89:1325-35. 
4.1. Choice of Ages to Measure Proteasome Function in Mice Based on Neuropathology 
Time points for measuring proteasome activity were based on previous 
characterization ofneuropathological and clinical disease in the B6SJL-TgN(SODIG93A)IGur 
line of transgenic mice and verification of certain endpoints (glial activation, detergent-
insoluble mutant SODl) in mice of the same line raised in our laboratory. 
Clinical disease in the mutant SODI transgenic mice begins most obviously with 
hindlimb involvement and several studies have demonstrated that neuropathological changes 
developing in the lumbar spinal cord, which contains the motor neurons innervating these 
limbs. Loss of lumbar and cervical motor neurons reaches statistical significance at 
approximately P90 (Gurney et al., 1994; Chiu et al., 1995; Chiu et al., 1995). Interestingly, no 
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significant loss of thoracic or cranial motor neurons occurred, although sorne cytopathology 
was noted in symptomatic mice (Chiu et al., 1995). 
Earlier, presymptomatic changes include the presence of detergent-insoluble, high 
molecular weight complexes of SODI on Western blots of spinal cord from P30 mice 
(Johnston et al., 2000) vacuolation ofmitochondria in ventral root axons at 37 days of age and 
motor neuronal perikarya at P45 (Chiu et al., 1995), and up-regulation of ICAM-l and the 
immunological markers, IgG and FcrRI, in ventral spinal cord of P40 mice (Alexianu et al., 
2001). Mitochondrial abnormalities in lumbar motor neurons first documented as swelling 
and vacuolation of mitochondria as early as P37 (Chiu et al., 1995). Activation of the 
unfolded protein response of the ER was demonstrated by up-regulation of two ER-resident 
chaperones, protein disulfide isomerase (PDI) and endoplasmic reticulum protein 57 (Erp57) 
as early as post-natal day 60 (Atkin et al., 2006). Cytoplasmic inclusions containing mutant 
SODI were visible in sections of lumbar spinal cord by immunhistochemistry at P112 of 
SODIG93A mice (Watanabe et al., 2001) and were isolated from symptomatic mice using a 
filter-trap assay (Wang et al., 2002). 
Experimental Approach and Results 
4.1.1 Gliosis at Different Stages ofDisease Pathogenesis 
Increased numbers of microglia and reactive astrocytes are detected about P75 and 
increase thereafter (Hall et al., 1998; Alexianu et al., 2001; Batulan et al., 2003). Because 
death of motor neurons and glial reactivity could potentially alter proteasome activities 
measured in tissue extracts, the presence of gliosis was evaluated by immunohistochemistry in 
this study. Markers of reactive astrocytes (GF AP immunoreactivity) (Figure 4A), and of 
microglia (MAC-l immunoreactivity) (Figure 4B) were minimal in lumbar spinal cord ofP45 
SODI G93A mice, but were evident by 75 days of age and progressively increased until the time 
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that symptoms appeared (Figure 4), in accordance with previous studies (Hall et al., 1998; 
Alexianu et al., 2001; Batulan et al., 2003). These pathological markers were not prevalent in 
the lumbar spinal cord from LM or SODIWT transgenic mice [B6SJL-TgN(SODl)2Gur] at 
any ages examined. 
These pathogenic markers defined three stages of disease at which to determine the 
role of the ubiquitin-proteasome pathway: P45, early pre-symptomatic, prior to motor neuron 
death and gliosis (Figure 4); P75, pre-symptomatic in the early stages of gliosis (Figure 4), but 
before significant motor neuron loss; symptomatic and at onset of hindlimb paralysis when 
both gliosis and motor neuron loss are extensive (mean PI27). 
4.1.2 Ubiquitin-Proteasome Dysfunction Leads to Increased Expression of Ubiquitinated 
Proteins and Altered Solubility of Mutant SODI 
In order to obtain evidence of malfunction of the ubiquitin-proteasome pathway, levels 
and localization of mutant SODI (Figure 5A) and poly-ubiquitinated proteins (Figure 5B), 
proteasomal substrates were detected in spinal cord sections of SODIG93A and SODIWT 
transgenic mice through the course of the disease pathogenesis. Early markers of mutant 
SODI toxicity that indicate inability to clear misfolded mutant SOD1 and other proteins 
include detection of insoluble SOD1 G93A, ubiquitinated proteins, SDS-resistant high molecular 
weight complexes containing SODI. Expression of SOD1 (Fig. 5A) and ubiquitinated 
proteins (Fig. 5B) was determined in mice raised in our Institution by immunohistochemical 
analysis of the lumbar region using specific monoclonal antibodies against SODI (clone SD-
G6 Sigma-Aldrich) and mono and poly-ubiquitinated proteins (clone FK2, Biomol) (refer to 
Section 3.9 for dilutions). Expression ofSOD1 (Figure 5A) and ubiquitinated proteins (Figure 
5B) remained similar in motor neurons of SODI G93A and SOD1 WT transgenic mice through 
the course of the disease. 
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Whereas SOD 1 WT is for the most part soluble in non-ionic detergent, SOD 1 G93A can be 
isolated from spinal cord tissue in three different forms: Triton-soluble, Triton-insoluble/SDS-
soluble, and SDS-insoluble, high molecular weight complexes. These chemical species were 
quantified in lumbar and thoracic spinal cord. The relative amounts of these forms in spinal 
cord segments of SOD 1 G93A transgenic mice and SOD 1 WT transgenic mice was assessed by 
SDS-PAGE/Western blotting of Triton-soluble tissue extracts and Triton-insoluble pellets 
solubilized by SDS/mercaptoethanol containing sample buffer (refer to Section 3.4). Thirty-
fold more Triton-insoluble protein was loaded onto gels relative to Triton-soluble extract. An 
average of 11% of SODI in the lumbar spinal cords of three symptomatic SODI G93A 
transgenic mice was SDS-insoluble compared to approximately 1.3% in three age-matched 
SODI WT transgenic mice, (Figure 6A), representing a 10 fold enrichment of insoluble SODI 
in lumbar spinal cords of SOD 1 G93A transgenic mice relative to SOD 1 WT mice. There was no 
significant difference in the amount of soluble SODI present extracted from these tissues 
(Fig. 6A). The SDS-insoluble, high molecular weight SODI-immunoreactive bands, first 
reported by Kopito's group (Johnston et al., 2000), as well as Triton-insoluble/SDS-soluble 
(monomeric SODI on Western blots of Triton-insoluble extract) and ubiquitinated proteins, 
were enriched in lumbar spinal cord tissue from SODI G93A transgenic mice, relative to 
thoracic spinal cord tissue (Fig. 6B). None of these ubiquitinated species were observed in 
insoluble tissue from to SODI WT mice and non-transgenic littermates (data not shown). These 
results point to inadequate clearance of modified proteins, including SODI in lumbar spinal 
cord of SODI G93A transgenic mice, but a lower load of abnormal mutant SODI substrate in 
thoracic cord. These results parallel the higher vulnerability and involvement of lumbar spinal 
cord cells to the disease process. AIso, a preferential accumulation of poly-ubiquitinated 
proteins, substrates of the 26S proteasome in the lumbar spinal cord of SOD 1 G93A transgenic 
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mice suggests that the ubiquitin-proteasome pathway is overloaded and possibly impaired in 
the.lumbar region of the spinal cord. 
4.2 Proteasome Impairment in in vivo and in vitro models of ALS 
Ubiquitinated inclusion bodies in astrocytes and motor neurons in animal models of 
fALS as weil as in spinal cord sections from sporadic and fALS patients suggest that the 
ubiquitin-proteasome pathway might play a role in ALS pathophysiology. Levels of mutant 
SODI, but not WT SODI are elevated upon treatment with proteasome inhibitors suggesting 
that mutant SODI is degraded by the proteasome and increased levels of mutant SODI might 
overload its activity (Hoffman et al., 1996; Johnston et al., 2000). Also motor neurons from 
primary spinal cord cultures were found to be preferentially vulnerable to low-level treatment 
with proteasome inhibitors indicating that proteasome impairment over time can lead to motor 
neuron degeneration (Urushitani et al., 2002). Further in vitro reports studying the proteasome 
activity in cell lines stably and transiently overexpressing mutant SODI have produced 
contradictory findings, showing total proteasomal activity to be decreased (Hyun et al., 
2002b; Urushitani et al., 2002; Allen et al., 2003), increased (Casciati et al., 2002; Aquilano et 
al., 2003) or unchanged (Lee et al., 2001). However, these studies did not report specific 
activities. Differences in physiological properties of clonaI cell lines, including ability to 
upregulate proteasomes or other protective mechanisms may have contributed to disparate 
measures of activity. In the experiments described in this section, the three proteolytic 
activities were measured in cell lines overexpressing SODIG93A and SODI G41S and were 
normalized to levels of the structural a subunits of the proteasome to derive the specifie 
proteasome activities in these cell lines. Aiso to test the hypothesis that dysfunction of the 
proteasome contributes to ALS pathogenesis, specific proteasome activities were measured in 
CNS area most affected by the disease (lumbar spinal cord), in a less affected CNS region 
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(thoracic spinal cord) and in non-affected tissue (liver) at various stages of disease 
pathogenesis in a transgenic line of mice overexpressing SODIG93A, a well characterized 
model of fALS. 
Experimental Approach and Results 
4.2.1 Early. Focal Reduction ofProteasomal Activities in Lumbar Spinal Cord ofSOD1G93A 
Transgenic Mice 
Proteasomal activities were measured in lumbar spinal cord, thoracic spinal cord (Figure 
7A,C,D upper and middle panels) and liver (Figure 7A,C,D lower panels) from SODIG93A and 
SOD 1 WT transgenic mice and their respective LM in the three stages of disease pathogenesis 
described in Section 4.1.1: P45, prior to motor neuron death and gliosis (Figure 4); P75, in the 
early stages of gliosis (Figure 4), but before significant motor neuron loss; and at onset of 
hindlimb paralysis when both gliosis and motor neuron loss are extensive (PI15-P136, mean 
P127 days) (Chiu et al., 1995; Hall et al., 1998; Alexianu et al., 2001). Since no ATP was 
added to the homogenizing buffer, the majority of proteasomal species must have been 
unassembled 20S complexes (see native gel results in Chapter 5). 
Assays were based on hydrolysis of fluorogenic substrates specific for each of the 
chymotrypsin-like, caspase-like and trypsin-like activities ofthe proteasome. At day 45, total 
chymotrypsin-like activity of the proteasome, calculated as nmol/min/mg normalized to actin, 
was significantly impaired in the lumbar spinal cords, at 67% of LM activity (Figure 7 A top 
panel). The lumbar region of the spinal cord contains cell bodies of motor neurons that 
degenerate during the course of the neurological disease in SODIG93A transgenic mice (Chiu 
et al., 1995f). By 75 days of age, an three major activities of the proteasome were 
significantly reduced, with chymotrypsin- (Figure 7 A top panel), caspase- (Figure 7C top 
panel) and trypsin-like (Figure 7D top panel) activities in SODIG93A mice being 47%, 66%, 
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and 54%, respectively, of the activities measured in LM controls. Chymotrypsin- (Figure 7A 
top panel), caspase- (Figure 7C top panel), and trypsin-like (Figure 7D top panel) activities in 
lumbar spinal cord from symptomatic animaIs (median: day 126) were 60%,67%, and 63% of 
LM control activities, respectively. No significant impairment in any total proteasome activity 
was measured in thoracic spinal cord (Figure 7A,C,D upper panel) or liver (Figure 7A,C,D 
lower panels) of SODI G93A transgenic mice, tissues previously shown to exhibit limited 
pathological changes (Chiu et al., 1995). Nor were any proteasomal activities significantly 
decreased in any tissue from SODI WT transgenic mice in comparison to respective LM 
controls (Figure 7A,C,D middle and lower panels). In summary, an early focal reduction of 
total proteasome activity was measured within the lumbar region of the spinal cord of 
SOD 1 G93A transgenic mice, which preceded both markers of gliosis and clinical symptoms. 
4.2.2 Reduction in Proteasome Specifie Activities in Lumbar Region of Spinal Cord of 
SOD1 G93A Transgenic Mice 
To assess whether the observed reduction in total proteasome activity in lumbar spinal 
cord of SOD 1 G93A mice was the result of decreased concentration of proteasomes or reduction 
in specific activity, the levels of the strucutural a subunits of the 20S proteasome in aIl 
samples were examined by Western blotting, using actin as a loading control (Fig. 7B). 20S a 
subunits were quantified as a measure of total proteasome concentration because they are non-
catalytic, structural components of aIl proteasomes, and in contrast to ~-subunits, do not 
change in response to interferon-y (Baumeister et al., 1998; Rock and Goldberg, 1999; Preckel 
et al., 1999; Goldberg et al., 2002). Microglial activation in the spinal cord induces over-
expression of interferon-y (Hensley et al., 2003), which could lead to a replacement of 20S (3-
subunits by the inducible (3i immunoproteasome subunits and subsequent changes in 
proteasomal degradation of substrates (Chiu et al., 1995; Gaczynska et al., 1996; Rock and 
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Goldberg, 1999). A representative blot is shown in Figure 7B. Expression of20S a-subunits 
in the lumbar spinal cord region of SOD 1 G93A or SOD 1 WT transgenic animais was similar to 
that in LM controls at all ages tested. Transgenic animais and LM controls for a given tissue 
(e.g., lumbar spinal cord, thoracic cord, or liver) were processed on the same gel for 
normalization. 
Total proteasomal activity (nmol/min/mg shown in Fig. 7 A,C,D) were normalized to the 
amount of 20S a-subunits quantified on Western blots (Figure 8A,C,D). Chymotrypsin-, 
caspase- and trypsin-like activities of SODI G93A mice normalized to 20S proteasome a-
subunits levels were respectively 71 %, 81%, and 91 % of LM controls at day 45; 39%, 56% 
and 45% at day 75, and 62%, 69% and 65% at the symptomatic stage (Fig. 8A,C,D upper 
panels). These results followed the same pattern as total proteasomal activities and the 
reductions were statistically significant at day 75 and day 120. These data indicated that the 
decrease in total proteasome activity observed in lumbar spinal cords of SOD 1 G93A mice was 
due to changes in the catalytic properties of the proteasome and not due to the overall 
proteasome levels. 
4.2.3 Proteasome AClivity is Reduced in Lumbar Spinal Cord of SODIG93A mice in 
Comparison 10 SODI WT mice 
In the preceding results, data obtained using tissues from SOD 1 G93A mice and their LM 
were compared. To control for over-expression of human SODl, data obtained using 
SODI G93A mouse tissues were compared to measurements in the same tissue from SODIWT 
mice. Similar reductions of specific activities of the proteasome in the lumbar region of spinal 
cord from SODI G93A were observed upon comparison to data from SODI WT mice (Figure 9). 
Within a litter, mean proteasome specific activity of lumbar spinal cords from transgenic 
animaIs was divided by the mean specific activity of LM controls. Normalizing the activities 
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for the two lines of transgenic animaIs to their littermates eliminates the effects of genetic 
background. At day 45, mean specific chymotrypsin-like activity was significantly reduced in 
lumbar spinal cord of SODI G93A mice to 73% of SODIWT activity (Figure 9A). At day 75 
mean chymotrypsin-, caspase-, and trypsin-like activities of lumbar spinal cords of SOD 1 G93A 
transgenic mice, were 36%,53%, and 38% ofSODIWT activity, respectively (Figure 9A,B,C). 
Similar significant reductions were measured at symptomatic age (Figure 9A,B,C). 
In thoracic spinal cord, there were no significant differences in total proteasomal 
activities in either SODI G93A or SODIWT transgenic mice in comparison to their respective 
LM controls (Figure 7A,C,D top and middle panels). However, after normalization to LM 
controls the chymotrypsin-like activity in thoracic cord of symptomatic SODI G93A was 
significantly lowered relative to SODI WT (Fig. 9D). This could represent late developing, 
disease-related functional impairment or could be due to the increase in proteasome activity of 
SOD 1 WT relative to their LM (Fig. 7 A,C,D middle panel). 
4.2.4 Proteasome Inhibition upon Stable Expression of Mutant SODi in NIH-3T3 Cel! Lines 
Total and proteasome-normalized chymotrypsin-, caspase-, and trypsin-like activities 
of the proteasome were impaired significantly in NIH 3T3 cells stably expressing SOD 1 G93A 
and SOD 1 G41S in comparison to either SOD 1 WT expressing or untransfected cells (Figure 10). 
The caspase-like activity of the SODIWT line was significantly increased to 130% of 
untransfected NIH 3T3 cells (Figure 10E), possibly a general effect of the overexpression of 
proteins (Hyun et al., 2002a). Proteasome-normalized mean chymotrypsin-, caspase-, and 
trypsin-like activities were reduced to 27%, 36%, and 55% of untransfected cells, in 
SODI G93A expressing cells, and 28%,40%, and 55% in those expressing SODI G41S (Figure 10 
D,E,F). Thus overexpression of different fALS associated (SODI G93A and SODIG41S) mutant 
SODlled to impaired proteasomal activity in NIH 3T3 celllines. 
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4.2.5 Decreased Expression orthe Proteasome in Motor Neurons ofLumbar Spinal Cord of 
SODI G93A Mice 
Motor neurons generally expressed high levels of 20S proteasomal Cl subunits 
compared to the surrounding neuropil (Fig. lIA) in agreement with a previously published 
report (Mengual et al., 1996). However, immunolabeling for Cl subunits of the 20S proteasome 
was considerably reduced in lumbar spinal motor neurons of symptomatic SOD1 G93A 
transgenic mice compared to motor neurons of LM and SOD1WT transgenic mice (Fig. llA). 
This was not due to a motor neuron specific and generalized reduction in protein expression 
because motor neurons stilliabeled strongly by an antibody directed against murine NF-L and 
the neuropillevels appeared similar in sections ofP45 and symptomatic SOD1 G93A transgenic 
mice (Figure lIB). These results demonstrate a motor neuron-specific loss of20S proteasome 
expression within the lumbar spinal cord of SOD 1 G93A mice. 
4.2.6. Increased Expression ofHsp70 in Lumbar Spinal Cord ofSODIG93A Mice 
It was previously demonstrated that expression ofHsp70, but not Hsp40 is rapidly up-
regulated upon treatment with low levels of proteasome inhibitors in primary spinal cord 
cultures in glia, but not in motor neurons (Batulan et al., 2003). Increased mRNA and prote in 
expression of Hsp70 has been measured in primary cortical neurons upon treatment with 
moderate, non-toxic levels of proteasome inhibitors as well as in neurons of the substantia 
nigra upon unilateral infusion of lactacystin in this CNS region (Rideout et al., 2005; Ahn and 
Jeon, 2006). Expression of two protein chaperones, Hsp40 and Hsp70 were determined in 
lumbar and thoracic tissue extracts of P75 SOD1G93A mice and LM. Levels of Hsp70 were 
significantly increased specifically in the lumbar, but not in the thoracic region, of the spinal 
cord of P75 SOD1G93A mice (Figure 12A). These results provide indirect evidence that the 
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proteasome activity is impaired specifically in the lumbar region of the spinal cord of P75 
SOD1 G93A mice, since Hsp70 up-regulation might reflect a certain level of proteasome 
inhibition. 
4.3 Discussion 
Results presented in this chapter demonstrate impaired proteasome function in cell line 
and transgenic mouse models of familial ALS due to mutations in the SODi gene. The major 
findings were: 
(1) In transgenic mice expressing the disease-causing mutant protein, SOD1 G93A, proteasomal 
activity relative to LM was reduced as early as 45 days of age, indicating that abrogation of 
proteasomal function is involved early in pathogenesis, not as a late consequence of disease. 
(2) Reduction in activity occurred in tissues most affected in the disease. At presymptomatic 
stages, reduction in activity was measured in lumbar spinal cord, but not in thoracic spinal 
cord or liver, tissues showing limited pathological changes (Chiu et al., 1995). Significant 
differences in proteasomal activity of thoracic spinal cord were only apparent in symptomatic 
mice, an observation consistent with their relative preservation. (3) Both total and specific 
proteasomal activities were reduced to a similar extent in lumbar spinal cord of SODI G93A 
transgenic mice. Thus, the reduced rate of proteasomal hydrolysis was not due to reduction in 
the amount of proteasome in the tissue or cell extract, but to rather impaired proteasome 
function. (4) Compounding regional reduction in specific proteasomal activity, the amount of 
proteasome progressively decreased in surviving motor neurons within the lumbar spinal cord 
of SODI G93A mice relative to the surrounding neuropil. (5) No significant changes in 
proteasomal activity were measured in spinal cord or liver from SODIWT transgenic mice. 
This line of mice does not develop ALS-like clinical disease, although mild vacuolar changes 
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in spinal motor neurons has been noted (DaI Canto and Gumey, 1995). (6) Reductions in both 
total and specific proteasomal activities were measured in NIH 3T3 cell lines stably 
expressing SODIG93A or SODI G41S• 
Motor impairment and neuropathological changes in the B6SJL-TgN(SODIG93A)IGur 
line of transgenic mice have been extensively documented and a similar time course of 
phenotypic presentation was observed in the present study. Motor neuronal loss occurs 
between 80-90 days of age (Chiu et al., 1995) and mutant SODl- positive inclusions were 
visible in sections oflumbar spinal cord by immunhistochemistry at day 112 (Watanabe et al., 
2001) and were isolated from symptomatic mice using a filter-trap assay (Wang et al., 2002). 
Early, pre-symptomatic changes include the presence of detergent-insoluble, high molecular 
weight SODI species on spinal cord from 30-day-old mice (Johnston et al., 2000; Wang et al., 
2002; Puttaparthi et al., 2003) vacuolation of mitochondria in ventral root axons at 37 days of 
age and motor neuronal perikarya at 45 days of age (Chiu et al., 1995), upregulation of 
ICAM-l and the immunological markers, IgG and FcrRI, in ventral spinal cord of 40-day-old 
mice (Alexianu et al., 2001) and markers of microglia and reactive astrocytes between 75-80 
days ofage (Hall et al., 1998; Alexianu et al., 2001; Batulan et al., 2003) (Fig. 4). 
Reduction of proteasomal activity in homogenates of lumbar spinal cord occurred with 
a time course similar to other early pathological markers (see above), before reported motor 
neuron loss, and did not reflect a change in the cell-type composition. Relative to non-
transgenic LM controls, significant reduction in total chymotrypsin-like activity (Fig. 7 A) 
occurred in lumbar spinal cord by 45 days of age, before gliosis, and peaked at 75 days (Fig. 
7 A,B,C), an early stage of microglial/astrocytic activation (Figure 4). 
Motor neurons comprise only a small percentage of the lumbar spinal cord. Thus, 
approximately 50% reduction in aIl three proteasomal activities in homogenates of lumbar 
spinal cord implies a regional impairment of proteasomal function involving multiple cell 
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types. Dysfunction of the proteasome in the surrounding non-neuronal cells could play a 
significant role in the death of motor neurons, since expression of mutant SOD 1 exclusively 
in neurons may not be sufficient to produce a phenotype in transgenic mice (Pramatarova et 
al., 2001; Howland et al., 2002; Lino et al., 2002; Clement et al., 2003). Although cells can 
survive partial inhibition of proteasomal activities, as measured using peptide substrates (Ding 
et al., 2003), ceIls with the lowest margin of proteasomal capacity relative to substrate load 
will be most vulnerable to additional stress. Given the high sensitivity of motor neurons to 
peptide proteasomal inhibitors, motor neurons are the ceIls most likely to succumb to levels of 
proteasomal inhibition sufficient to disrupt prote in catabolism and homeostasis (Urushitani et 
al. 2002; Kabashi et al. unpublished results). 
The present study has defined the role of the proteasome in ALS pathogenesis by 
evaluating mutant SODI 's effect on both proteasomallevel and activity in an affected tissue 
and relating changes to the known time course of neuropathology in a transgenic mouse 
model. To obtain measures of specific proteasomal activity, total activities in tissue/ce Il 
culture extracts (i.e., normalized to actin) were normalized to the level of 20S a-subunits, 
structural components of aIl proteasomal complexes. Previous studies have shown that the 
levels of 20S a-subunits assessed by Western blotting are representative of total proteasome 
content, being proportional to the increase in 20S/26S proteasome activity in conditions 
associated with induction ofproteasomes (Wing et al., 1995; Medina et al., 1995; Attaix et al., 
1999; Fang et al., 2000; Hasselgren et al., 2002). In the present study, overaIllevels of 20S a 
subunits in both mouse lumbar spinal cord and NIH 3T3 ceIllines expressing mutant SODI 
were comparable to LM (Fig. 7B), and the three major activities of the proteasome remained 
reduced after normalization to 20S a-subunits. The reductions in total and specific 
proteasomal activities were similar, indicating abrogation of proteasome function, rather than 
a decrease in the amount of proteasome. 
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The coordinate reduction in chymotrysin-like, trypsin-like and caspase-like activities 
indicates that proteasomal cleavage of substrates was being measured, not hydrolysis by other 
non-proteasomal enzymes in the extract. Supporting this conclusion is that similar results 
were obtained using either lactacystin or MG 132 to define total proteasome activity. These 
inhibitors have different affinities for non-proteasomal enzymes: MG 132 also inhibits 
calpains and cathepsins, whereas the more specific proteasomal inhibitor, lactacystin, also 
inhibits cathepsin A (Kisselev and Goldberg, 2001). 
Despite consistent expression of 20S a. subunits in extracts of lumbar spinal cord 
measured by Western blotting, immunohistochemical analysis of tissue sections revealed 
substantial reduction in labeling of lumbar motor neurons relative to the surrounding neuropil 
in symptomatic SODI G93A mice. Although a recent report indicates activities of proteasomes 
in spinal cord are relatively low compared to other tissues (Puttaparthi et al. 2003), 
proteasome levels are normally high in motor neurons relative to the surrounding neuropil 
(Fig 11) (Mengual et al., 1996). The high level expression of proteasomes and the high 
sensitivity of motor neurons to proteasome inhibitors (Urushitani et al. 2002; Kabashi et al. 
unpublished results) would indicate that these cells normally have a large substrate load. As 
motor neuron disease develops in the SOD 1 G93A mice, not only are lumbar motor neurons 
located in a region with impaired proteasome function, they are affected disproportionately 
because they lose proteasome expression relative to surrounding cells. 
High-molecular weight SODI complexes that are prominent in spinal cord tissues of 
SODI G93A transgenic mice very early in disease pathogenesis demonstrate a failure ofprotein 
"quality control" systems to properly dispose of misfolded proteins and suggest a central role 
in ALS pathogenesis of these quality control systems. The results presented here demonstrate 
that these high-molecular weight SODI species are more prominent in the lumbar region of 
the spinal cord pre-symptomatically relative to the adjacent thoracic tissue (Figure 6A). AIso, 
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several of these proteins might be proteasomal substrates since they label positively to an 
antibody that recognizes ubiquitinated proteins (Figure 6B). These results demonstrate in vivo 
that misfolded, SDS-insoluble, SODI species are proteasomal substrates and a failure and/or 
overload of the ubiquitin-proteasome pathway results in their accumulation in affected 
regions. These data suggest that prote in misfolding and failure of prote in chaperones and 
ubiquitin-proteasome pathway play a central role in ALS pathogenesis. 
In fALS and other familial neurodegenerative diseases, the ability of cells to prevent 
accumulation or aggregation of mutant protein and to withstand toxicity would depend upon 
their ability to activate or induce protective pathways, including prote in chaperones and 
proteolytic pathways (see Section 1.2.6). Our previous studies showed presymptomatic 
reduction in prote in chaperoning activity specifically in lumbar spinal cord of another line of 
SODI G93A transgenic mice (Bruening et al., 1999). In this study, proteasomal activities 
decreased in lumbar spinal cord of SOD 1 G93A mice. Moreover, proteasome levels decreased in 
lumbar motor neurons relative to surrounding cells. Motor neurons are impaired in stress-
induced upregulation of heat shock proteins with chaperoning activity. This results from lack 
of activation of the major heat shock transcription factor, HSF l, subsequent to its binding to 
heat shock promoter elements (Batulan et al., 2003). Interestingly, the protein levels of 
Hsp70, but not Hsp40, were also selectively elevated in the lumbar region of the spinal cord 
pre-symptomatically in SODI G93A transgenic mice. Hsp70 is not a proteasomal substrate per 
se, but several studies have demonstrated that Hsp70 mRNA and protein levels are rapidly up-
regulated following low levels of proteasomal inhibition in cell lines and animal tissues 
(Batulan et al., 2003; Ahn and Jeon, 2006), including astrocytes but not motor neurons of 
primary spinal cord cultures (Batulan et al., 2003). These results suggest that increased 
expression of several prote in chaperones as well as a specific elevation of proteasomal 
activity is required in the affected tissue (lumbar spinal cord) in the affected cell types (motor 
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neurons) in order for them to properly cope with the increased load of misfolded proteins 
during the course of ALS pathogenesis. Altematively, other molecular mechanisms could lead 
to increases in Hsp70, such as ER stress. More research is needed to determine whether 
strategies to specifically target the ubiquitin-proteasome pathway and prote in chaperones are 
beneficial in fALS animal models. 
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Figure 4 
Astroglial and microglial markers of disease progression in ventral horn of the lumbar 
spinal cord from SODIG93A transgenic mice 
Twenty IJm frozen cross-sections were labeled with antibody to (A) GFAP or (B) MAC-1 as markers of activated 
(A) astrocytes and of (B) microglia, respectively. Labeling was absent or minimal at day 45, evident in the ventral 
horn at day 75, and prominent throughout the lumbar cord at symptomatic ages (day 110-130) in lumbar spinal 
SODIG93A •• cord sections of transgemc ffilce. Scale bar = 40 IJm. 
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Figure 5 
Cellular distribution of proteasomal substrates in the lumbar spinal cord of mutant 
SODt transgenic mice 
Twenty lllll frozen cross-sections of lumbar spinal cord from 45- and 75-day-old and 
symptomatic SODI G93A mice, age-matched LM and SODIWT transgenic mice were labeled 
with antibody to human SODI (A) and to mono-and poly-ubiquitinated proteins (B). Motor 
neurons were labeled strongly by both antibodies. However, no obvious changes in the 
localization of these proteins were observed in motor neurons throughout the course of the 
disease in SOD 1 G93A transgenic mice. Scale bar = 40 lllll. 
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Figure 6 
High-molecular weight, SDS-insoluble SOD! species are ubiquitinated and are increased 
in affected tissue of SOD! G93A mice 
A. Even though the amount of soluble SODI in spinal cords of symptomatic SODI G93A 
transgenic mice is similar to the soluble SODI fraction in age-matched SODI WT transgenic 
mice, there is an increase of detergent-resistant SOD 1 in spinal cord tissue from SOD 1 G93A 
transgenic mice. Mouse tissue was homogenized in TrislEDT A buffer as previously 
described, sonicated and centrifugated at 15000 g for 10 minutes. The pellets were washed 
three times with 0.1 % TritonX in TrislEDTA and in 0.1 % SDS in TrislEDTA and 
resolubilized in urea. The SDS-insoluble fraction as weIl as the soluble fraction were run in 
SDSIPAGE gels and immunoblotted using a human SODI specific antibody (SODI00; 
Stressgen). We determined a 10 fold increase of SODI in the insoluble fraction in the spinal 
cord of SODI G93A transgenic mice as compared to the SODIWT transgenic mice with no 
change in the soluble fraction. 
B. High-molecular weight SODI species that are detergent-resistant are visible as early as 
P30 in the spinal cord ofSODI G93A transgenic mice and accumulate with disease progression. 
Even though the se species represent a very small fraction of the total insoluble SOD 1, they 
are accumulated in the lumbar region as compared to the thoracic portion of the spinal cord as 
early as P75 in SOD 1 G93A transgenic mice. We have reported a major impairment of aIl three 
activities in the lumbar region of the spinal cord early in disease pathogenesis (P75). 
Furthermore, the blots containing detergent-resistant proteins were re-probed with antibodies 
specific to ubiquitinated proteins, and a similar enrichment of the ubiquitinated species was 
seen selectively in the lumbar region of the spinal cord ofSODIG93A transgenic mice. 
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Figure 7 
Total proteasomal activities were reduced in lumbar spinal cord of SOD1 G93A transgenic 
mice 
Chymotrypsin-like (A), caspase-like (C) and trypsin-like (D) activities expressed as 
nmol/min/mg normalized to actin levels (B) were measured in homogenates of lumbar and 
thoracic segments of spinal cord from SOD 1 G93A (upper panels) and SOD 1 WT (middle panels) 
transgenic mice and compared to LM at 45 and 75 days of age and after development of 
symptoms (sympto; days 115-136). Lower panels show assays of liver from both lines of 
mice. Dark bars represent transgenic mice (SODI G93A or SODIWT), whereas light bars 
represent their age-matched LM. Chymotrypsin-like activity (A) was significantly reduced at 
day 45 in lumbar spinal cord of SODI G93A transgenics (upper panels), but not in thoracic 
spinal cord (upper panels) or liver (lower panels). Significant decrease in chymotrypsin- (A), 
caspase- (C) and trypsin-like (D) activities occurred at day 75 and at symptomatic stage, again 
only in lumbar spinal cord of SODI G93A mice. Proteasomal activities are expressed as means 
± SEM (nmol/min/mg) of four independent measurements in three to five animaIs per group. 
Significantly different from LM control: * p<0.05; ** p<O.OI; *** p<0.005. (B) Western blots 
of spinal cord homogenates from SODI G93A (upper blot) and SODI WT (lower blot) transgenic 
mice and their respective LM controls labeled by antibodies against actin and 20S proteasome 
a-subunits. 
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Figure 8 
Specific proteasome activities were reduced in lumbar spinal cord of SOD 1 G93A 
transgenic mice 
Chymotrypsin-like (A), caspase-like (C) and trypsin-Iike (D) activities expressed as 
fluorescence units (F.U.) normalized to 20S a-subunit levels (B) were measured in 
homogenates of lumbar and thoracic segments of spinal cord from mice transgenic for 
SODIG93A (upper panels) and SODIWT (middle panels) and compared to non-transgenic 
littermates (LM) at 45 and 75 days of age and after development of symptoms (sympto; days 
115-136). Lower panels show assays of liver from both Iines of mice. Dark bars represent 
transgenic mice (SODI G93A or SODIWT), whereas light bars represent their age-matched non-
transgenic littermates. Significant decrease in specific chymotrypsin- (A), caspase- (C) and 
trypsin-like (D) activities occurred at day 75 and at symptomatic age, only in lumbar spinal 
cord of SODIG93A transgenic mice, not in thoracic spinal cord (upper panels) or liver (lower 
panels). Shown are means ± SEM (mnol/min/mg) of four independent measurements in three 
to five animais per group. Significantly different from littermate control: * p<0.05; ** p<O.OI; 
*** p<0.005. (B) Western blots of spinal cord homogenates from SODIG93A (upper blot) and 
SODI WT (lower blot) transgenic mice and their respective controls labeled by antibodies 
against actin and 20S proteasome a-subunits. 
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Figure 9 
Deerease in specifie activities of the proteasome in lumbar spinal eord of SODt G93A 
relative to SODtWT transgenic mice 
To compare specifie proteasomal activities in tissue homogenates from the two lines of mice, 
specifie aetivities for tissue from each mouse were ca1culated by normalizing total aetivity in 
nmollmin/mg first to actin then to the levels of 20S proteasome a-subunits (see Figure 8). 
Then specific aetivities from transgene-expressing mice were expressed as percent of specific 
activity in LM. Shown are specifie ehymotrypsin- (A,D), caspase- (B,E) and trypsin-like 
(C,F) activities of lumbar (A,B,C) and thoracie (D,E,F) spinal eord homogenates. Shown are 
means ± SEM. Signifieant difference between SODI G93A and SODIWT: * p<0.05; ** p<O.OI; 
*** p<0.005. 
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Figure 10 
Total proteasome activities and activities normalized to proteasome levels are reduced in 
NIH 3T3 celllines stahly expressing mutant SODI 
Total (A,B,C: normalized to actin) and normalized to 20S a-subunits (D,E,F) chymotrypsin-
(A,D), caspase- (B,E) and trypsin-like (C,F) activities of the proteasome were significantly 
reduced in homogenates of NIH 3T3 cells stably expressing human mutant SODIG93A or 
SODI G41S compared to untransfected NIH 3T3. Shown are means ± SEM (nmol/minlmg) of 
three independent cultures for each celI line with each sample analyzed in quadruplicate. 
Significantly different from untransfected NIH 3T3: * p<0.05; ** p<O.Ol; *** p<0.005. 
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Figure Il 
Levels of a subunits of the 20S proteasome in the lumbar motor neurons of mutant 
SOD1 transgenic mice 
Lumbar spinal cord was obtained from 45- and 75-day-old and symptomatic SODI G93A mice, 
and from age-matched littermates and SODI WT transgenic mice. Twenty Jlm frozen cross-
sections were labeled with antibody to a-subunits of the 20S proteasome core (A). Labeling 
of motor neurons in cord from 75-day-old and symptomatic SODI G93A transgenics (arrows) 
appeared markedly reduced relative to the surrounding neuropil and to motor neurons of non-
transgenic littermates and SODI WT transgenics, despite the labeling for NF-L (B), mono- and 
poly-ubiquitinated proteins and human SODI (see Figure 4) did not change in motor neurons. 
Scale bar = 40 Jlffi. 
90 
A 
~ 045' 
o 
U) 
ca 
S 075 o 
l-
D.. 
en 
~Sympto 
B 
...J 
1 
LI. 
Z 
045 
Sympto 
G93A800-1 wr 800-1 
G93A800-1 Non Tg Littermates 
Figure 11 
91 
Figure 12 
Elevation of Hsp70 early in pathogenesis of fALS suggests dysfunction of the UPS 
A. That levels of Hsp70 are increased in lumbar, but not in thoracic, spinal cord of P75 
SODI G93A transgenic mice provides in vivo evidence of an impairment of the proteasome 
pathway, since levels of this prote in chaperone have been found to be increased upon low 
levels of proteasome inhibition in primary spinal cord cultures. Levels of another protein 
chaperone, Hsp40, which is not up-regulated upon moderate inhibition of the proteasome 
using peptide inhibitors of the 20S proteasome did not change in the lumbar region of the 
spinal cord ofP75 SODI G93A transgenic mice. The levels of20S (l subunits and actin (loading 
control) were not changed (* p<O.05). 
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Chapter 5 Understanding the Mechanisms of Proteasome 
Impairment in ALS Pathogenesis 
The assays of enzyme activity described in Chapter 4 measure the ability of small 
exogenous peptide substrates to compete with endogenous substrates in tissue homeogenates 
for cleavage by proteolytic acitivities of the proteasome. Thus, graduaI reduction in specific 
chymotrypsin-, trypsin- and caspase-like proteasomal activities could reflect either changes in 
composition, assembly or post-translational modification of proteasome complexes or 
inhibition of the proteasome by a specific protein including, but not limited to, mutant SODI. 
In this chapter, as stated in Specific Aim 2, the mechanisms of proteasome impairment were 
studied in affected tissue of the murine model of fALS, SODI G93A transgenic mouse. These 
results have been submitted for publication to the Journal ofBiological Chemistry. 
5.1 Changes in Composition of Proteasome Complexes Correspond to Impairment of 
Proteasome Activity 
Focal dysfunction of proteasome activity early in development of disease in the fALS 
mou se cannot be explained fully by reduction in amount of structural a. subunits of the 20S 
proteasome. As discussed in the previous chapter, except for the late but dramatic reduction in 
lumbar motor neurons, levels of 20S a. subunits remained constant in the examined tissues 
from SODI G93A transgenic mice (Figure 7B). Other possibilities for proteasomal impairment 
would include: reduced levels of functional p subunits of the 20S core; isoform switching of 
catalytically active 20S p subunits (Allen et al., 2003), altered 20S:26S ratio, association of 
20S with 19S or Il S regulatory subunits, or a combination (Keller et al., 2000b); impaired 
assembly of proteasomal subunits into active complexes, and modification (e.g., oxidation, 
hyperphosphorylation) of proteasomal subunits that impair enzyme activity, as documented in 
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ischemia-reperfusion in jury (Keller et al., 2000b) and ethanol treatment (Bardag-Gorce et al., 
2004). 
The composition of the 20S/26S/immunoproteasome was assessed further by 
analyzing expression of two ~ subunits of the 20S core parti cIe at the prote in and mRNA 
levels and determining if these subunits were assembled into 20 or 26S proteasomes: 1) the 
catalytic subunit (~5) with predominantly chymotrypsin-like activity; thought to be the major 
proteolytic activity of the proteasome and the earliest reduced activity in the lumbar spinal 
cord of SOD1 G93A mice; and 2) a structural ~ subunit (~3). Also the levels of the 19S and 
Il S regulatory partic1es of the proteasome were determined in affected and less affected CNS 
tissue of SOD1 G93A transgenic mice early in disease pathogenesis as weIl as at symptomatic 
stages. 
Experimental Approach and Results 
5.1.1 Early Reduction in B Subunits of the 20S Proteasome in Lumbar Spinal Cord of 
SODI G93A Transgenic Mice 
In order to analyze the expression of various subunits that compose the proteasome 
complexes, the expression of the functional subunit harbouring chymotrypsin-like activity of 
the proteasome, ~5 and its inducible counterpart, ~5i the expression of ~3, a structural subunit 
of the 20S core as weIl as subunits of the 19S and Il S regulatory particles of the proteasome 
were determined.by Western blot analysis in lumbar and thoracic spinal cord eXtracts from 
SOD 1 G93A transgenic mice, SOD 1 WT transgenic mice and their non-transgenic littermates at 
three stages of disease pathogenesis described in Chapter 4 using specifie antibodies (see 
Section 3.9). Subunits ~5 and ~3 of the 20S core were substantially reduced in lumbar spinal 
cord of 45 day-old (Figure 13) and 75 day-old (Figure 14) SOD1 G93A transgenic mice 
compared to their non-transgenic littermates (LM) and to mice transgenic for SOD 1 WT. No 
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significant changes in these subunits were detected on Western blots of extracts of thoracic 
spinal cord from SOD 1 G93A or SOD 1 WT transgenic mice relative to their nontransgenic 
littermates (Figure 15A). AIso, no changes of 19S6b subunit of the 19S regulatory particle as 
weIl as the Il S regulatory particle of the 20S core were determined in lumbar spinal cord of 
45 day-old and 75 day-old SOD 1 G93A transgenic mice (Figure 15B). 
The decrease in p5 immunoreactivity correlated with our previous experiments 
showing a decrease of specific chymotrypsin-like activity in lumbar spinal cord of SOD 1 G93A 
transgenic mice, but not the adjacent thoracic/cervical region at this age, and subsequent 
decrease in caspaselPGPH-like and trypsin-like activities by P75. Unfortunately, the 
commercially available antibodies to the pl and p2 subunits that harbour these activities were 
not sufficiently specific to confidently assess their levels by Western blotting. An antibody 
commercially available from Calbiochem which recognizes several 20S p subunits was tested 
in spinal cord extracts and did not label any 20S proteasomal subunits at the right molecular 
weight (20-30 kDa). 
5.1.2 Reduction in 20S 83 and 85 is not due to Substitution ofImmunoproteasome Subunits 
Immune reactions can be accompanied by substitution of immunoproteasomes for 
constitutive proteasomes. However, at presymptomatic stages of disease, the reductions in p5 
were not accompanied by significant increase in amount of p5i subunit (Figures 13 and 14), 
nor were there significant alterations in markers of either the constitutive 19S regulatory 
subunit (19S6b), or of Ils (l1Sa), which is substituted in immunoproteasomes (Figure 15). 
According to CUITent understanding of proteasome composition, such drastic reduction in 
labelling of the proteolytically inactive p3 subunit would not be expected simply from a 
switch to immunoproteasomes. AIso, P45 is prior to the reactive gliosis that characterizes 
latter stages of disease, although there may subtle changes in immune markers. P75 is prior to 
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significant motor neuron loss, but sorne activated microglia and astrocytes may be present. 
However, as expected from previous studies, lumbar spinal cord from symptomatic mice 
(approximately 120 days of age) showed significant upregulation of ~5 i and Il S, as well as 
decrease in ~5 (Figure 16A), consistent with the prominent microglial activation at this stage. 
Collectively, these data argue against the reduction in ~3 and ~5 being altered in 
presymptomatic mice because of substitution of immunoproteasome subunits. 
5.1.3 Motor Neurons in the Spinal Cord Have a Progressive Decrease in Constitutive 20S B 
Subunits 
lmmunohistochemical analysis of the lumbar region of the spinal cord using specific 
antibodies to ~3 (Figure 17A) and ~5 (Figure 17B) at P45 and at P75 revealed that motor 
neurons express high levels of constitutive ~ subunits. Similarly, motor neurons label robustly 
using an antibody to the 20S core and antibodies directed against 20S a subunits. However, 
there is a progressive depletion of constitutive ~ subunits expression as the ALS-like disease 
progresses in lumbar motor neurons of SOD 1 G93A transgenic mice (Fig. 17 A and B lower 
panels). The depletion of constitutive ~ subunits in the lumbar region observed by Western 
blotting is not observed in the immunohistochemical analysis due to certain cross-reactive 
higher molecular weight (60+ kDa) bands (data not shown). We and others found a similar 
decrease in the expression of a subunits of the 20S core in lumbar motor neurons only in the 
late stages of the disease (Cheroni et al., 2005). Also, no cell-specific changes in expression of 
19S and 11 S as well as 20S ~5 i at any stage of the disease in SOD 1 G93A transgenic mice as 
compared to their non-transgenic LM were observed (data not shown). 
5.2 No Translational Dysfunction of 20S Proteasome Subunits in Lumbar Spinal Cord 
and Motor Neurons of SODt G93A transgenic mice 
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As reviewed in Section 1.4.4, little is known about molecular mechanisms regulating 
constitutive and stress-induced expression of 20S proteasome subunits in mammalian cells. 
Treatment of cell lines with proteasome inhibitors as well as gene silencing of 26S subunits 
lead to increases in gene transcripts encoding certain proteasomal subunits (Meiners et al., 
2003). However, other mechanisms appear to be involved in affected tissues of the fALS 
mouse, since impairment of proteasome activity led to decreased prote in expression of 20S ~ 
subunits (referto Section 5.1.1). 
Experiments were conducted to determine whether the decrease in levels of 20S ~ 
subunits in lumbar spinal cord of SODI G93A transgenic mice (Section 4.1), or a (Figure 11) 
and constitutive ~ subunits (Figure 17) lowered specifically in motor neurons at the later 
stages of disease (Section 5.2.1), occurred due to reduced transcription of 20S proteasome 
genes. 
20S proteasome rnRNA transcripts were analyzed in extracts of lumbar, thoracic and 
cervical spinal cord of SOD 1 G93A transgenic mice and age-matched non-transgenic littermates 
at P55, an intermediate time point between P45 and P75. Following reverse-transcription (rt) 
amplification of rnRNA, transcripts for a7, ~3 and ~5 were quantitated by rt-PCR using 
primers listed in Table 4, as described in section 3.8. To quantitate the rnRNA levels of 
proteasome subunits specifically in lumbar motor neurons, motor neurons were collected by 
laser capture at PI00. These experiments were conducted in collaboration with the laboratory 
of Dr. Denise Figlewicz, University of Michigan Ann Arbor. 
Experimental Approach and Results 
5.2.1 Reduction in 20S 83 and 85 Subunits in Lumbar Spinal Cord ofSOD1G93A Transgenic 
Mice does not Result (rom Decreased mRNA Levels 
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To detennine if the decrease in levels of constitutive ~ subunits of the proteasome at 
P45 and P75 was due to a transcriptional defect, mRNA levels were quantified by rt-PCR in 
extracts of lumbar, thoracic and cervical (Figure 18) spinal cord from P55 SODI G93A 
transgenic mice and nontransgenic littennates. Primers used to amplify mRNA for 20S core 
subunits ~3, ~5, ~5i and a7 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
control (refer to Table 4), as well as assays to detennine specificity of primers in murine 
tissues were perfonned. Results normalized to GAPDH are presented in Figure 18. There was 
no significant decrease in mRNA encoding any of the 20S core subunits in the spinal cord of 
SOD 1 G93A transgenic mice compared to their nontransgenic littennates. In contrast, ~5 subunit 
mRNA was significantly increased in the lumbar and cervical region of the spinal cord 
(Figure 18), ~5i mRNA was increased in thoracic and cervical regions (Figure 18), and a7 
mRNA was increased in the thoracic region of spinal cord from P55 SODI G93A transgenic 
mice (Figure 18). 
These results provided no evidence of defects in transcription of proteasomal genes in 
this early phase of pathogenesis, pointing to abnonnalities of proteasome assembly and/or 
post-translational modification of subunits. 
5.2.2 The Late Decrease in 20S Core Prolein Levels in Lumbar Molor Neurons ofSOD1G93A 
Transgenic Mice is nol due 10 a Reduction in mRNA Levels 
We and others have reported decreased levels of structural a subunits of the 20S 
proteasome in lumbar motor neurons from symptomatic SODI G93A transgenic mice (Kabashi 
et al., 2004; Cheroni et al., 2005). To investigate if the decrease in 20S proteasome subunits 
that occurred with disease progression occurred at the mRNA level, 20Sa7, ~3, ~5 and ~5i 
transcripts were quantified by rt-PCR in lumbar motor neurons captured by laser 
microdissection from lumbar spinal cord of 100 day old SODI G93A transgenic mice and 
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nontransgenic littermates (Figure 19A) At this stage of the disease, there is documented motor 
neuron loss in the lumbar spinal cord of SODI G93A transgenic mice (Chiu et al., 1995i), but 
morphologically healthy motor neurons still remain (Figure 19A,B). Immunological analysis 
confirmed decreased levels of 20S a subunits in lumbar motor neurons in the same tissue 
block as used for rt-PCR experiments, whereas levels of GAPDH (used as a control in rt-PCR 
experiments) appeared similar in sections from SODI G93A transgenic mice and their 
littermates (Figure 19B). 
No significant difference was found in mRNAs encoding constitutive ~ and a7 
subunits in lumbar, cervical or thoracic motor neurons of SODI G93A transgenic mice 
compared to their littermates. However, an increase of ~5i mRNA levels was measured 
specifically in lumbar motor neurons, consistent with the increased protein levels detected by 
Western blotting (Fig. 19C). However, the data indicate that the decrease in protein levels of 
the constitutive ~ subunit and 20Sa proteins in lumbar motor neurons from symptomatic 
SOD 1 G93A transgenic mice did not result from decreased gene transcription or RNA stability. 
5.3 Proteasome Assembly and Complex Formation in Lumbar Spinal Cord of SODl G93A 
Transgenic Mice 
As described in Section 1.4.3, the assembly of the mammalian proteasome is not weIl 
understood. Sorne of the ~ subunits need to be cleaved to proforms prior to being assembled 
as heptameric rings in the proteasome complex. Several steps are required for 28 monomeric 
a and ~ subunits to form the 20S core of the proteasome which assembly in mammalian cells 
is mediated by POMP and Hsc73 chaperone (Kruger et al., 2001; Heink et al., 2005). AIso, 
another chaperone, Hsp90 plays an important role in assembly of mammalian 20S and 19S 
complexes and maintenance of the resulting 26S proteasome (lmai et al., 2003). A better 
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understanding of the important steps involved in the formation of the proteasome complex is 
required in order to better understand its role in neurodegenerative disorders and aging. 
In Drosophila brain, decreases in proteasome activity associated with aging 
corresponded to decreased immunoreactivity of ~5 subunit in the 26S proteasome complex 
(Wang et al., 2006b). However, the role that assembly and maintenance of 20S, 
immunoproteasome and 26S proteasome complexes play in ALS or other neurodegenerative 
disorders pathogenesis that are associated with dysfunctional ubiquitin-proteasome pathway 
has not been characterized. By the experiments described in this section, assembly and 
maintenance of 20S and immunoproteasome complexes were studied in the lumbar region of 
SOD1 G93A transgenic mice compared to littermates.using two-dimensional Coomassie Blue 
native/SDS-PAGE analysis as described below. AIso, formation of the 26S complexes was 
determined using a one-dimensional native gel approach enriched in ATP and glycerol to 
maintain the integrity of 26S proteasome complexes, as developed by Finley and colleagues 
(Elsasser et al., 2005) to study formation of proteasome complexes in yeast. 
Experimental Approach and Results 
5.3.1 20S and 26S Proteasome Complexes are Assembled, but Have Reduced 
Immunoreactivity to B subunits in the Lumbar Spinal Cord ofSOD1G93A Transgenic Mice 
To investigate if a decrease in proteasome activity reflected dysfunctional formation of 
the 20S/26S proteasome complexes, Blue native-SDSIPAGE was performed (Figure 20A). In 
the fIfSt dimension (Coomassie Blue native gel electrophoresis), protein complexes are 
separated according to their size, then subsequently broken into subunits in the second 
denaturing dimension (SDSIPAGE). By Western analysis using antibodies to specifie 
proteasomal subunits (20Sa, ~3 and ~5) showed that most of the se proteasomal proteins, from 
extract of lumbar spinal cord from either SOD1 G93A transgenic mice or nontransgenic 
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littermates, ran assembled in 20S proteasome complexes, with a small amount of 20Sa 
migrating as monomer (Figure 20A). Although there was no significant difference in levels of 
assembled or nonassembled 20S a subunits in lumbar spinal cord ofP75 SODI G93A transgenic 
mice compared to littermates, levels of ~5 and ~3 subunits in 20S proteasome were 
substantially decreased in lumbar spinal cord ofP75 SODI G93A transgenic mice. Co-Iabelling 
of these complexes with 19S antibodies revealed that most of the proteasomal complexes 
were arranged as 20S core with minimal assembled 26S complexes (Figure 20A). 
To examine the composition of intact 26S complexes, native gel electrophoresis was 
carried out in the presence of ATP and glycerol, which maintains the association of 19S 
regulatory partic1es and 20S proteasome core (Elsasser et al., 2005). A complex 
approximately 2.5 MDa in size was observed on Western blots of these gels probed with 
antibodies to a, ~ subunits as weIl as the S5a subunit of the 19S regulatory partic1e (Figure 
20B). Co-migration of 19S5a and 20Sa confirmed 26S as the major species of proteasome 
present. These results were similar to those obtained with Blue native/SDS-PAGE that poorly 
preserves the association 20S proteasome core with regulatory partic1es; i.e., decrease of ~5 
and ~3 in lumbar spinal cord tissue from SODI G93A transgenic mice, but no changes in a 
subunits in assembled proteasomes. 
5.4 No nirect Inhibition of the Proteasome br Mutant SOn1 in Lumbar Spinal Cord of 
son1 G93A Transgenic Mice 
That many tissues express high levels of transgenic SODI G93A, yet reduction in 
specific proteasome activities was predominant in lumbar spinal cord, argues against direct 
inhibition of the proteasome by mutant SODI. However, certain post-transiationally modified 
forms or small oligomers could be inhibitory substrates. The biophysical basis of altered 
detergent-solubility and polymerization of mutant SODI proteins in vivo remains to be 
identified, but is under investigation. Studies of recombinant proteins in vitro or transfected 
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cultured cells subjected to oxidizing conditions show that dimer destabilization and 
polymerization of monomers are promoted by disease-causing mutations, demetallation, 
disulphide reduction, and oxidative modifications (Urushitani et al., 2002; Rodriguez et al., 
2002; Rakhit et al., 2002; Tiwari and Hayward, 2002; Cardoso et al., 2002; Strange et al., 
2003; DiDonato et al., 2003; Chung et al., 2003; Elam et al., 2003; Hough et al., 2004; Rakhit 
et al., 2004; Zhang et al., 2004; Furukawa et al., 2004). Full biophysical characterization of 
mutant and WT SODI proteins from tissues will be required to resolve which states occur 
under physiological conditions and correlate with disease markers. In this section, in vivo 
association of mutant SODI with proteasome complexes in tissues from SODI G93A transgenic 
mice was determined in native gels. AIso, proteasome activities were determined in lumbar 
spinal after mutant SODI were immunodepleted from symptomatic SODI G93A transgenic 
mice. 
Experimental Approach and Results 
5.4.1 Mutant SODI was not Found Associatedwifh 20S Proteasomes in Lumbar Spinal Cord 
Western blots of Blue native-SDSIPAGE were reprobed with antibody to human 
SOD 1 in order to assess whether mutant prote in remained associated with proteasome 
complexes. No SODI-immunoreactivity co-migrated with 20S proteasomes (labeled with 
antibody to 20Sa subunits) (Figure 2IA). Monomeric and high molecular weight forms of 
mutant SODI were detected in the lower molecular weight region of the blot. 
AIso, immunoprecipitation of mutant SODI from lumbar spinal cord tissue of 
symptomatic SODI G93A transgenic mice using an antibody that preferentially binds to human 
SODI (SOD100) led to approximately 93% depletion ofhuman SODI from spinal cord tissue 
extract as determined by Western blotting (Figure 2IB). Subsequently, the three activities of 
the proteasome were assayed out in lumbar tissue before and after SODI immunodepletion. 
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No changes in the chymotrypsin-, caspase-, and trypsin-like activities of proteasome were 
measured as presented in Figure 21B. These results suggest that mutant SODI does not 
directly inhibit the proteasome by blocking the entrance and choking the 20S core as was 
previously hypothesized (Bennett et al., 2005). 
5.5. Discussion 
Prote in levels of functional ~5 subunit (subunit responsible for chymotrypsin-like 
proteolytic degradation) and structural ~3 subunit of the 20S core of the proteasome were 
significantly decreased specifically in the lumbar spinal cord region of P45 (Figure 13) and 
P75 (Figure 14) SOD 1 G93A transgenic mice. These results demonstrate that impairment of 
proteasome activity coincides with decreased levels of 20S ~ subunits (refer to Section 4.2). 
Levels of 20S ~ subunits did not change in insoluble extracts of lumbar spinal cord from P75 
SODI G93A transgenic mice (data not shown) demonstrating that the decrease in the 20S ~ 
subunit levels was not due to their precipitation from the soluble fraction. Proteasome 
impairment in lumbar spinal cord early in fALS disease pathogenesis did not induce increased 
expression of subunits of the 20S core as suggested by cellline studies (Meiners et al., 2003). 
Rather, most of the subunits of the ubiquitin-proteasome that were quantified were not 
change d, whereas levels of 20S ~ subunits were decreased. AIso, immunohistochemical 
analysis of lumbar spinal cord revealed that similar to previously reported depletion in 
structural a subunits (Figure Il), ~3 and ~5 subunits (Figure 17) ofthe 20S core are decreased 
in lumbar motor neurons with disease progression. 
During an immune and inflammatory response, cytokines such as IFN-y induce up-
regulation in the level of the inducible subunits, ~5i, ~2i and ~li, to replace the corresponding 
constitutive subunits, ~5, ~2, ~1. The resulting "immunoproteasome" and are very efficient in 
generating several antigenic peptides (Rivett et al., 2001). We measured the levels of ~5i in 
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lumbar spinal cord to determine if this occurs early in disease pathogenesis.of SODI G93A 
transgenic mice. No changes in ~5i were measured in the lumbar region of spinal cord of P45 
and P75 SODI G93A transgenic mice. These results strongly suggest that the impairment of 
proteasome activity and decreases in levels of 20S ~ subunits are very early events in fALS 
pathogenesis and occur prior to induction of an inflammatory response due to microglial 
activation (Figure 4). AIso, no changes were measured in the levels of subunit S6b of the 19S 
regulatory particles, nor in Il Sa of the regulatory subunit of the immunoproteasome in the 
lumbar spinal cord of P45 and P75 SODI G93A transgenic mice (Figure 15). These results 
demonstrate that regulatory particles and inducible subunits of the proteasome might not be 
involved in the early stages of fALS disease pathogenesis. 
Levels of proteasomal subunit proteins were measured in lumbar spinal cord tissue of 
symptomatic SODI G93A transgenic mice. As previously reported, an increase in the level of 
the inducible subunit, ~5i protein levels occurs at this stage (Cheroni et al., 2005; Puttaparthi 
and Elliott, 2005) and an increase in the regulatory particle of the immunoproteasome, Il Sa, 
was associated with a decrease of subunit S6b of the 19S regulatory particle. These data 
suggest a fundamental change in proteasomal composition in the lumbar region of the spinal 
cord of SOD 1 G93A transgenic mice due to the glial response and the pronounced loss of motor 
neurons. 
To determine whether this decrease in prote in levels is due to transcriptional defects, 
rt-PCR was performed in laser captured motor neurons from various regions of the spinal 
cord. Surprisingly, the decrease in protein levels did not correspond to decreases in mRNA 
transcripts of any of these 20S core proteasomal subunits. These results confirm that the 
changes in protein levels of proteasomal subunits in the lumbar spinal cord and motor neurons 
are not due to transcriptional defects, but to possible defects in the assembly of proteasome 
complex and/or post-translational modifications of individual subunits. However, an increase 
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in certain subunits in spinal cord tissue of SODIG93A transgenic mi ce that was not seen in 
motor neurons suggests that this increase might occur solely in non-neuronal cells. Similarly 
to prote in chaperones (Batulan et al. 2003), non-neuronal cells, unlike motor neurons, might 
be able to up-regulate proteasomal subunits when the proteasome activity is inhibited. 
Analysis of the composition of 20S/26S proteasomes by native gel electrophoresis 
demonstrated that in lumbar spinal cord tissue of SOD 1 G93A transgenic mice these complexes 
show unchanged immunoreactivity for a subunits, but decreased immunolabelling for ~3 and 
~5 subunits. These results suggest complex changes in the structure of the proteasome in 
SODI G93A transgenic mice during the course of the disease. The possibility that the 
constitutive ~5 subunit was replaced in the proteasomal complexes with ~5i was excluded 
since the levels of ~5i did not increase as measured by Western blotting (Figure 13 and 14). 
AIso, normal levels of ~ subunits were present as monomers which exclude the possibility 
that these subunits are rate-limiting in lumbar spinal cord tissue as was suggested by celllines 
studies (Chondrogianni et al., 2003). 
Another possibility is post-translational modifications to 20S ~ subunits that impair 
recognition by the antibodies and/or affect incorporation into proteasomal complexes. A 
major post-translational modification of 20S subunits that affects proteasomal activity and 
complex formation is HNE-modifications of certain amino-acids (Farout et al., 2006). An 
antibody immunoreactive to HNE adducts was obtained from Dr. Luke Szweda (University of 
Oklahoma Health Sciences Center). Immunoprecipitation and Western blotting of lumbar 
spinal cord of SODI G93A transgenic mice were performed, but no HNE-modified proteasomal 
subunits were detected in these Western blots (data not shown). Semi-purification of 
proteasome complexes by gradient centrifugation and analysis of the subunits by 2D gel 
electrophoresis is required to detect HNE-modified proteasomal subunits in vivo (Dr. Szweda, 
personal communication). 
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Another option was to immunoprecipitate intact proteasomal complexes and use mass-
spectrometry analysis to determine prote in composition and post-translational modifications 
of proteasomal subunits. In our preliminary experiments, the only commercially available 
antibody known to immunoprecipitate intact proteasomes that recognizes a subunit of the 20S 
core, immunoprecipitated the subunit, but not the whole 20S complex as determined by co-
labelling with antibodies to f3 subunits. Finally, spots from the second dimension of blue 
native gels that correspond to 20S proteasomal bands in murine tissue were excised and their 
identity was analyzed by mass spectrometry. However, the signal was very low only 20S a 
subunits were recognized and the sequence coverage was minimal (2-7%). 
Due to technical limitations in proteasomal subunit purification and characterization, 
we could not study the post-translational modification of subunits in affected tissues of 
SOD1 G93A transgenic mice. An alternative possibility to explain a reduction proteasomal 
activity without a decrease in the expression of structural a subunits is alteration in 
proteasome complex assembly. However, from our experiments using native gel 
electrophoresis, 20S and 26S proteasomes from lumbar spinal cord of SOD1 G93A transgenic 
mice run as intact complexes similar to complexes from spinal cord tissue of non-transgenic 
littermates. AIso, no increase in free subunits or intermediate proteasomal complexes were 
observed implying there is no obvious structural changes in proteasome complex formation. 
Further studies are required to resolve which mechanisms are involved in proteasome activity 
decrease observed in affected tissue of mutant SOD1 transgenic mice. What remains of 
essence from these results is that impairment of the proteasome activity and a corresponding 
decrease of the f3 subunits of the 20S proteasome occur early in disease pathogenesis and can 
contribute to fALS motor neuronal pathology in the transgenic mouse model. 
Studies of neuronal cell lines have demonstrated that mutant SOD 1 aggregates 
associate with subunits of the 20S core and this association leads to proteasome overload and 
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progressive inhibition of its activity (Matsumoto et al., 2005). To determine if this 
phenomenon occurs in vivo, an antibody specific to human SODI (SODIOO) was used to test 
whether mutant SODI associates with the proteasome complex (Figure 2IA) and whether 
SODI immunodepletion ofSODI relieves proteasome impairment measured in lumbar spinal 
cord of SOD 1 G93A transgenic mice. This antibody can recognize high-molecular weight, SDS-
insoluble, SODI species that accumulate in spinal cord during the course of the disease 
(Figure 6) and oxidatively modified mutant SODI (Agar, Kabashi et al. manuscript in 
preparation). However, immunodepletion of soluble SODI from the lumbar spinal cord did 
not relieve the proteasome impairment (Figure 2IB). AIso, mutant SODI, including SDS-
insoluble SODI species did not migrate with the 20S proteasome complex as seen in the 2nd 
dimension of Blue Native gels (Figure 2IA). These experiments argue against direct 
association and choking of the proteasome complex by mutant SODI (Bennett et al., 2005). 
However, these results do not exclude the possibility that post-translationally modified forms 
of mutant SODI that are not recognized by the antibody might lead directly to proteasome 
impairment. Interestingly, this antibody does not recognize the cleaved SODI peptides from 
the 20S proteasome that have been proposed to be associated with toxicity (Di Noto et al., 
2005), and it does not label the inclusion bodies formed when various forms of mutant SODI 
are injected in motor neurons (Durham et al., 1997). Full biophysical characterization of 
mutant and wild type SODI proteins from tissues will be required to determine which states 
occur under physiological conditions and correlate with disease markers. Generation of 
reliable antibodies to recognize these modified forms of SODI for immunoprecipitation and 
mass spectrometry characterization of the se peptides are aiso required. 
In conclusion, these studies identify two events occurring simultaneously in lumbar 
spinal cord tissue during disease progression in SODI G93A transgenic mice; a focal 
impairment of proteasome activity associated with decreased levels of 20S ~ subunits early in 
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disease pathogenesis and a progressive decrease of 20S Il and ~ subunits in lumbar motor 
neurons that peaks at symptomatic stages. Further research is required to determine what 
causes the se changes in enzymatic activity and protein levels of the proteasomal machinery 
and whether the phenomena described here occur in affected tissues from sporadic and fALS 
patients as weB as in other animal models of fALS 1. 
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Figure 13 
The decrease in constitutive 20S core Il subunits initiates at P45 in SOD1 G93A transgenic 
mice and is not associated with changes in inducible Il subunits 
Expression of specific proteasome subunits measured by SDSIP AGE immunoblotting of 
soluble extracts of lumbar spinal cord (l0 J.lg per lane) from four groups of mice: SOD 1 G93A 
transgenic mice, SODI WT transgenic mice and their age-matched non-transgenic littermates 
(GLm and WLm). Spinal cord tissue extracts from two litters of P45 SODI G93A transgenic 
mice and one litter of SOD 1 WT transgenic mice were analyzed in duplicate. 
The bands on exposed blots from representative Western blots in (A) were normalized to the 
levels of actin, which was used as loading control. A significant decrease of two ~ subunits, 
~3 (structural subunit) and ~5 (harbouring the chymotrypsin-like activity) were measured 
solely in lumbar spinal cord extracts ofSODI G93A transgenic mice. No changes were 
measured in 20S a subunits or in the inducible ~ subunit (~5i) (* p<0.05). 
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Figure 14 
The decrease in Il subunits is accentuated in P75 SOD1 G93A transgenic mice, whereas the 
expression of inducible Il and a subunits of the 20S core were not affected 
A. Western blots of soluble spinal cord extracts (10 Ilg per lane) separated by SDS-PAGE 
probed with antibodies specific to various proteasomal subunits. Four groups of mice were 
analyzed: SOD 1 G93A transgenic mice, SOD 1 WT transgenic mice and their age-matched non-
transgenic littermates (GLm and WLm). Spinal cord tissue extracts from two litters of P75 
SOD 1 G93A transgenic mice and one litter of SOD 1 WT transgenic mice were used. A significant 
decrease of two P subunits, p3 (structural subunit) and p5 (harbouring the chymotrypsin-like 
activity) were measured solely in lumbar spinal cord extracts of SOD1 G93A transgenic mice. 
No changes were measured in other proteasomal subunits, including 20S a subunits, I9S5a 
and 1ISa. AIso, no concurrent increase in the inducible P subunit (P5i) was observed. 
B. Exposed films from Western blots using spinal cord tissue extracts from two litters ofP45 
SODIG93A transgenic mice and one litter of P75 SOD1WT transgenic mice were quantified 
using the ScionData program. AlI results shown in (A) were repeated twice in different 
Western blots and normalized to actin levels, which were used as loading control. 
Quantification of the exposed blots in (A) reveals an impairment of20S P subunits that is not 
associated with changes in other proteasomal subunits. The decrease of p5 and p3 with no 
increase in the inducible p5i subunit of the 20S was repeated in at least three litters of 
SOD 1 G93A transgenic mice and age-matched non-transgenic littermates (* p<0.05). 
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Figure 15 
No changes in 20S subunits in thoracic spinal cord of pre-symptomatic SODIG93A 
transgenic mice. A1so, two subunits of the regulatory particle (19S and 11S) of the 
proteasome were Dot affected in the lumbar spinal cord in the pre-symptomatic stages 
A. Thoracic spinal cord tissue obtained from P45 and P75 SOD1 G93A transgenic mice and age-
matched non-transgenic littermates were immunobloted for 20S ~ (~5, ~5i, ~3) and for a 
subunits of the 20S core of the proteasome. No change was detected (panel B) in the 
expression of any of these subunits. This confIrms that the pre-symptomatic changes in 20S 
constitutive ~ subunits is focal to the lumbar region and corresponds to specifIc impairment of 
proteasome activity in this region. 
B. Western blots from Figure 12 and 13 were reprobed with antibodies to subunit S6b of the 
19S and Il Sa regulatory particles of the proteasome. We determined no pre-symptomatic 
decrease in their levels (panel D) suggesting that the expression of the regulatory particles is 
not altered at the early stages of ALS pathogenesis (* p<0.05). 
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Figure 16 
The decrease in 20S core constitutive Il subunits in symptomatic SODI G93A transgenic 
mice is associated with an increase in levels of the inducible Il subunits and the 
regulatory particle (11S) ofthe immunoproteasome 
A. Western blots of soluble spinal cord extracts (10 J.lg per lane) separated by SDS-PAGE 
probed with antibodies specific to various proteasomal subunits. Four groups of mice were 
analyzed: symptomatic SOD1 G93A transgenic mice and their age-matched non-transgenic 
littermates (GLm approximately 120-130 day old). Spinal cord tissue extracts from two litters 
ofsymptomatic SOD1 G93A transgenic mice were used. Increased prote in levels of20S ~5i and 
the regulatory subunit of the immunoproteasome, Il Sa, confirm that there is an elevation of 
the immunoproteasome expression in lumbar spinal cord of symptomatic SOD 1 G93A 
transgenic mice due to the glial inflammatory response. Levels of ~5 and 19S6b were found to 
be decreased at this stage reflecting large changes in spinal cord proteasome composition at 
this late stage of the disease. 
B. Western blots were quantified revealing significant increases in prote in levels of 20S ~5i 
and Il S as weIl as significant decreases in 20S ~5 and 19S6b, whereas levels of 20S a 
subunits were not changed. Quantified levels were normalized to actin which was used as a 
loading control (* p<0.05). 
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Figure 17 
Expression of constitutive 20S Il subunits in lumbar spinal motor neurons of 
symptomatic SODI G93A transgenic mice 
Expression of (A) ~3 and (B) ~5 subunits in lumbar motor neurons of SODI G93A transgenic 
mice with disease progression detennined by immunolabeling 20 J.UIl spinal cord sections. 
Motor neurons express high levels of constitutive ~ as weIl as a subunits of the 20S core of 
the proteasome (see Figure 10). A progressive decrease in ~5 and ~3 immunolabeling was 
observed in motor neurons as the disease progressed, but not in age-matched non transgenic 
LM. 
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Figure 18 
No reduction in expression of proteasome subunit mRNAs in the spinal cord of mutant 
SOD1 transgenic mice 
Shown is expression of mRNAs encoding murine ~3, ~5, ~5i and 0,7 proteasome subunits 
relative to GAPDH as a control housekeeping gene. rt-PCR of whole tissue extracts of 
lumbar, thoracic and cervical spinal cord was performed using specific primers listed in Table 
4. No decrease in levels of 20S subunit mRNAs was measured. Instead, a significant increase 
in ~5 mRNA levels in lumbar and cervical spinal cord of SODI G93A transgenic mice was 
determined, as weIl as an increase of ~5i in the thoracic and cervical sections of the spinal 
cord. AIso, rnRNA levels of the 20S 0,7 subunit were increased in thoracic spinal cord extracts 
from SOD 1 G93A transgenic mice (* p<0.05). 
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Figure 19 
Normal levels of 20S subunit mRNAs despite decrease in 20S core protein levels in 
lumbar motor neurons of symptomatic SODI G93A transgenic mice 
To analyze expression of rnRNAs encoding proteasome subunits specifically in motor 
neurons, motor neurons were removed by laser microdissection from sections of lumbar, 
thoracic and cervical regions of spinal cord from PlOO SODI G93A transgenic mice and non-
transgenic LM. Panel A shows section before (upper) and after (lower) laser capture of a 
motor neuron from an SODI G93A transgenic mouse. 
B. Immunolabeling of sections of lumbar spinal cord with antibody to proteasome core shows 
reduction in labeling of 20Sa subunits in SODI G93A transgenic mice relative to LM, but 
maintained expression of the control housekeeping prote in, GAPDH. 
C. Quantitation of reverse transcribed mRNA in approximately 20 pooled motor neurons per 
primer by rt-PCR revealed no significant difference in levels of 20Sa7, ~3 or ~5 subunits 
from lumbar, thoracic and cervical motor neurons of SODI G93A transgenic mice or LM. ~5i 
mRNA was significantly increased possibly due to the immune response that is a prominent 
feature at this stage of disease (* p<0.05). 
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Figure 20 
The assembly of 20S and 26S proteasome complexes is not impaired whereas 
incorporation of Il subunits is affected in the lumbar spinal cord of SODt G93A transgenic 
mice 
A. 2-D Blue native/SDS-PAGE was used to separate protein complexes (including 
monomeric a and p subunits of the 20S core, immature precursors, and assembled proteasome 
complexes) in the first dimension, then analyze subunit composition of complexes in the 
second, denaturing dimension. By this method, most of the proteasomal complexes were 20S 
because they were labelled by 20S core antibodies, but not by antibodies to 19S regulatory 
particle (data not shown). Extracts oflumbar spinal cord from P75 SODIG93A transgenic mice 
and nontransgenic LM were analyzed. Second dimension gels were transferred to 
nitrocellulose and labelled with antibodies to 20Sa, p3 and p5 proteasome subunits. 
Antibodies labelled proteins of the same high molecular weight mobility representing 20S 
proteasome (major bands on left side of blots), with very few monomeric subunits being 
detected (small spots on far right of blots). lmmunolabeling of p5 and p3 subunits in the 
assembled 20S core was reduced in lumbar spinal cord of P75 SODI G93A transgenic mice 
relative to LM, without concomitant increase in species with lower molecular weight. 
B. To maintain integrity of 26S complexes, a protocol modified from that developed by 
Finley and colleagues was utilized. A complex approximately 2.5 MDa in size was observed 
upon probing blots of lumbar or thoracic spinal cord with antibodies to a, and p 20S subunits 
as weB as the S5a subunit of the 19S regulatory particle. As with 20S complexes shown in 
(A), (35 and (33 immunolabeling was decreased in in the assembled 26S complexes of lumbar 
spinal cord of P75 SODIG93A transgenic mice without any change in labeling of 20S a 
subunits. 
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Figure 21 
Mutant SODI was not associated with proteasome complexes in lumbar spinal cord 
from SODIG93A transgenic mice 
A. Western blots prepared :from 2-D Blue native/SDS-PAGE of lumbar spinal cord extracts 
:from P75 SOD 1 G93A transgenic mice were probed with antibodies to 20Sa and SOD 1 
(SODIOO; Stressgen) to determine any association of mutant SODI with proteasome 
complexes. No co-migration of mutant SOD 1 with the proteasome was observed. 
Overexposure of the blots revealed high molecular weight SOD 1 species in the lumbar region 
of SOD 1 G93A transgenic mice spinal cord in the low molecular weight region of the gel, not 
with proteasomes. 
B. SODI was immunodepleted (IMD) :from lumbar spinal cord homogenates :from three 
individual mice using an antibody that preferentially binds human SODI. Left-most bands in 
exposed Western blot using the SODIOO antibody represent pre-immunodepleted samples 
:from lumbar spinal cords of three SODI G93A transgenic mice (LI, L2, L3). Ta make 
quantitation possible, immunodepleted samples were run at ten-times the concentration of 
pre-IMD samples and are shown on the right of each pre-immunodepleted sample. According 
to quantitation of band densities by Scion Image, approximately 93% of total hum an SODI 
was immunodepleted :from the lumbar spinal cord of SODI G93A transgenic mice. 
Immunodepleting mutant SODI :from lumbar spinal cord extract did not affect proteasome 
activities as measured by hydrolysis of peptide substrates. 
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Chapter 6 Role of the ubiquitin-proteasome pathway in sporadic 
ALS 
Experiments in this chapter were conducted in order to determine if prote in levels and 
activities ofvarious proteasomal proteins and complexes are altered in autopsy tissue from 
sporadic ALS patients (Specific Aim 3). Three main activities of the proteasome were 
determined in dorsal and ventral sections ofthe thoracic spinal cord (an affected region) and 
less affected CNS tissue (cerebellum) obtained post-mortem from sporadic ALS patients and 
control cases. AIso, the levels of a and ~ subunits of the 20S core, and representative subunits 
ofthe regulatory particles (19S and lIS) ofthe proteasome were assessed. As in the fALS 
mouse model, reduction in all three proteasomal activities was measured in thoracic spinal 
cord of ALS patients. This was accompanied by a decrease of the 20S catalytic subunit ~5, 
but no significant changes in the expression of other proteasomal subunits were measured. 
6.1 Evidence orthe ubiguitin-proteasome pathway involvement in sporadic ALS 
Studies in experimental models point to inadequacy of cellular stress responses and 
dysfunction of the proteasomal proteolytic pathway in the pathogenesis of familial ALS due 
to mutations in SODI. Decreased specific proteasomal enzymatic activities in lumbar spinal 
cord ofSOD1 G93A transgenic mice early in pathogenesis was restricted to lumbar spinal cord 
tissue, the region eventually most affected by disease (refer to Chapter 4.2). This was 
compounded by altered expression of at least two ~ subunits in lumbar spinal cord as well as 
depletion of20S core subunits in lumbar motor neurons later in the disease (see Chapter 4 and 
5). It is important to determine the relevance of these fmdings in experimental models to 
pathogenesis of sporadic ALS patients since they account for about 90% of cases. The 
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working hypothesis was that compromise in handling of abnormal proteins is an early, 
common event in ALS pathogenesis. 
Cytosolic prote in inclusion bodies visible by light microscopy are common in sporadic 
(Leigh et al., 1988; Shibata et al., 2001) and fALS (Kato et al., 2000; Watanabe et al., 2001), 
mutant SODI transgenic mice (DaI Canto and Gumey, 1995; Bruijn et al., 1997) as weIl as 
primary cultured motor neurons (Durham et al., 1997), suggesting that protein misfolding and 
aggregation play an important role in ALS pathogenesis generaIly. Since these inclusions are 
often labeled positively by antibodies specific to ubiquitin, it was suggested that the ubiquitin-
proteasome pathway is involved in degrading the proteins that are trapped in these inclusion 
bodies. 
To evaluate the role of proteasome dysfunction in sporadic ALS, it was essential to 
measure proteasome activities, to evaluate the expression of its subunits, as weIl as to 
determine if any changes occurred globally or were restricted to tissues atIected in this 
neurodegenerative disorder. 
6.2 Feasibility of Assessing Levels and Activities of Proteasomes in Post-Mortem Tissue 
of ALS Patients 
Since interpretation of biochemical measurements in postmortem, end-stage tissue can 
be challenging, it was important to determine levels and activities of the proteasome in 
banked autopsy tissue and to compare it to results in murine tissues using the same 
methodology as results presented in Chapter 4 and 5. AIso, the stability of the proteasome 
complexes for at least 12 hours post-mortem was determined in murine tissue by measuring 
proteasome activities as weIl as protein levels of structural a subunits ofthe 20S core. 
Experimental Approacb and Results 
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6.2.1 Autopsy rime Does Not Have an EfJect in Proteasome Activity and Levels 
In order to determine if activity and levels ofthe proteasome change with post-mortem 
interval (refer to Table 3), a preliminary study was conducted in mice. Murine spinal cord 
tissue was frozen immediately after dissection or left at room temperature at various time 
point intervals up to 12 hours. Six non-transgenic mice with B6SJL background were used. 
Spinal cord was removed and cut in half and hemicords were placed in tubes and frozen 
immediately (0 hours), or left in the dark at room temperature and placed at -80°C 3, 6 and 12 
hours after spinal cord removal. Liver tissue from the se mice was also removed and 
immediately frozen. No changes in the chymotryptic activity ofthe proteasome were observed 
among aIl four test conditions (frozen right away, t = 0; frozen after 3,6, and 12 hours left at 
room temperature) (Figure 22A). Western blot analysis showed that the postmortem interval 
did not affect levels or integrity of prote in bands representing a structural subunits of the 20S 
core or actin (Figure 22B). It was concluded that post-autopsy intervals up to 12 hours do not 
have a significant impact in proteasome activity and levels, and therefore conducting the se 
experiments using postmortem human tissue was feasible and meaningful. 
6.1.2 Activity and Levels ofProteasome in Frozen Human Spinal Cord is Comparable to 
Murine Tissue 
The next step in this series of control experiments was to measure aIl three 
proteasomal activities in human autopsy tissue maintained frozen at -80°C and compare these 
activities and levels of proteasome to murine tissue. The three proteolytic activities of the 
proteasome, namely chymotrypsin-like (Figure 23A), caspase-like (Figure 23B) and trypsin-
like (Figure 23C) activities, and levels of 20Sa subunits (Fig. 23D) were measured in spinal 
cord tissue from a control case (Fig. 23A,B,C; bars in right-hand side) and from liver tissue of 
a nontransgenic mouse (Fig. 23A,B,C; bar in left-hand side). The data was normalized to 
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murine spinal cord tissue from previous experiments (Fig. 23A,B,C; right panels). AIso, 
protein levels ofa structural subunits of the 20S core in frozen human and murine spinal cord 
samples were determined. The activities and levels of the proteasome in frozen human tissue 
were remarkably similar to frozen mouse tissue (Figure 23). 
6.3 Impairment of the Ubiquitin-Proteasome Pathway in the Spinal Cord of Sporadic 
ALS Patients 
Having established that meaningful measurements of proteasome composition and 
activity are feasible in frozen human autopsy tissue, we proceeded with experiments to 
compare these measures in tissues from sporadic ALS patients and non-neurological controls 
and to conduct an immunohistochemical analysis of expression of proteasome subunits. 
Frozen tissue (spinal cord and cerebellum) as well as paraffin-embedded spinal cord sections 
from the same region were obtained from the tissue bank of Dr. Michael Strong (Robarts 
Research Institute, London, Ontario). 
Experimental Approach and ResuUs 
6.3.1 Focal Dysfunction ofProteasome Activity in Spinal Cord ofSporadic ALS Patients 
20S/26S proteasomal activities were measured in ventral as well as dorsal section of the 
spinal cord, (Fig. 24A,B,C left panels) tissue extracts obtained from five sporadic ALS 
patients (thoracic region of the spinal cord), thoracic region oftwo control cases and cervical 
spinal cord from two other controls (cervical). Proteasome activities were also measured in 
cerebellar tissue from the same individuals (Fig. 24A,B,C right panels). Assays were based on 
hydrolysis of fluorogenic substrates specifie for each of the chymotrypsin-like, caspase-like 
and trypsin-like activities of the proteasome. Chymotrypsin-like activity of the proteasome, 
calculated as omol of AMC/min/mg, was significantly impaired in the thoracic spinal cords, 
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activity in the ventral and dorsal regions of ALS samples being 60% and 65% of the activity 
in control cases, respectively (Figure 24A). Also the other two major activities of the 
proteasome were significantly reduced, with caspase- (Fig. 23B) and trypsin-like (Figure 24C) 
activities in spinal cord of ALS tissue being 54%, and 65%, in the ventral region and 68% and 
46% in the dorsal region respectively, of the activities measured in control cases. No 
significant reduction in any of the three proteasomal activities were measured in cerebellar 
tissue of sporadic ALS patients (Fig. 24A,C,D left panel), tissues previously shown to exhibit 
limited pathological changes (Tandan and Bradley, 1985). In summary, a focal reduction of 
proteasome activity was measured within the thoracic region of the spinal cord of sporadic 
ALS patients. 
6.3.2 Deereased Levels of 85 Catalytie Subunit Corresponds to Proteasome Impairment in 
Tissues Aflèeted by Sporadie ALS 
Focal reduction of the proteasome activity, normalized to levels of20Sa. structural 
subunits, corresponded to decreased levels of20S structural ~3 and functional ~5 subunits in 
mutant SOD1 transgenic mice. To determine if the levels of20S subunits and subunits of the 
regulatory particles, 19S and Ils are affected in sporadic ALS, SDSIPAGE and Western 
blotting were conducted using extracts of spinal cord and cerebellum from the five ALS and 
four control cases. The amount of catalytic 20S ~5 subunit was decreased in thoracic spinal 
cord, but not cerebellum of ALS samples, but was not due to an increase in the expression of 
the inducible subunit, ~5i (Figure 25A). AIso, a decrease measured in levels of S5a subunit of 
the 19S was not associated with an increase in the levels of the regulatory particle of the 
immunoproteasome, Ils a. (Figure 25B). The decreases of20S ~5 and 19S5a were specific to 
spinal cord tissue since no changes were observed in the cerebellar tissue extracts (Figure 
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25B). Unlike the fALS mou se, no changes in the structural ~3 subunit ofthe 20S core were 
observed. 
6.3.3 Further Evidence oflmpairment orthe ubiquitin-proteasome pathwav in Spinal Cord 
Tissue orAIS Patients 
As previously discussed, proteasome inhibition in rat substantia nigra leads to a rapid 
up-regulation ofmRNA and prote in levels of Hsp70, but not Hsp40 (Ahn and Jeon, 2006). In 
a previous study from our laboratory, no upregulation ofHSP70 was observed in motor 
neurons of ALS spinal cord, except for labeling of occasional inclusion bodies (Batulan et al., 
2003). However, when levels ofHSP70 and HSP40 were examined in the present study by 
Western blotting of tissue extracts from sporadic ALS and control cases, Hsp70 levels were 
increased in thoracic spinal cord of ALS patients, whereas levels ofHsp40 were not affected. 
This is another similarity between the fALS mouse model and sporadic ALS and is evidence 
of an increased load of misfolded proteins, which could accumulate if proteasomal 
degradation is inadequate. 
6.4 Discussion 
Since most inclusion bodies from sporadic and fALS patients were immunopositive 
for ubiquitin, a dysfunction of the ubiquitin-proteasome pathway was hypothesized as an 
essential factor for protein aggregation into inclusion bodies in ALS pathogenesis. However, 
one antibody raised against the 20S core failed to label these ubiquitin-positive inclusion 
bodies in matar neurons and astrocytes from sporadic and fALS cases (Watanabe et al., 
2001). Recently, a paper published while this thesis was in preparation, and using another 20S 
proteasome antibody, reported an increase in proteasome immunolabeling in motor neurons 
with inclusion bodies suggesting an up-regulation of the proteasome complex in sporadic 
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ALS (Mendonca et al., 2006). This study is in discordance with results :from two independent 
studies in SOD1G93A transgenic mice where a decrease ofproteasomal subunit levels was 
observed in motor neurons as disease progressed (Figure Il) (Kabashi et al., 2004). In fact, 
Cheroni et al. illustrated by double-label immunocytochemistry that 20S core levels were 
lowest in motor neurons with ubiquitin-positive inclusion bodies (Cheroni et al., 2005). 
Antibody non-specificity as weIl as epitope masking in human tissue might have contributed 
to this discrepancy. Studies using antibodies directed against specific subunits of20S, 19S 
and Il S as weIl as ubiquitinated proteins are needed to determine levels of components of 
ubiquitin-proteasome pathway in afTected tissue :from ALS patients. Various protein 
chaperones have been found in protein aggregates :from SOD 1 G93A and SOD 1 G85R transgenic 
mice, including moderate expression ofHsp40, Hsp60, Hsp70, Hsp90 as weIl as strong 
expression of Hsc70 in inclusion bodies (Watanabe et al., 2001). Interestingly, Hsc70, but not 
other protein chaperones, was also found in protein inclusion bodies found in motor neurons 
and astrocytes :from sporadic and fALS cases (Watanabe et al., 2001). 
In order to perform a biochemical assessment of the proteasome acitivity and levels in 
tissues obtained :from sporadic ALS patients as weIl as control cases, a series of preliminary 
experiments demonstrated that proteasomal proteins and their catalytic activities are quite 
stable post-mortem and that proteasome activities and level of20Sa subunits in human and 
mouse nervous tissue are comparable under similar conditions of preservation and as say 
(Figure 22 and 23). Thus, assay ofproteasome function and composition is realistic in human 
autopsy tissue at least up to 12 hours post-mortem. 
Ali three activities of the proteasome were reduced by 55-70% in thoracic spinal cord 
of ALS patients relative to controls with the trypsin-like activity in ventral sections being the 
most afTected at 46%. Interestingly, activities were reduced in dorsal spinal cord samples as 
weIl as in the ventral region where motor neurons are located. That proteasomal impairment is 
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present in both the ventral and dorsal regions of the spinal cord suggests that proteasomal 
impairment is not limited to the motor neurons and the sorrounding neighbourhood, but is a 
more widespread phenomenon. This could be due to the advanced state of spinal cord 
degeneration where other ceU types (neuronal and non-neuronal) might be affected. 
Altematively, proteasomal impairment as well as sporadic ALS pathogenesis might initiate 
simultaneously in both ventral and dorsal sections of the spinal cord. 
In order to determine if the proteasome activity was generaUy affected in CNS tissues 
from ALS patients, tissue from cerebellum obtained from the same five sporadic ALS patients 
and four control cases was analyzed. The cerebellum shows minimal involvement 
morphologically in ALS (Tandan and Bradley, 1985). AIso, no changes in markers of 
oxidative damage were detected in cerebellar regions of sporadic and fALS patients, whereas 
the motor cortex ofthese patients had increased oxidative damage (Ferrante et al., 1997). No 
change was detected in all three activities of the proteasome in cerebellar tissue extracts of 
sporadic ALS patients when compared to control cases (Figure 24A-C), evidence that the 
impairment of 20S/26S proteasome activity was specific to the tissue most affected by ALS. 
The decrease in proteasomal activities in thoracic spinal cord of ALS patients, as seen 
in a decrease in the level of the ~5 subunit ofthe 20S core and ofthe S5a subunit of the 19S 
regulatory particle of the proteasome, was determined in the ventral section of thoracic spinal 
cord tissue of ALS patients (Figure 25A). These proteins remained at normallevels in 
cerebellar tissue (Figure 25B). 
Even though a focal impairment of the proteasome activity associated with a specific 
decrease in 20S functional subunits rneasured in affected spinal rnotor nuclei was a cornmon 
finding in sporadic ALS patients and SODI G93A transgenic mice, sorne important differences 
were observed. Unlike results obtained from lumbar spinal cord tissue of symptomatic 
SOD 1 G93A transgenic mice, there was no increase of the regulatory particle Il Sa. and the 
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inducible subunit ~5i ofthe immunoproteasome (Figure 25A) suggesting that either a lesser 
immune response is activated in tissue from sporadic ALS patients or glial reactivity and an 
immune response do not lead to a massive up-regulation of immunoproteasome subunits. 
lmmunohistochemical analysis of the tissue from these patients with antibodies that label glial 
markers (GFAP, MACl), immune markers (TNPa., IFNy) and members of the 
immunoproteasome (11 Sa., ~5i) as weil as other members of the ubiquitin-proteasome 
pathway will allow determination of the extent of the immune reaction in these tissues. A full 
analysis was not possible in this prelimary study because of limitations in the amount of 
material available to us. 
Another difference between the mouse mode! of fALS and sporadic human ALS is 
that no decrease in the structural subunit of the proteasome, 20S ~3, was measured in thoracic 
spinal cord of ALS cases, even though the expression of this subunit was decreased very early 
in disease pathogenesis in the lumbar spinal cord tissue of SOD 1 G93A transgenic mice. These 
results suggest that several converging molecular mechanisms might lead to proteasome 
impairment during ALS pathogenesis and a further analysis of these abnormalities is required 
to clarify the involvement in disease pathogenesis. AIso, immunohistochemical ànalysis in 
archived paraffin-embedded slides derived from spinal cord sections from the same sporadic 
ALS patients and control cases were performed. Unexpectedly, several antibodies specific for 
a. and ~ subunits well-characterized in murine studies (Figure Il and 17) that immunolabel 
specific bands in Western blots of human spinal cord tissue extracts (Figure 25) labelled very 
faintly motor neurons as weil as the spinal cord background (data not shown). Whether there 
are problems with the protocol used for immunohistochemistry and antigen retrieval, the 
quality of paraffm-emhedded tissue or if motor neurons in human spinal cord are not 
immunoreactive for subunits of the 20S core remains to he determined. 
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Results from post-mortem tissue are very difficult to interpret since generally the 
spinal cord of ALS patients is atfected at the morphologicallevel and cellular ditferences 
were observed in spinal cord sections (motor neuron loss, gliosis) from these patients. 
Altematively, the proteasomallevels and activities can be determined in spinal cord 
cerebrospinal fluid derived from early symptomatic and late symptomatic ALS patients, 
where there is evidence of prote in misfolding, to determine the importance that the ubiquitin-
proteasome pathway plays during disease progression in sporadic ALS patients. 
The experiments reported in this thesis were conducted as a preliminary study to 
determine the relevance of proteasomal abnormalities to the more general problem of sporadic 
ALS and the feasibility of conducting these experiments with post-mortem tissue. The results 
support a full analysis of proteasome composition and assembly in a larger number of 
samples. The difficulty in obtaining additional control tissues makes the se experiments 
beyond the scope of this thesis. 
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Figure 22 
No change in proteasome activity was measured in mouse spinal cord tissue up to 12 
hours post-mortem and structural subunits of the proteasome appeared intact 
Following anesthetic overdose mouse spinal cord tissues were dissected and either was 
immediately frozen (time 0) or stored at room temperature for 3, 6 and 12 hours. Spinal cord 
tissue (3 mice per time point) was processed and tissue extracts were used for activity assays 
and SDSIPAGE gels. No changes were measured in chymotrypsin-like activity of the 
proteasome (A) and no difference was determined in the structural a subunits of the 20S core 
(B) in murine spinal cord tissue from each time point. 
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Figure 23 
Proteasomal activities measured in banked human spinal cord were similar to those of mouse 
spinal cord processed immediately post-mortem 
Each of the three main proteasome activities was measured in frozen human thoracic spinal 
cord (non-ALS) obtained from Dr. Michael Strong's tissue bank of autopsied material [case 
was 73 yr-old male; autopsy was carried out 10 hrs post-mortem]. Samples of mouse liver 
(from 120 day old mice processed immediately post-mortem) were run at the same time as a 
technical control (see right hand panels in A,B,C). Left panels show activities of lumbar and 
thoracic spinal cord relative to liver in mice. Chymotrypsin-like (A), caspase-like (B), trypsin-
like (C) activities ofhuman thoracic spinal cord tissue separated in ventral and dorsal sections 
were quite similar to activities of lumbar and thoracic murine spinal cord. (D) Proteasomal 
proteins remain intact in human spinal cord tissue as detected by Western blot. 
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Figure 24 
Proteasome Activities are reduced in Thoracic Spinal Cord, but not Cerebellum from 
Sporadic ALS Patients 
Chymotrypsin-like (A), caspase-like (B) and trypsin-like (C) activities expressed as 
nmol/minlmg after being normalized to actin levels were measured in homogenates of dorsal 
and ventral sections of thoracic spinal cord from five ALS patients and two control cases. 
Dark bars represent ventral and dorsal regions of the spinal cord of ALS patients, whereas 
light bars represent their age-matched, sex-matched controls. Chymotrypsin- (A), caspase-
(B), and trypsin-like (C) activities were significantly reduced in both ventral and dorsal 
portions of the thoracic spinal cord of ALS patients. Proteasomal activities are expressed as 
means ± SEM (nmol/minlmg) of four independent measurements in tissue from five sporadic 
ALS patients and four control cases. Significantly different from LM control: (* p<O.05; ** 
p<O.OI; *** p<O.005). 
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Figure 25 
Levels of constitutive 20S ilS subunits and a 19S subunit were reduced in tboracic spinal 
cord tissue from sporadic ALS patients, but tbis was not associated witb an increase of 
immunoproteasome subunits 20S 1l5i or l1S 
Measurements of proteasome activity in post-mortem spinal cord tissue of sporadic ALS 
patients revealed decreased activity of the proteasome (Figure 24). SDSIP AGE and Western 
blotting were performed to determine levels of proteasomal subunits in spinal cord tissue and 
cerebellum (less affected CNS tissue) of five ALS patients and four control cases. Levels of 
~5 and 19S5a were decreased, reflecting significant changes in proteasome composition in an 
affected region of spinal cord at the end stage of ALS (panel A). However, unlike studies 
performed in an animal model offALS, SODI G93A transgenic mice, the levels of the inducible 
subunit responsible for chymotrypsin-like activity, 20S ~5i, and the regulatory subunit of the 
immunoproteasome, Il S, were not elevated (panel A). AIso, there was no change in levels of 
structural ~3 and various a subunits of the 20S core. No changes were measured in the subunit 
levels of 20S core (~5, ~5i, ~3, 0.1-7), 19S (S5a) and llSa regulatory particles of the 
proteasome in cerebellar tissue of sporadic ALS patients (panel B) indicating that the changes 
measured in 20S ~5 and 19S5a occurred only in regions affected by ALS. In panels C and D, 
statistical analysis of pixel density of every lane from spinal cord and cerebellar tissues 
obtained from five sporadic ALS patients and four control cases was normalized to actin and 
quantified as described in Chapter 3 (* p<0.05). 
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Figure 26 
Increased levels of Hsp70 suggests a dysfunction of the ubiquitin-proteasome pathway 
A. Levels of Hsp70, but not Hsp40 were found to be increased in spinal cord, but not in 
cerebellar tissue of sporadic ALS patients. As in murine studies, proteasome impairment 
coincides with increased expression of the protein chaperone, Hsp70. Quantitations of bands 
from representative Western blots in (A) were performed as described in Chapter 3 and 
averages ofthese bands ± SEM are presented in panel B (* p<O.05). 
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Chapter 7 General Discussion 
In this chapter, the evidence that proteasomal impairment contributes to the 
pathogenesis of fALS will be summarized and discussed in light of recent advances 
illustrating the essential role that the ubiquitin-proteasome pathway plays in the pathogenesis 
of several neurodegenerative disorders. Similarities and differences in approach, 
methodology, and results obtained in these studies in comparison to those described in this 
thesis will be presented. The consequences and potential mechanisms of proteasome 
impairment will be discussed, including the impact that focal dysfunction of the proteasome 
may play in mediating the toxic-gain-of function in a specifie cellular and tissue setting. 
Finally, the efficacy of treatments envisaged to relieve the impairment of the ubiquitin-
proteasome pathway in treating ALS as weIl as other neurodegenerative disorders will be 
considered. 
7.1 Proteasome Impairment Contributes to fALS Pathogenesis 
The following paragraphs summarize the evidence supporting the involvement of the 
ubiquitin-proteasome pathway in fALS: 
7.1.1 The ubiquitin-proteasome pathway is important for degrading mutant SODI 
Treatment of cell lines overexpressing mutant SOD 1 with proteasomal inhibitors 
(MG 132 and lactacystin), but not calpain inhibitors, led to increased levels of mutant, but not 
SODIWT (Hoffinan et al., 1996; Johnston et al., 2000). The E3 ligase, dorfm, identified in 
ubiquitinated inclusion bodies of sporadic and fALS patients, and CHIP ubiquitinate mutant 
SODl, but not WT SODl, and promotes its rapid degradation by the 26S proteasome (Niwa 
et al., 2002) (Urushitani et al., 2004). Overexpression of dorfin rescued neuronal cell lines 
from mutant SODI toxicity (Niwa et al., 2002). Overexpression of these proteins in animal 
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models of fALS is crucial to determine if these E3 ligases have an impact in this 
neurodegenerative disease progression. However, a recent study has shown that recombinant 
SOD 1 mutants do not need to be ubiquitinated. They are good substrates for the 20S 
proteasome in vitro, particularly as metal deficient monomers lacking the intrasubunit 
disulfide bond (Di Noto et al., 2005). AIso, preferential degradation by the 20S proteasome 
has been previously demonstrated when SODI WT recombinant protein was oxidatively 
damaged (Salo et al., 1990). 
7.1.2 Proteasome activities are reduced in some ceU lines and in lumbar spinal cord of 
transgenic mice overexpressing mutant SODi. but not SODi WF 
Stable and transient overexpression of mutant and SOD 1 WT in various cell lines led to 
decreased (Urushitani et al., 2002; Hyun et al., 2002b; Allen et al., 2003), increased (Casciati 
et al., 2002; Aquilano et al., 2003) or unchanged (Lee et al., 2001) total proteasomal activities. 
A decrease of the proteasome specific activities as normalized to structural (l subunits of the 
20S core was measured in NIH3T3 cell lines (Figure 10) (Kabashi et al., 2004). A number of 
factors could influence the disparate results depending on cell lines and conditions including 
differences in conditions promoting misfolding of mutant SOD 1 and responsiveness of 
ubiquitin-proteasome components and other protective pathways. 
As reported in this thesis, abnormalities in proteasome activities and structure were 
identified in vulnerable tissue of mutant SOD 1 transgenic mice at three stages of disease 
pathogenesis defined by the extent of glial activation (Figure 4): P45 with minimal glial 
activation; P75 when the glial response has initiated but no signs of behavioural symptoms 
and motor neuronal death are present (Chiu et al., 1995), and at symptomatic stage where 
there is massive gliosis and over 50% of motor neurons have been lost. Even when levels of 
structural (l subunits of the 20S core remained unchanged, a specific decrease of the 
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chymotrypsin-like activity of the proteasome was measured within the lumbar spinal cord 
(Figure 8A), but not in the thoracic region ofthe spinal cord, a region less affected during the 
course of ALS pathogenesis (Chiu et al., 1995), and/or in whole spinal cord extracts of 
SODIG93A transgenic mice (Kabashi et al., 2004). By P75, aIl three proteolytic activities of the 
proteasome were severely reduced at about 50% of the proteasomal activities in SODI wr 
transgenic mice and their age-matched non-transgenic littermates (Figure 8A,C,D). 
7.1.3 Impaired proteasome activity occurs in tissue most vulnerable to disease 
At this stage of the disease no changes were measured in the total and/or specific 
activities ofthe 20S/26S proteasome in the thoracic region of the spinal cord (Figure 7A,C,D 
and 8A,C,D) and in whole spinal cord tissue (Kabashi et al., 2004; Cheroni et al., 2005; 
Puttaparthi and Elliott, 2005). 
7.1.4 Proteasome impairment corresponds to the presence ofSDS-insoluble. high-molecular 
weight mutant SOD1 species 
These species were ubiquitinated and were enriched in lumbar spinal cord (Figure 6). 
AIso, levels of the prote in chaperone, Hsp70, which is up-regulated upon proteasome 
inhibition in spinal cord cultures (Batulan et al., 2003) and rat substantia nigra (Ahn and 
Jeon, 2006) were found to be specifically increased in lumbar spinal cord (Figure 12). 
7.1.5 Proteasome levels decrease with disease progression in lumbar spinal cord ofSOD1G93A 
Finally, even though motor neurons express high levels of 20S (l subunits compared to 
other cell types in the spinal cord, the proteasome levels progressively decreased in surviving 
motor neurons within the lumbar spinal cord of SOD-l G93A mice relative to the surrounding 
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neuropil (Figure Il and 17). 
These results demonstrate that there is a focal dysfunction of proteasome activity early 
in disease pathogenesis in lumbar spinal cord and later as expression of 20S subunits is 
depleted in motor neurons of a fALS mou se model (Kabashi et al., 2004). However, the cell 
types involved and the functional consequences remain to be elucidated. Bendotti's group is 
attempting to answer this question by crossing SOD1 G93A mice with UbG76v_GFP transgenic 
mice. As discussed in Section 1.2.6.5, a limitation of the GFP reporters of proteasomal 
function is that significant loss of activity may be required before GFP accumulates to readily 
visible levels ((Dantuma et al., 2000; Bennett et al., 2005) and how long various spinal cord 
cells can live with this level of functional impairment is not known. 
7.1.6 Antibody-based techniques identifv structural defects in proteasome composition 
Decreased levels of two 20S ~ subunits, ~5 catalytic subunit and the structural 20S ~3 
subunit, of the proteasome occurred early in lumbar but not in thoracic spinal cord of 
SOD1 G93A mice and coincided with impairment ofproteasome activity (P45 and 75) (Figure 
13 and 14). 
7.1.7 Proteasome activities are reduced in spinal motor nuc/ei ofsporadic ALS patients 
As presented in Figure 24 proteasome impairment measured as a significant decrease of 
aIl three major activities of the proteasome occurred in both ventral and dorsal sections of 
thoracic spinal cord (Figure 24A,B,C right panels) but not in cerebellar tissue (Figure 
24A,B,C left panels). 
7.1.8 Decreased subunit expression coincides with proteasome impairment in sporadic ALS 
patients 
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As presented in Figure 25, impairment of the activity coincided with a specifie decrease 
in protein levels of 20S ~5 and 19S5a subunits in spinal cord tissue. No changes in other 
subunits of the proteasome were measured in spinal cord tissue and cerebellum. AIso, an 
increase in Hsp70 levels in spinal cord suggests an impairment of the ubiquitin-proteasome 
pathway (Figure 26). 
7.1.9 Proteasome impairment is not directly caused by mutant SOD1 expression 
In celllines, fluorescent vital imaging techniques showed that mutant SOD 1 aggregates 
form inclusion bodies that stably associate with subunits of the proteasome causing 
progressive impairment of its activity (Matsumoto et al., 2005) as determined using a GFP-Ub 
reporter (Bennett et al., 2005). Using 2-D blue native/SDS-PAGE to assess the composition of 
proteasomes in lumbar spinal cord tissue of SOD 1 G93A mice, mutant SOD 1 was not found to 
be directly associated with the proteasome complexes (Figure 21A), and immunodepletion of 
mutant SODI from samples did not increase proteasome activities in homogenates of these 
tissues. Although these experiments are not conclusive, they do not support the hypothesis of 
"choking" of the proteasome by mutant prote in as was suggested by studies in cell lines 
(Bennett et al., 2005). Rather our results point to structural alterations associated with 
decreased proteasome activity. 
7.1.10 No evidence oftranscriptional impairment ofproteasomal subunits and malformation 
ofproteasomal complexes in atfected murine tissue 
None of the changes in levels of proteasomal proteins resulted from decreased gene 
transcription, as mRNA levels were at control levels (Figure 18 and 19). In accordance with 
our results, recently, Kato and colleagues demonstrated that in the wobbler mouse (model of 
motor neuron disease - see Section 1.1.5.2) but not in mutant SODI transgenic mice, mRNA 
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level of the ~7 subunit of the 20S core was decreased in spinal cord tissue of pre-symptomatic 
mice (perrin et al., 2005). Nor were there increases in levels ofunassembled ~ subunits in 20S 
and 26S proteasome complexes measured in lumbar spinal cord of SOD-I G93A transgenic 
mice (Figure 20A). Purification of the proteasome and subunit analysis might detect post-
translational modifications that lead to proteasome impairment in affected tissue of mutant 
SODI transgenic mÏce. 
7.1.11 Not a simple matter ofimmune response 
Early in disease pathogenesis, the decrease in ~5 was not compensated for by an 
increase in the inducible immunoproteasome subunit, ~5i. However, at symptomatic stage, 
levels of the inducible subunit ~5i and the regulatory particle lISa of the immunoproteasome 
were increased (Figure 15), due to the inflammatory response at this stage of the disease as 
previously demonstrated in the spinal cord of SOD_IG93A mice (Cheroni et al., 2005; 
Puttaparthi and Elliott, 2005). 
7.1.12 Are motor neurons particularly sensitive to proteasome inhibition? 
In primary spinal cord cultures and organotypic spinal cord slices, treatment with the 
proteasome inhibitor, lactacystin, led to selective motor neuronal death (Urushitani et al., 
2002; Tsuji et al., 2005). These studies have come under controversy, since long-term low-
level proteasomal inhibition by lactacystin led to degeneration ofboth interneurons and motor 
neurons at the same rate (Vlug and Jaarsma, 2004). AIso, proteasome inhibition by lactacystin 
in organotypic slices and fibroblasts derived from SOD 1 G93A transgenic mice caused increases 
in SODI-positive inclusion bodies and SDS-insoluble mutant SODI (Puttaparthi et al., 2003; 
Turner et al., 2004). These data suggest that mutant SODI toxicity can be amplified by 
inhibiting the proteasome. However, it is important to determine whether treatment of spinal 
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cord tissue of rodents with proteasome inhibitors would lead to selective death of motor 
neurons and a neurodegenerative disorder similar to the course of the disease in mutant SODI 
transgenic mice. 
7.1.13 Proteasome aetivity in models orfAIS and tissue (rom sporadie AIS patients: Specifie 
meehanisms ofimpairment? 
As previously discussed In Chapter 6, impairment of the proteasome activity was 
measured in affected tissue of sporadic ALS patients as weIl as in an animal model of fALS. 
However, certain differences are worth discussing. No increases in levels of 
immunoproteasome components were observed in sporadic ALS patients, even though 
elevation of immunoproteasomes at late stages of the disease is a well-documented feature of 
the SODI G93A transgenic mouse (Kabashi et al., 2004; Cheroni et al., 2005; Puttaparthi and 
Elliott, 2005). Whereas levels of the subunit harbouring the chymotrypsin-like activity of the 
proteasome, 20S ~5, were decreased both in tissues from sporadic ALS patients and in an 
animal model of fALS, levels of the structural ~3 subunit were unaffected in sporadic ALS 
patients but were altered very early in disease pathogenesis in SODIG93A transgenic mice. 
Finally, a recent report suggested that expression of the 20S core is increased in degenerating 
motor neurons from ALS patients (Mendonca et al., 2006). These data are contrary to studies 
in murine models of fALS that illustrated a severe depletion of proteasomal subunits in 
lumbar motor neurons of symptomatic SOD 1 G93A transgenic mice. 
As it will be discussed in the next section, it is possible that several molecular 
mechanisms of disease can lead to proteasome impairment. A better understanding of 
proteasome biogenesis and the development and maintenance of proteasome activity in 
mammalian cells and tissues will certainly aid in unravelling the se mechanisms of proteasome 
impairment in ALS and other neurodegenerative disorders and provide avenues of 
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pharmacological treatments designed to reverse proteasome impairment in ALS pathogenesis. 
7.2 Role of the Ubiquitin-Proteasome Pathway in Neurodegenerative Disorders and 
Aging 
The first direct evidence for involvement of the ubiquitin-proteasome pathway in 
neurodegenerative disorders was identification of parkin, an E3 ligase whose mutations cause 
autosomally recessive PD (Kitada et al., 1998). Other genes that participate in this pathway 
and are mutated in human disorders include two E3 ligases, E6-AP and VHL, which can 
cause respectively Angelman syndrome and the von-Hippel-Lindau disease (Kishino et al., 
1997; Kamura et al., 1999). AIso, UCHL-1, a gene which is mutated in a rare form of 
dominant PD (Lincoln et al., 1999), encodes a prote in that was shown to function 
simultaneously as a DUB enzyme and an E3 ligase (Liu et al., 2002). Despite the numerous 
studies, the protein substrates that these E3 ligases are involved in degrading are not well 
defined. Recently, gigaxonin, the product of a gene mutated in Giant Axonal Neuropathy, was 
found to bind to an El at its N-terminus and to MAP1B through its C-terminal domain 
gigaxonin is involved in the degradation ofMAP1B (Wang et al., 2005c), which is impaired 
when gigaxonin is mutated or ablated (Allen et al., 2005). Currently, no mutations in genes 
that would encode members of the ubiquitin-proteaome pathway have been identified in fALS 
or "sporadic" ALS patients. 
There is a large body of evidence to suggest that the proteolytic capacity of the 
proteasome is impaired in aged organisms. Decreases in proteasome activity have been 
reported in various mammalian tissues (Chondrogianni and Gonos, 2005), such as spinal cord 
(Keller et al., 2000a), brain regions (Abd El Mohsen et al., 2005), retina (Louie et al., 2002), 
heart (Bulteau et al., 2002), liver (Shibatani et al., 1996), and proteasome impairment has 
been shown in senescent human fibroblasts (Sitte et al., 2000b). However, little is known 
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about the molecular mechanisms that lead to this proteasome impairment. Progressive 
overload of the ubiquitin-proteasome pathway due to increased errors in translation and 
transcription and increased oxidative modifications of proteins has been proposed (Grune et 
al., 2004). Severely oxidized proteins, including glycated proteins or proteins conjugated by 
HNE, can inhibit the 20S core of the proteasome (Carrard et al., 2003). AIso, fluorescent 
pigments of oxidatively damaged aggregated polymers, such as lipofuscin and ceroid have 
been shown to inhibit an three activities of the proteasome (Sitte et al., 2000a). It has been 
proposed that these cross-linked proteins cannot be properly unfolded and block the entrance 
gate of the proteasome, although no in vivo data exist to support this hypothesis (Kisselev et 
al., 2002). Even though there is evidence that glycated (Kato et al., 2000), HNE-modified 
(Perluigi et al., 2005), lipofuscin and ceroid (McHolm et al., 1984) accumulate in ALS with 
disease progression in affected tissue it remains to be determined whether their accumulation 
leads to proteasome inhibition and impaired degradation of other important substrates, and 
whether this occurs early in ALS disease pathogenesis. 
Oxidative damage to 20S subunits has also been proposed as a possible mechanism for 
proteasome impairment during aging (Chondrogianni et al., 2003). Indeed, HNE-
modifications of several a and ~ subunits of the 20S core that can impair proteasome activity 
have been demonstrated in aged tissue and certain subunits were shown to be more sensitive 
to these modifications (Bulteau et al., 2000). Indeed, Keller and colleagues demonstrated 
HNE-modification of~, but not a subunits occurs in aged spinal cord of rats (Keller et al., 
2000a). Finally, decreased expression of three functional subunits ~1, ~2, ~5, but not other 
subunits of the 20S and 19S components in human fibroblasts occurs with aging and 
correlates with impairment of proteasome activity (Chondrogianni et al., 2003). The authors 
suggested that the se subunits are the rate-limiting ones for proteasome activity, and recently 
they reported that stable overexpression of ~5 can lead to increases in mRNA of other 
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functional ~ subunits, their assembly into proteasomal complexes and increased rates of 
proteasome activities (Chondrogianni et al., 2005). It remains to be determined if the 
functional ~ subunits are the rate-limiting subunits in CNS tissue and if overexpression of 
these subunits can relieve proteasome impairment in fALS affected cells and tissues and 
lower the toxicity of mutant SOD 1 and possibly delay the onset of symptoms in mutant SOD 1 
transgenic mice. As previously discussed, a specific decrease in 20S proteasome levels of ~ 
subunits in lumbar spinal cord of mutant SODI transgenic mice contributed to proteasome 
impairment. However, our characterization of 20S and 26S complexes in the lumbar spinal 
cord demonstrated that both a and ~ subunits are present as monomers (Figure 20), therefore 
no evidence of ~ subunits being rate-limiting was found in murine spinal cord tissue extracts. 
Kirino and his group (Asai et al., 2002) were the first to report a proteasomal 
dysfunction in a murine model of brain stroke. Occlusionlreperfusion leads to delayed 
neuronal death in the CAl area of the hippocampus. Proteasome activity was decreased by 
60% in a general area of the CNS (frontal cortex and hippocampus) right after occlusion, but 
the activity was restored during the reperfusion period. However, in the CAl area the activity 
of the proteasome remained reduced leading these researchers to hypothesize that proteasome 
inhibition in the affected region causes neurodegeneration (Asai et al., 2002). We 
demonstrated that in a murine model of ALS, proteasome impairment occurs early in disease 
pathogenesis and is restricted to the lumbar spinal cord, the region most affected by the 
disease (Kabashi et al., 2004). 
Further studies in animal models of neurodegenerative disorders confirmed the 
important role that the ubiquitin-proteasome pathway plays in neurodegenerative disorders. 
Proteasome impairment and a corresponding increase in autophagic pathways were 
determined in the sciatic nerve from mice that have a duplication of peripheral myelin prote in 
22 (PMP22), a mouse model of hereditary neuropathy (Fortun et al., 2005; Fortun et al., 
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2006). On the other hand, proteasome activity was reported not to be affected in certain 
animal models of neurodegenerative disorders. No changes in proteasome activity, levels, 
composition and assembly were observed prior to disease onset (gliosis) in diseased tissue 
from mice that overexpressed mutant a-synuclein (Martin-Clemente et al., 2004), whereas 
another report showed significant impairment of proteasome activity in affected tissue 
(substantia nigra) of symptomatic mice overexpressing mutant a-synuclein (Chen et al., 
2006). AIso, in two murine models of polyglutamine disorders, R6/2, which expresses a 
fragment of mutant huntingtin, and mutant SCA 7, no increase of proteasome activity was 
measured early in the disease (Diaz-Hemandez et al., 2003; Bowman et al., 2005). At 
symptomatic stage, an increase in activity of the proteasome as weIl as levels of its inducible 
subunits was possibly due to the high rate of gliosis and immune response present at this stage 
in atfected tissue of CNS (Valera et al., 2005). These results demonstrate that the ubiquitin-
proteasome pathway might be less affected in several neurodegenerative disorders. 
Interestingly, a mouse model expressing full-Iength mutant huntingtin exhibits impaired 
proteasomal activity in affected areas (Seo et al., 2004) suggesting that in ditferent models of 
neurodegenerative disorders the proteasome activity might be atfected at various rates or 
through different mechanisms. More studies in mouse models of neurodegenerative disorders 
and better techniques to directly measure in vivo proteasome activity are needed to determine 
if the ubiquitin-proteasome pathway is directly affected by mutant, post-translationally 
modified and/or misfolded proteins. 
Proteasome impairment has recently been shown to directly cause neurodegeneration. 
Systemic treatment of mouse and rat brain with three selective proteasome inhibitors, 
lactacystin, epoximicin and Z-Ile-Glu(OtBu)-Ala-Leu-al (PSI) led to selective degeneration 
of substantia nigral and striatal dopaminergic neurons and development of PD-like features in 
these mice. This represents additional strong piece of evidence supporting this hypothesis 
158 
(McNaught et al., 2002; McNaught et al., 2004). These findings have come under strong 
debate recently since there are several reports that support (McNaught and Olanow, 2006; 
Zeng et al., 2006a) and argue against (Manning-Bog et al., 2006; Bove et al., 2006) 
nigrostriatal death upon proteasomal inhibition. AIso, continuous injections of MPTP lead to a 
PD-like model in rodents, inhibited the proteasome activity (Fomai et al., 2005). With respect 
to ALS, it will be important to determine whether these proteasome inhibitors would cause 
degeneration of motor neurons, cells that have been shown in cultures to be particularly 
vulnerable to proteasome inhibition. 
As introduced in Chapter 6, similar to the situation in ALS patients, 
immunohistochemical analysis has shown that various members of the ubiquitin-proteasome 
pathway are sequestered in inclusion bodies of AD, PD and HD with high frequency 
(Ciechanover and Brundin, 2003). Recently, a ubiquitin variant, ubiquitin-B+ 1 (UBB+ 1) has 
been demonstrated to accumulate in neurons of patients with Alzheimer's disease (AD) and 
other pathologies associated with tau-positive inclusion bodies but not in pathologies with (l-
synuclein-positive inclusion bodies (De Vrij et al., 2001). This ubiquitin variant was recently 
shown to directly inhibit 26S proteasome activity and induce HSP expression in cell lines 
(Hope et al., 2003). Since there is evidence of tau deposition, it would be interesting to 
determine if this ubiquitin variant is accumulated in tissue from ALS patients (Strong et al., 
2006). 
7.3 Consequences ofProteasomal Dysfunction in ALS Pathogenesis 
As presented in the First Chapter of this thesis, several hypotheses attempt to explain 
the toxic gain of function that mutant SODI might exert to cause fALS. In this section, the 
role that a dysfunctional ubiquitin-proteasome pathway may play in these molecular 
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mechanisms will be briefly discussed suggesting the central role that proteasomal-dependent 
degradation plays in the pathogenesis of ALS and other neurodegenerative disorders. 
Studies by Davies and colleagues have shown that most oxidatively modified protein 
substrates (including SODl) are degraded by the proteasome (Grune et al., 2004). Thus, the 
proteasome plays a crucial role in regulating oxidative damage, with preservation of 
proteasome function preventing oxidative stress, and proteasome inhibition being a mediator 
of oxidative stress. Mild, physiological oxidative stress leads to unfolding of proteins and 
exposure of hydrophobic patches that can be selectively recognized by the 20S proteasome 
and degradation of these substrates could occur without a need for ubiquitin targeting or ATP 
activation. However, severely oxidized, aggregated, and crosslinked proteins are poor 
substrates for degradation and eventually inhibit the proteasome (Grune et al., 2005). For this 
reason generation of reactive oxygen species might corresponds to a decline in proteasome 
activity in aged tissue and could play an important role in the pathogenesis of 
neurodegenerative disorders, resulting in the progressive accumulation of oxidatively 
damaged prote in aggregates that eventually contribute to cellular dysfunction and senescence. 
The high level of glutamatergic input to motor neurons is a contributing factor to their 
vulnerability to toxicity, in part due to the presence of calcium-permeable AMP A receptors 
(Carriedo et al., 1996; Roy et al., 1998). Formation of inclusions containing mutant SODI and 
death of cultured motor neurons are reduced by AMPA receptor blockers (Roy et al., 1998). 
Little is known about how proteasome dysfunction in neurons can contribute to glutamatergic 
toxicity. However, proteasome function is required for proper synaptic plasticity, including 
intemalization of GluR2 receptors (Ehlers, 2003). Recently, PSD95, a major scaffolding 
protein that tethers NMDA- and AMPA-type glutamate receptors, was found to be a 
proteasomal substrate (Colledge et al., 2003). NMDA receptor activation leads to rapid 
ubiquitination and degradation of PSD95 and selective intemalization of GluR2 receptors 
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(Colledge et al., 2003). As presented in section 1.2.2.1, levels of GluR2 contribute to selective 
vulnerability of motor neurons and might play an important role in ALS pathogenesis. The 
proteasome could play an important role in this molecular pathway since an impairment of 
proteasome function early in disease pathogenesis would lead to improper intemalization of 
GluR2 receptors. Improper GluR2 recycling and intemalization due to proteasome 
malfunction in ALS pathogenesis requires more attention. AIso, other molecular pathways 
that wou Id link proteasome degradation and glutamate toxicity in motor neurons need to be 
studied. 
Motor neurons in SODIG93A and SODI G37R transgenic mice exhibit mitochondrial 
abnormalities (Chiu et al., 1995; Kong and Xu, 1998; Bendotti et al., 2001; Jaarsma et al., 
2001; Jung et al., 2002; Higgins et al., 2003; Liu et al., 2004), although these changes are not 
prominent in mice expressing lower copies of these mutant or another mutant 
SODI G85R(Bruijn et al., 1997). Impaired mitochondrial function and vacuolation have been 
attributed to accumulation of mutant SODI in the intermembrane space (Jaarsma et al., 2000; 
Higgins et al., 2003; Liu et al., 2004), but the involvement of proteasomal dysfunction 
deserves investigation. Low level, non-toxic proteasome inhibition in cell lines can disrupt 
mitochondrial homeostasis through inhibition of mitochondrial complex 1 and complex II 
activities and increased generation of reactive oxygen species (Ling et al., 2003; Sullivan et 
al., 2004). Injection of two pharmacological agents, MPTP and rotenone, known to disrupt 
mitochondrial homeostasis in primates and rodents leads to selective degeneration of 
substantia nigra neurons and Parkinsonian-like syndromes (Langston et al., 1983; Betarbet et 
al., 2000). Both MPTP and rotenone were found to inhibit proteasome activity in affected 
tissues. Interestingly, treatment with rotenone leads to reduction of functional 20S ~ subunits 
(Wang et al., 2006a), whereas MPTP is associated with decreases in prote in expression of20S 
a subunits, but not ~ subunits and regulatory particles (19S and lIS) (Zeng et al., 2006b) 
161 
suggesting that several structural changes of the proteasome complex can lead to impairment 
of its activity. 
Impaired proteasome functioning would lead to activation of other proteolytic 
pathways, including cal pains, caspases and autophagy. Since cancer cells are more susceptible 
to apoptosis, treatment with proteasome inhibitors leads to up-regulation of caspases and 
selective apoptosis (Adams, 2003). For this reason, bortezomib, a proteasome inhibitor has 
proved beneficial in animal models and is already in clinical trials for cancer patients 
(Princiotta et al., 2001; Cavo, 2006). Subunits that participate in formation of 
autophagosomes, a less selective prote in and organelle degradatory machinery, are also up-
regulated upon proteasome impairment (Ding et al., 2003) and autophagy might play a role in 
the dissolution of ubiquitinated inclusion bodies in neurodegenerative disorders (Rideout et 
al., 2004). Recently, two groups demonstrated that inhibition of basal autophagy, by 
eliminating genes in the CNS responsible for formation of autophagosomes, led to 
neurodegeneration in mice (Hara et al., 2006) (Komatsu et al., 2006). This evidence suggests 
that autophagy might play a role in ALS pathogenesis, particularly if proteasomal pathways 
for proteolysis are not operating optimally. This needs to be investigated. 
Proteasome malfunction that results in accumulation of misfolded proteins can trigger 
ER stress (VanSlyke and Musil, 2002). The ER stress response may play an important role 
since this organelle, apart from processing secretory and plasma membrane targeted proteins, 
also regulates Ca2+ storage and signalling (Turner and Atkin, 2006). There is mounting 
evidence that ER stress is up-regulated pre-symptomatically in animal models of fALS. An 
ER chaperone, Grp78 was found to be up-regulated and associated in vivo with neuronal 
protein deposits in SODI G93A transgenic mice (Tobisawa et al., 2003). AIso, proteomic studies 
found the ER-resident prote in disulfide isomerase (PDI) family members to be up-regulated in 
lumbar spinal cord of SODI G93A transgenic rats (Atkin et al., 2006). Fragmentation of the 
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Golgi apparatus is a major pathological feature of ALS and has been reported in motor 
neurons of sporadic and fALS as weIl as animal models of fALS (Fujita et al., 2000; Stieber et 
al., 2000). It is not weIl understood which forms of mutant SODI (soluble, insoluble, 
ubiquitinated), if any, lead to Golgi fragmentation in motor neurons, but in celllines, mutant 
SOD 1 has been demonstrated to impair retrograde axonal transport, which results in dispersal 
of the Golgi (Atkin et al., 2006). Interestingly, it was demonstrated recently that mutant SODI 
binds to components of neurosecretory vesicles, chromogranins, and is exported outside the 
neurons where it can trigger activation of microglia (Urushitani et al., 2006). However, the 
role of chromogranin-mediated secretion in vivo, at what point in ALS pathogenesis it occurs 
and whether the ubiquitin-proteasome pathway plays a role in this response remains to be 
determined. 
As introduced in Section 1.2.4, disruption ofaxonal organization and transport is an 
important aspect of ALS pathogenesis. The ubiquitin-proteasome pathway and its degradatory 
capacity play very important roles in the process ofaxonal degeneration as demonstrated in 
Wlds, an animal model in which Wallerian axonal degeneration following distal nerve trans-
section occurs more slowly than normal (Raff et al., 2002). Experiments in this strain of mice 
have demonstrated that axonal degeneration is not a passive process, but involves severa} 
degradatory pathways, including caspases, 26S proteasomes and autophagy (Korhonen and 
Lindholm, 2004). Studies in mutant SODI mice, including a recent report by Caroni and 
colleagues, demonstrated that in SOD 1 G93A transgenic mice motor neuronal axonal 
abnormalities occur prior to motor neuronal death early during disease pathogenesis. Most 
large axons of motor neurons in the lumbar spinal cord are lost and become abruptly 
denervated between post-natal day 48 to 55 (Pun et al., 2006). Since the activity of the 
proteasome as measured in results reported in this thesis is first decreased at day 45 and is 
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severely impaired by day 75, it is important to determine the role that the ubiquitin-
proteasome pathway might play in axonal degeneration during ALS pathogenesis. 
7.4 Future Perspectives in the Role of the Ubiquitin Proteasome Pathway in ALS 
In this section of the General Discussion, several strategies to unravel the gain of 
function through which mutant SODI causes toxicity in motor neurons that eventually leads 
to their demi se and whether the proteolytic capacity of the proteasome plays a central role in 
this gain of function will be discussed. Understanding these mechanisms of toxicity will be 
necessary to design proper pharmaceutical treatments for sporadic and familial ALS patients. 
Studies using recombinant mutant SODI have demonstrated that this prote in is unstable, 
making it prone to aggregation and post-translational modifications, and can become 
insoluble (Hart, 2006). There is an immediate need to carry out large-scale proteomics studies 
in animal models of fALS as weIl as in affected tissue of sporadic ALS patients. SDS-
insoluble, high-molecular weight species of mutant SODI are detected in spinal cord of 
SODI G93A transgenic mice very early in disease pathogenesis (post-natal day 30) (Johnston et 
al., 2000). Therefore, the biophysical characterization of mutant SODI should be carried out 
at various stages of disease progression in affected tissues of animal models in order to 
dissociate pathogenic from pathologic mutant SODI. These experiments are currently 
underway in our laboratory as well as in others (Agar, Kabashi et al. manuscript in 
preparation). Also, techniques to purify and characterize by mass spectrometry various forms 
of mutant SODI that have been associated with toxicity are required. These forms include 
non-ionic detergent insoluble SODI, high molecular weight SDS-insoluble species species, 
components of prote in aggregates trapped in filter paper, proteins immunopurified with 
antibodies that recognize oxidative damage markers (HNE), and proteolytic fragments of 
mutant SODI that have been demonstrated to be present in spinal cord tissue of mutant SODI 
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transgenic mice. Finally, characterization of SODI-positive inclusion bodies that develop 2-3 
days following microinjection of mutant SODI genes in primary cultured motor neurons 
would be very informative to determine what other proteins are trapped in these inclusions 
and whether these polymers undergo any post-tranlational modifications. 
Once isolated and identified, it could be determined whether various forms of mutant 
SODI can impair the activity of the prote in quality control systems, prote in chaperones and 
the ubiquitin-proteasome pathway. Kinetic analysis of the rate of proteasome impairment 
could be carried out by adding different forms of monomers and polymers to commercially 
available or purified 20S proteasomes, as previously described with aggregated a-synuclein, 
which directly inhibits 20S but not 26S proteasome activity in vitro (Snyder et al., 2003). 
AIso, the mutant SODI variants can be added to spinal cord extracts and the effect on 
proteasomal and chaperoning activity determined. 
There are technicallimitations to the se studies since the amount of material necessary to 
carry out these experiments is quite large and the amount of mutant SODI that can be 
immunopurified from affected tissue early in disease pathogenesis is quite small. Necessary 
steps to improve protein analysis by mass spectrometry as weil as purification methods that 
would yield more material are required to carry out most of the studies proposed above. 
Experiments should also be carried out in tissue from sporadic ALS patients to identify 
post-translationally modified, misfolded proteins that could contribute to disease. Antibodies 
specifie to HNE-modified proteins, glycated proteins and other forms of oxidative damage 
can be used to determine which proteins are post-translationally modified. Furthermore, the 
time point in disease pathogenesis at which modification of the se protein substrates occurs 
can be assessed in affected tissue of animal models offALS. 
Another question that could be addressed by proteomic studies is whether subunits of 
the ubiquitin-proteasome pathway are post-translationally modified in affected tissue early in 
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disease pathogenesis. Since an impairment of the proteasome associated with a decrease of ~5 
subunit of the 20S core occurs as early as post-natal day 45, these modifications can he 
prominent very early in disease pathogenesis. Previous studies that have demonstrated post-
translational modifications of proteasome subunits involved semi-purification of proteasome 
complexes by gradient centrifugation, electrophoretical separation of the subunits using 2D 
gels and finally, analysis ofthe resolved subunits by mass spectrometry. Semi-purification of 
proteasomal complexes by gradient centrifugation from lumbar spinal cord of mutant SODI 
transgenic mice is not feasible because of tissue limitations. However, this method might be 
feasible by pooling lumbar spinal cords of mutant SODI transgenic rats, which are larger. In 
fact, recently a proteomic study of ER stress in lumbar spinal cord of pre-symptomatic rats 
were carried out by Atkin and colleagues (Atkin et al., 2006). Altematively, the development 
of new antibodies against subunits of the 20S core to immunoprecipitate proteasomal 
complexes is necessary since the existing commercial antibodies are not suitable for the se 
purposes. These antibodies are essential for characterization by mass spectrometrie analysis of 
post-translational modifications in proteasomal subunits in ALS and other neurodegenerative 
disorders. 
Finally, more biophysical and biochemical studies in various physiological contexts are 
needed to understand the biogenesis, formation of the structre, and complex activity of the 
proteasomal species at a cellular, tissue, organ, and organism level. Through these studies it 
would be possible to understand how the decrease of certain subunits at the protein levels 
observed during ALS pathogenesis can correspond to changes in proteasome activity. 
Interestingly, the half-life of certain subunits could be modified due to post-translational 
modifications. In vitro studies of the half-life ofproteasomal subunits in celllines treated with 
proteasomal inhibitors or overexpressing mutant SOD 1 could indicate sorne of the changes 
that might occur in vivo. 
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The studies in spinal cord tissue of sporadic ALS patients demonstrate that there is a 
focal proteasome dysfunction. lmmunohistochemical analysis with specifie antibodies in 
spinal cord sections of these patients is required to determine if there are changes in 
localization of proteasomal subunits and whether loss of proteasomal subunits occurs in motor 
neurons of sporadic ALS patients, as documented in animal models of fALS. A recent screen 
of gene expression in laser captured motor neurons of sporadic ALS patients compared to 
controls by gene array did not identify proteasomal subunits. However, these genes are not 
weIl represented on the array that was used (Jiang et al., 2005). It would be important to 
assess specifically levels of mRNA expression by rt-PCR using specifie primers for various 
subunits of the 20S core. Finally, assembly of 20S and 26S proteasome complexes and post-
translational modifications of proteasome subunits should be determined in spinal cord tissue 
obtained from post-mortem sporadic ALS patients. These studies are necessary to determine 
the mechanisms that lead to impairment of proteasome activity in sporadic ALS patients and 
how these mechanisms might be different from results derived from animal models of fALS 
prior to designing therapies to target the ubiquitin-proteasome pathway to treat ALS patients. 
Even though research describing physiological and pharmacological drugs to boost the 
ubiquitin-proteasome pathway and/or relieve proteasomal inhibition is still limited, several 
avenues of research to directly target this pathway to treat ALS already exist. Nrf2, a 
transcription factor that regulates the expression of ARE genes (see Section 1.2.1) has also 
been demonstrated to up-regulate gene expression of several subunits of the 20S core (K wak 
et al., 2003b). Several chemical agents that lead to up-regulation of Nrf2 such as 3H-l,2-
dithiole-3-thione (D3T) and tert-butylhydroquinone (tBHQ) are known. Treatment with tBHQ 
decreased toxicity that astrocytes purified from SODIG93A transgenic rats exerted on motor 
neurons possibly by up-regulating glutathione and decreasing oxidative stress in the astrocytes 
(Vargas et al., 2006). Treatment of animal models of fALS with 3H-l,2-dithiole-3-thione 
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(D3T), a drug known to protect against a variety of chemical carcinogens and up-regulate 
Nrf2, specifically in lumbar spinal cord might slow down disease progression by decreasing 
levels of oxidatively damaged proteins as weIl as increasing levels of proteasome expression 
in tissue affected by the disease. 
Other studies should be carried out to assess whether overexpression of a key ubiquitin-
proteasome subunit could increase proteolytic capacity and lower mutant SODI toxicity. 
Since overexpression of 20S pS in human fibroblasts promotes the expression of other 20S 
subunits and de novo formation of proteasomes, it will be necessary to determine whether 
overexpression of this subunit in murine primary spinal cord leads to increased proteasome 
activity and protein levels of other 20S subunits. One experiment would be to express this 
subunit in motor neurons from primary spinal cord cultures by microinjection of plasmid 
expression vector and determine its effect on expression of other proteasomal subunits and 
toxicity of SOD 1 G93A. Similar studies could be conducted to evaluate protective properties of 
the E3 ligases, CHIP and dorfin which have been demonstrated to ubiquitinate mutant SOD 1 
in vitro. These studies would further establish the ubiquitin-proteasome pathway as a 
causative factor in ALS pathogenesis. 
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and damaged proteins might contribute to their vulnerability to disease. We have been studying how mutations in 
the enzyme, CulZn-superoxide dismutase (SOD 1) cause a familial form of amyotrophic lateral sclerosis (ALS). 
We showed that proteasome function is disrupted specifically in lumbar spinal cord of G93A SOD 1 transgenic 
mice, the tissue that will eventually be most affected in the disease. In the renewal of funding for this project, we 
propose to identify the mechanisms responsible for the tissue-specific 108s of proteasome activity and the 10ss of 
proteasomes in motor neurons that precedes their death, and to determine if treatments that increase expression 
of protein chaperones prevent proteasome dysfunction. 
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SODI and wild type SODIlines. For each line, 75 non-transgenic mice would be generated and used as 
littennate controls (strains 3 and 5). 
Unsuitable products ofbreeding are euthanized (i.e., not required for study or breeding stock). 
Submit to your local Facility Animal Care Committee. Please note that after two renewals, a full protocol needs 
to be submitted. 
This approval does not imply that space will be made available. If a major increase of space needs is 
anticipated, please contact the appropriate animal facility manager. 
